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PREFACE 
 
The idea of this thesis was born many years ago. The clinical observation that 
supplementation with Vitamin D, for the prevention of metabolic bone disease, improve 
Systemic Lupus Erythematosus (SLE, Lupus) patients, has become almost a certainty 
for the “lupulogists”. This supplementation was done without clinical guidelines and 
without measuring the levels of Vitamin D. This empirical recognition happened before 
the explosion of randomised controlled trials and small studies on the effect of this 
hormone in human disease. Lupus was still a disease with large acknowledgement to 
achieve, still over treated, regardless of the fact that treating asymptomatic patients 
with steroids and immunosuppressors was inappropriate. Hydroxychloroquine was 
used as immunomodulator, but many clinicians ignored or dismissed it. At that time, 
Vitamin D was undervalued. The observations in the nineteenth and early twentieth 
centuries of its antimicrobial effects were forgotten with the advent of new antimicrobial 
molecules.  
At the beginning of the XXI century, the world awakens to this hormone and 
begins an intense investigation that cuts across all areas of medicine. After all, it is a 
steroid hormone with a nuclear receptor, capable of activating or suppressing a myriad 
of genes and acting as a natural regulator of thousands of metabolic pathways and 
cytokines. In Lupus, despite the switch of using Vitamin D supplementation regularly, 
based in the theoretical concept of being an innocuous immunomodulator, there is still 
much to know regarding its effects in the disease and to define the best dosage. 
Additionally, much of the research has been carried out with scarse theoretical 
reflection and based on limited practical experience. The experience of working in a 
multidisciplinary unit with more than 3000 autoimmune diseases patients, led us to 
accumulate empirical observations of Vitamin D benefits. Nevertheless, basic 
questions about its mechanism of action and the best way to use it, came to 
prominence.  
 Thus, this project entitled “Vitamin D deficiency and resistance state - 
association with clinical and immunological deregulation in Systemic Lupus 
Erythematosus” was born. Its aim was to create a conceptual framework based on 
questions that arised over the past years and came from the accumulated experience 
of its use in hundreds of patients. Its structure was systematized through the creation of 
a theoretical concept of resistance to Vitamin D, based on clinical observation and 
supported by hundreds of articles; and trying to prove it in clinical practice. As a 
secondary aim, we intended to show that the Portuguese population is largely deficient 
in Vitamin D, as well as patients with SLE, and that Vitamin D is related to disease 
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susceptibility, severity, damage accrual and disease stabilization throughout their lives. 
We also intended to demonstrate that standard recommendations for metabolic bone 
disease are inappropriate to autoimmune diseases. Sustained serum levels and 
biomarkers of efficacy should individualize Vitamin D supplementation for Lupus 
patients. For this purpose, we have collected clinical, epidemiological, serological and 
DNA data from a cohort with more than 600 SLE patients. 
We elaborated six hypotheses, answered with in vivo data and not in vitro 
studies, and we categorized new concepts tailored to the clinical practice. At the end of 
this project, more questions remained than at the beginning, but also the notion that 
many of the questions are innovative and perhaps give new insights on the treatment 
of SLE patients. 
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ABSTRACT 
 
The clinical practice in “autoimmunology”, challenged us to question the relation 
of Vitamin D and SLE disease. The aim of this thesis was to answer some of those 
questions, according to the following hypotheses: 
 
Hypothesis 1: Vitamin D levels in our SLE patients are lower than in a healthy 
population with the same demographic characteristics (age and sex). 
Hypothesis 2: Vitamin D status is related to SLE susceptibility. 
Hypothesis 3:  SLE severity is related to VDR Single Nucleotide Polymorphisms 
(SNPs). 
Hypothesis 4: Vitamin D deficiency is associated with SLE severity. 
Hypothesis 5: Supplementation with Vitamin D alters the clinical expression and 
immunological deregulation of SLE patients (T-CD4+ cells expressing Forkhead FoxP3 
(FoxP3) and T-CD4+ cells producing interleukin (IL)-17A). 
Hypothesis 6: Clinical and Immunological response to Vitamin D supplementation is 
limited by SLE disease activity.  
 
 
To achieve those answers, the following studies were developed: 
 
– Two epidemiologic studies in Portuguese SLE patients (n=124) and in healthy 
controls (n=198), in order to evaluate Vitamin D levels in both populations. 
 
– An immunogenetic study with more than 1000 patients in order to prove the 
effect of different alleles of Major Histocompatibility Complex (MHC) class II to 
AIDs susceptibility. 
 
– Two immunogenetic studies with 170 SLE patients (DNA databank): 
 To correlate VDR polymorphisms with different disease aspects (activity, 
flares and damage accrual). 
 To correlate baseline Vitamin D levels and mean levels (in a 10-year follow-
up) with different disease aspects (activity, flares and damage accrual). 
 
– Two interventional studies with Vitamin D supplementation  were performed: 
 To study the effect of Vitamin D supplementation (despite baseline levels) 
in 24 stable SLE patients, regarding disease severity, T-CD4+ cells 
expressing FoxP3 and T-CD4+ cells producing IL-17A. 
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 To study the effect of Vitamin D supplementation (despite baseline levels) 
in 4 severely active SLE patients, regarding Tregs, T-CD4+ cells producing 
IL-17A and miR-146a expression. 
 
Concerning Vitamin D levels, in the winter period, 74.2% of the healthy studied 
population had a 25(OH)D concentration below 50.0 nmol/L compared with 22.8% in 
the summer period (p<0.0001). In the SLE group, 85% of the patients have Vitamin D 
deficiency. The mean Vitamin D levels were 48.9±27.2 and there were no significant 
differences between summer and winter (p=0.117). Comparing with the control group, 
a significant difference was only observed during the summer time (p=0.0003). 
We documented that Human Leukocyte Allele (HLA)-DRB1*13 act as protective 
allele for four autoimmune diseases (AIDs): SLE (OR=0.58, p=0.016), Psoriasis and 
Psoriatic Arthritis (OR=0.621, p=0.050), Rheumatoid Arthritis (RA) (OR=0.58, p=0.044) 
and Systemic Sclerosis (SSc) (OR=0.42, p=0.035). HLA-DRB1*03 was found to be a 
risk factor for SLE (OR=2.49, p=4.2x10-5). 
SLE damage, according to Systemic Lupus International Collaborating Clinics 
Damage Index (SLICC) values, was higher in SLE patients with FokI CT and TaqI TT 
VDR genotypes (p=0.031 and p=0.046 respectively).  
We observed a higher number of flares in patients with low baseline Vitamin D 
levels (p=0.045). We also observed that patients with three or more flares had 
significant lower baseline Vitamin D levels (p=0.004). 
 The mean Vitamin D levels in the previous 10 years of disease in 68 patients 
were lower in patients with more severe flares, although not statistacally significant 
(p=0.178). However, if we consider two subgroups (patients with three or more and 
less than three severe flares), the difference is significant (p=0.044). 
The FoxP3+/IL-17A ratio in patients with stable SLE after 6 months of Vitamin D 
supplementation was higher than that in the baseline (p<0.001), even in patients with 
normal 25(OH)D levels at baseline (≥75 nmol/L) (p=0.043). 
Considering IL-17A T CD4+ producing cells, Tregs and Tregs/IL-17A ratio before 
and after high dose Vitamin D supplementation, in patients with severely active 
disease, no enhancement of Tregs or Tregs/IL-17A  was observed. 
Finally, no significant differences were found in miR-146a expression, when 
comparing controls and SLE active patients, before and after Vitamin D 
supplementation. 
In conclusion, Vitamin D levels are insufficient in at least two thirds of Portuguese 
healthy adult population and 85% of SLE patients. However, in these patients, mean 
levels are lower than in general population, only during the summer time. These results 
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allow us to conclude that hypovitaminosis D in SLE population may differ, from that 
observed in healthy population. This is probably due to deficient sun exposure during 
summer time, and not to a disease effect on Vitamin D metabolism. 
We confirmed and described original genetic data in our SLE Portuguese 
population, that can allow new studies, which will be able to determine a Vitamin D 
effect in SLE susceptibility: HLA-DRB1*03 risk and the HLA-DRB1*13 protective effects 
in disease susceptibility. We should study the possibility of this effect to be mediated by 
presence of the canonical Vitamin D Response Element (VDRE) in HLA-DRB1 genes.  
Specific VDR polymorphisms are related to a higher long-term cumulative 
damage in SLE patients. These effects seem to be unrelated to vitamin D levels. Lower 
baseline Vitamin D levels at SLE diagnosis (before supplementation) and mean 
Vitamin D levels in a 10-year follow-up, correlate negatively with disease severity 
(resulting in more aggressive SLE phenotypes). 
Vitamin D supplementation seems to provide favourable immunological effects in 
patients with stable SLE; this effect is probably independent of the 25(OH)D patients’ 
status, but not independent from SLE activity. 
Finnaly, our results suggest that in Lupus patients, severe active disease may 
cause resistance to Vitamin D therapeutical effects. 
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RESUMO 
 
A prática clínica em "autoimunologia", desafiou-nos a questionar a relação da 
Vitamina D com o Lúpus. O objetivo desta tese foi o de responder a algumas dessas 
perguntas, de acordo com as seguintes hipóteses: 
 
Hipótese 1: Os níveis de Vitamina D nos nossos doentes com Lúpus são mais baixos 
do que em uma população saudável com as mesmas características demográficas 
(sexo e idade). 
Hipótese 2: o nível de Vitamina D está relacionado com a susceptibilidade ao Lúpus. 
Hipótese 3: A gravidade do Lúpus está relacionada com os polimorfismos do VDR. 
Hipótese 4: A deficiência de Vitamina D está associada com a gravidade do Lúpus. 
Hipótese 5: A suplementação com Vitamina D altera a expressão clínica e 
desregulação imunológica dos doentes com Lúpus (células T-CD4 + expressando 
FoxP3 e T-CD4+produtoras de IL -17). 
Hipótese 6: A resposta clínica e imunológica à suplementação de Vitamina D é 
limitada pela atividade da doença lúpica. 
 
Para conseguir essas respostas, os seguintes estudos foram desenvolvidos: 
 
– Dois estudos epidemiológicos em doentes com Lúpus (n=124) e controlos 
saudáveis (n=198), de modo a avaliar os níveis de Vitamina D em ambas as 
populações. 
  
– Um estudo imunogenético com mais de 1000 doentes, a fim de provar o efeito 
de diferentes alelos do Complexo Principal de Histocompatibilidade (MHC) da 
classe II para a susceptibilidade às doenças autoimunes. 
 
– Dois estudos de imunogenética com 170 doentes com Lúpus (Banco de DNA). 
 Para correlacionar os polimorfismos do VDR, com os diferentes aspectos 
da doença (actividade,flares e dano). 
 Para correlacionar os níveis basais de Vitamina D e os seus níveis médios 
(em 10 anos de follow-up), com os diferentes aspectos da doença 
(actividade,flares e dano). 
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– Dois estudos intervencionais com suplementação de Vitamina D: 
 Para estudar o efeito da suplementação de Vitamina D 
(independentemente dos níveis basais) em 24 doentes com Lúpus estável, 
em relação à gravidade da doença, células T-CD4 + expressando FoxP3 e 
T-CD4 + produtoras de IL-17A. 
 Para estudar o efeito da suplementação de Vitamina D 
(independentemente dos níveis basais) em 4 doentes com Lúpus grave 
ativo, sobre as células T reguladoras, T-CD4 + produtoras de IL-17A e a 
expressão do miR-146a. 
 
Relativamente aos níveis de Vitamina D, no período de inverno, 74,2% da 
população saudável estudada tinha uma concentração de 25(OH)D abaixo de 50,0 
nmol/L, em comparação com 22,8% no período de verão (p <0,0001). Em doentes 
com Lúpus, 85% dos doentes tinham deficiência de Vitamina D. Os níveis médios de 
Vitamina D nos doentes com lúpus, foram 48,9 ± 27,2 e não houve diferenças 
significativas entre verão e inverno (p=0,117). Comparando com o grupo controle, uma 
diferença significativa foi observada somente durante o horário de verão (p=0,0003). 
Foi documentado que o HLA-DRB1*13 era um alelo de protecção para quatro 
doenças autoimunes: Lúpus (OR=0,58, p=0,016), Psoríase e Artrite Psoriática 
(OR=0,621, p=0,050), Artrite Reumatóide (OR=0,58, p=0,044) e Esclerose Sistémica 
(OR=0,42, p=0,035). O HLA-DRB1*03 é um factor de risco para o desenvolvimento de 
Lúpus (OR=2,49, p=4.2x10-5). 
De acordo com os valores do SLICC, o dano em doentes com lúpus foi maior 
nos que apresentavam os genótipos FokI CT e TaqI TT do VDR (p=0,031 e p=0,046, 
respectivamente).  
Observou-se um maior número de flares em doentes com níveis basais de 
Vitamina D baixos (p = 0,045). Também foi observado que doentes com três ou mais 
flares tinham níveis de Vitamina D significativamente mais baixos do que os restantes 
(p=0,004). 
 
Os níveis médios de Vitamina D nos últimos 10 anos de doença em 68 doentes 
foram menores em doentes com mais flares graves, embora não estatísticamente 
significativo (p=0,178). No entanto, se considerarmos dois subgrupos (doentes com 
três ou mais e menos do que três flares graves), a diferença é significativa (p=0,044). 
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A proporção FoxP3+/IL-17A em doentes com Lúpus estável após 6 meses de 
suplementação com Vitamina D foi maior do que na linha de base (p<0,001), mesmo 
em doentes com níveis normais de 25(OH)D no início do estudo (≥75nmol/l) (p=0,043). 
Em relação às células T produtoras de IL-17A, células T reguladoras e razão de 
Tregs/IL-17A, antes e após a suplementação de altas doses de Vitamina D, em 
doentes com doença severa ativa, nenhum aumento de Tregs e do ratio Tregs/IL-17A 
foi observado. Finalmente, não foram encontradas diferenças significativas na 
expressão de miR-146a, quando se comparam os controlos e doentes ativos com 
Lúpus, antes e após a suplementação de Vitamina D. 
 
Em conclusão, os níveis de Vitamina D são insuficientes em, pelo menos, dois 
terços da população adulta saudável Portuguesa e 85% dos doentes com Lúpus. No 
entanto, nestes doentes, os níveis médios são inferiores à população em geral, 
apenas durante o tempo de verão. Estes resultados permitem concluir que a 
hipovitaminose D na população com lúpus pode ser diferente da observada na 
população saudável. Isto deve-se, provavelmente, à deficiente exposição solar durante 
o verão, e não devido a um efeito da doença sobre o metabolismo da Vitamina D. 
Nós confirmamos e descrevemos dados genéticos originais na nossa população 
Portuguesa com Lúpus, que podem permitir novos estudos, capazes de determinar um 
efeito da Vitamina D na susceptibilidade ao Lúpus: efeito de risco do HLA-DRB1 * 03 e 
protector do HLA-DRB1 * 13 na susceptibilidade à doença. Devemos estudar a 
possibilidade de este efeito ser mediada pela presença de um “Vitamin D Responsive 
Element” (VDRE) funcional no gene HLA-DRB1. 
Polimorfismos específicos do VDR estão relacionados a um maior dano 
cumulativo a longo prazo em doentes com Lúpus. Estes efeitos parecem não estar 
relacionados com níveis de Vitamina D. Os polimorfismos do VDR não se 
correlacionam com os flares e com envolvimento de órgãos específicos. 
Níveis mais baixos de Vitamina D de base na data do diagnóstico de Lúpus 
(antes da suplementação) e os níveis médios de Vitamina D num follow-up de 10 
anos, correlacionam-se negativamente com a severidade da doença (resultando em 
fenótipos lúpicos mais agressivos). 
A suplementação de Vitamina D parece proporcionar efeitos imunológicos 
favoráveis em doentes com lúpus estável; este efeito é provavelmente independente 
dos níveis de 25(OH)D, mas não independentes da atividade do LES. 
Finalmente, os nossos resultados sugerem que em doentes com lúpus, a doença 
activa grave pode causar resistência aos efeitos terapêuticos da Vitamina D.  
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Vitamin D resistant state in SLE – the concept and state of the art 
 
1.1. Systemic Lupus Erythematosus 
This chapter introduces basic concepts on SLE and presents the evidence of the 
non-classical effects of Vitamin D on lupus. 
Systemic lupus erythematosus is a systemic autoimmune disease with multi-
organ inflammation (Carvalho et al., 2015a; Lauwerys et al., 2013), linked to loss of 
immune tolerance to self-antigens and the production of a diversity of autoantibodies. It 
mainly affects women of childbearing age. This disease has a female to male ratio in 
adults of approximately 9:1, a peak age to diagnosis between 15 and 44 years, and a 
negative impact on the quality of life, including reduced levels of employment and 
income. Despite phenotypic heterogeneity and the unpredictable disease evolution, a 
strong genetic and environmental contribution to the development of SLE is supported 
by broad evidence, including the reproducibility of the clinical picture in all continents 
(Morais & Isenberg, 2016). SLE is characterized by the presence of autoantibodies, 
primarily directed against chromatin and ribonucleic particle constituents 
(nucleosomes, single- and double-stranded deoxyribonucleic acid (DNA)) (Jiang, 2011; 
Lahita, Tsokos, Buyon, & Koike, 2011; Lauwerys, Ducreux, & Houssiau, 2014; 
Lauwerys et al., 2013), that may play a pathogenic role (Lauwerys et al., 2014). The 
hyperreactivity to these self-antigens leads to the formation of immune complexes that 
cause local inflammation and tissue damage (Mandal et al., 2014). 
B cell regulation is important in the maintenance of immune balance due to the 
production of autoantibodies and their prolonged cell life. B cells from patients with SLE 
have been shown to present autoantigens, induce CD4+ T helper cells (Th1/Th2), 
inhibit Tregs, and secrete pro-inflammatory cytokines (Guerra, Vyse, & Cunninghame 
Graham, 2012). 
Thus, SLE is a complex disease, involving diverse immune system mechanisms 
with multiorganic involvement and failure. 
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1.2. SLE – Classification, diagnosis, monitoring and treatment 
1.2.1. SLE Classification and diagnosis 
Considering the heterogeneity in clinical manifestations and multisystem 
involvement, SLE diagnosis as well as the classification criteria have been subject of 
debate over time. From a conceptual point of view, classification and diagnosis are not 
synonymous. Classification criteria apply to patients diagnosed with Lupus in order to 
recognize patterns that allow the comparison of the disease among centres anywhere 
in the world. Usually they correspond to signs, symptoms and laboratory data of high 
sensitivity and specificity. As such, some patients with these key data are used as a 
comparison reference for multicenter studies. 
 
This means that experience is necessary in the diagnosis of SLE and is incorrect 
to support this conviction on classification criteria. For that purpose some examples are 
given. 
 
Example 1: 19 years old white man, fever with 1 week of evolution, malar rash 
during febrile periods, arthralgia, cervical lymphadenopathy, myalgia, pharyngeal 
exudate and positive antinuclear antibodies (ANAs) 1/160 speckled pattern; absence of 
other autoantibodies. 
In this case, the fact of being male, having an acute disease, rash during fever 
periods and having an autoantibody that has low specificity for SLE, points, most likely, 
to a viral disease. If we consider the 1997 and 2012 revised classification criteria, we 
could classify the patient as having SLE, with both of them. 
 
Example 2: female, 18 years old, appears with petechiae, has 10,000 platelet/µl, 
and no other clinical finding. It has positive ANAs 1/1280 mottled pattern. There is no 
complement consumption and no other autoantibodies. 
In this example, the patient has no classification criteria, but, with the analytical 
finding, age, sex, and high titers of ANAs (though not specific), many clinicians would 
give her the diagnosis of SLE. 
 
Therefore, to a correct diagnosis of SLE, a set of epidemiological, clinical and 
laboratory findings that allow the patient to complete this syndrome is necessary. Table 
1 shows the sensitivity and specificity of autoantibodies for the diagnosis of SLE. 
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Therefore, in the present context, SLE remains a difficult clinical diagnosis based 
on experience and not in classification models.  
 
Table 2 presents the fundamental data that distinguish classification criteria from 
diagnosis criteria. 
 
 
 
 
 
 
 
 
 
 
 
Table 1 - Sensitivity and specificity of autontibodies to SLE diagnosis (adapted from (Aringer, 
Dorner, Leuchten, & Johnson, 2016)). 
Table 2 – Differences between diagnosis and classification criteria (adapted from (Aringer et al., 
2016)). 
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Finally, some considerations on SLE classification. SLE is a disease involving 
any organ or system and having different manifestations among patients, and even in 
the same patient along the disease. It was necessary to create a common language 
allowing the comparison between patients and disease patterns. This pressure 
increased because a large number of available drugs were failing their targets in 
clinical trials, and, this effect is due to the small number of patients involved in these 
trials and to the impossibility of comparing patients in real life. In 1982, the American 
College of Rheumatology criteria were published (Tan et al., 1982) and revaluated in 
1997 (Hochberg, 1997). Tables 3 and 4 present the 1982 SLE classification criteria. 
 
Table 3 - The 1982 revised criteria for classification of SLE (adapted from (Tan et al., 1982). 
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Table 4 - The 1982 revised criteria for classification of SLE (continuation of table 3) (adapted 
from (Tan et al., 1982). 
 
 
 
In these criteria, and for the first time, each clinical syndrome had its 
characteristics defined, increasing the ability to distinguish self-limiting findings and / or 
common findings with specific characteristics. As examples: the painless aphthosis and 
the non-erosive arthritis. However, the analytical characteristics are sparse, in 
particular, the lack of specific autoantibodies. On the other hand, all disease features 
are placed in the same "bag". 
The clinical and analytical findings are not associated and it would make sense to 
create a group of well-defined analytical and clinical criteria, separated as clinical and 
analytical features. As an example, the use of complement factors, long used in clinical 
practice as SLE characteristic, is not a criteria feature in the 1982 and 1997 
classification. 
In 2012, following the needs identified above, Petri et al. (Petri et al., 2012) 
published a review of criteria that separate the clinical from the laboratory components 
of the disease (Table 5). 
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Since then, many studies have compared the old criteria with the current ones. A 
study of the Iberian Peninsula evaluated 2055 patients (Ines et al., 2015) and 
concluded that the new criteria can classify patients early in the disease course. This 
means a trend towards diagnostic criteria. This is clearly an evolution and new criteria 
revisions are on the horizon in the next two years. 
 
 
 
 
 
 
Table 5 - Classification criteria for SLE by Petri et al., 2012.  
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1.2.2. Lupus Monitoring   
SLE monitoring is complex, as the disease is heterogeneous. Monitoring a 
chronic systemic disease comprises many factors: disease activity, disease damage, 
quality of life, drug monitoring and side effects. 
 
European League Against Rheumatism (EULAR) published, in 2010, 10 general 
recommendations summarized in the following chapter. 
 
 
1.2.2.1. Definitions (adapted from Mosca et al., 2010) 
Monitoring involves observing and recording the evolution of the disease and 
anticipating outcomes based on knowledge of the disease. Monitoring is different from 
diagnosis, but may overlap with screening. Monitoring includes the observation and 
anticipation of complications of the disease, of comorbidity, and of side effects of the 
medication. 
Active SLE refers to the presence of symptoms, signs, or abnormal investigations 
related to active inflammation and that indicate organ involvement that is likely to be 
reversible with therapy. 
Definition of remission is the absence of relevant symptoms and signs of 
inflammatory activity in any organ or system. Remission implies the absence of 
immunosuppressive therapy, with the exception of hydroxychloroquine. Clinical 
remission on therapy defines “complete response”. Autoantibodies may be present, 
even when patients achieve clinical remission. 
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1.2.2.2. Minimal requirements for assessment of organ involvement in SLE 
 
 
Table 6 - Minimal requirements for assessment of organ involvment in SLE (adapted from 
(Mosca et al., 2010). 
Laboratory 
assessment 
Erythrocyte Sedimentation Rate (ESR), Complete Red Blood Cell Count 
(CRP), Complete Blood Count (CBC), serum albumin, serum creatinine 
or Glomerular Filtration Rate (GFR), urinalysis, protein/creatinine ratio (or 
24 h proteinuria), Complement (C) 3, C4 
Autoantibody 
assessment 
At baseline: ANA, Anti-double-strand DNA (anti-dsDNA), Anti-Ro (SSa) 
Antibody (anti-Ro), Anti-La (SSb) Antibody (anti-La), Anti-
Ribonucleoprotein Antibody(anti-RNP), Anti-Smith Antibody (anti-Sm), 
Anti-Phospholipid Antibodies (aPL). 
Re-evaluation in previously negative patients: 
- Anti-phospholipid antibodies: prior to pregnancy, surgery, transplant, 
and oestrogen containing treatments, or in the presence of new 
neurologic or vascular event. 
- Anti-Ro and anti-La antibodies before pregnancy. 
Joint involvement Ask for the presence of arthralgias, assess joints for arthritis, if present 
perform a joint count 
Mucocutaneous 
involvement 
Mucocutaneous lesions should be characterized according to the existing 
classification systems (lupus specific, lupus non-specific, lupus mimickers 
or drug-related) 
Kidney involvement 
 
Protein/creatinine ratio (or 24 h proteinuria), urine microscopy, 
immunological tests (C3, C4, anti-dsDNA), blood pressure 
CNS involvement Focused history for neuropsychiatric symptoms (seizures, paraesthesia, 
numbness, weakness, headache, epilepsy, depression, etc.) 
Pulmonary 
involvement 
History: pleuritic chest pain, dyspnea New York Heart Association 
(NYHA), cough. 
Examination: pulmonary crackles/rales, pleural effusion 
Heart involvement 
History: Chest pain, dyspnea (NYHA), atherosclerosis risk factors 
Examination: peripheral oedema, arterial blood pressure, heart and 
carotid murmurs, heart rate 
Eye assessment Examination by an ophthalmologist or an optician 
Vascular involvement Inquire about Raynaud's, thrombotic risk factors, and intermittent 
claudication 
Gastrointestinal tract Ask about symptoms 
 
 
 
 
1.2.2.3. Recommendations (adapted from Mosca et al., 2010) 
 
Recommendation #1: Patient assessment 
In addition to the standard of care of non-lupus patients of the same age and sex, the 
assessment of an SLE patient must include the evaluation of disease activity by a validated 
index at each visit and organ damage annually. Registry of general quality of life his done with 
patient history and/or by a 0 to 10 Visual Analogue Scale at each visit, comorbidities and drug 
toxicity. 
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In recent years, indices have been developed and validated to measure these 
parameters. The most frequently used activity indices are the British Isles Lupus Assessment 
Group (BILAG), the European Consensus Lupus Activity Measurements (ECLAM), the Systemic 
Lupus Activity Measure (SLAM), and the Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) and revised versions as SLEDAI-2K and Safety of Estrogens in Lupus National 
Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI). The 
SLICC Damage Index was developed to assess irreversible damage in SLE patients occurring 
after disease onset. Recently, SLE-specific indices to assess patient’s quality of life have been 
developed and validated as well, although the Short Form (SF-36) is the most widely used to 
assess quality of life. 
 
Recommendation # 2: Cardiovascular risk factors 
At baseline and during follow up at least once a year*: 
 Assess smoking, vascular events (cerebral/cardiovascular), physical activity, oral 
contraceptives, hormonal therapies, and family history of cardiovascular disease. 
 Blood tests: blood cholesterol and glucose. 
 Examination: Blood pressure, BMI (and/or waist circumference). 
*Some patients may need more frequent follow-up (i.e. patients on glucocorticoids). 
 
Recommendation # 3: Other comorbidities 
1.  Osteoporosis 
All SLE patients  
 Should be assessed for adequate calcium and Vitamin D intake, regular exercise, and 
smoking habit, 
 Should be screened and followed for osteoporosis according to existing guidelines 
o For postmenopausal women 
o For patients on glucocorticoids, or on any other medication that may reduce 
Bone Mineral Density (BMD) 
2. Cancer. Cancer screening recommended according to the guidelines for the general 
population, including Papaniculau smears (PAP). 
SLE patients’ screening, according to the existing guidelines for postmenopausal women 
and/or for patients treated with medications that may affect bone mass. 
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Table 7 - Drugs that may affect bone mass. 
Drugs that may affect bone mass 
Glucocorticoids 
Immunosuppressive drugs 
- Cyclosporine 
- Tacrolimus 
- Methotrexate 
Heparin 
Thyroxine 
Aromatase inhibitors 
Long-term anticonvulsants (phenytoin, 
phenobarbital, carbamazepine, piramidone) 
Gonadotropin releasing hormone antagonists 
Proton pump inhibitors (omeprazole) 
Loop diuretics 
Antidepressants (particularly selective serotonin 
reuptake inhibitors) 
 
 
Recommendation #4: Infection risk 
# 4.1 Screening 
We recommend that patients to be screened for: 
 Human Immunodeficiency virus based on patient’s risk factors, 
 Hepatitis C virus, hepatitis B virus based on patient’s risk factors, particularly before 
immunosuppressive drugs including high dose glucocorticoids are started, 
 Tuberculosis, according to local guidelines, especially before IS drugs including 
high dose glucocorticoids are started, 
 Cytomegalovirus testing considered during treatment in selected patients. 
 
# 4.2 Vaccination 
SLE patients are at high risk of infections and prevention his recommended. The 
administration of inactivated vaccines (especially influenza and pneumococcus), following the 
Centres for Disease Control guidelines for immunosuppressed patients, should be strongly 
considered in SLE patients on Immunosuppressive drugs, preferably administered when the 
SLE is inactive. For other vaccinations, an individual risk/benefit analysis his recommended. 
 
# 4.3 Monitoring 
At follow up visits, continuous assessment of the risk of infection by taking into 
consideration the presence:  
 Severe neutropenia (<500/mmc), 
 Severe lymphopenia (<500/mmc), 
 Low Immunoglobulin (Ig) G (<500mg/dL). 
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Recommendation #5: Frequency of assessments 
Patients with no activity, no damage, and no comorbidity, are recommending 
assessments every 6 to 12 months. Preventive measures during this visits, are important to 
implement. 
 
Recommendation #6: Laboratory assessment 
#6.1 Laboratory assessments 
We recommend to monitor the following autoantibodies and complement: 
 At baseline: ANA, anti-dsDNA, anti-Ro, anti-La, anti-RNP, anti-Sm, anti-phospholipid, C3, 
C4. 
 Re-evaluation in previously negative patients: 
o Anti-phospholipid antibodies: prior to pregnancy, surgery, transplant, and 
oestrogen containing treatments, or in the presence of a new neurologic or 
vascular event. 
o Anti-Ro and anti-La antibodies before pregnancy. 
o Anti-dsDNA/ low C3 or C4 may support evidence of disease activity / remission. 
 
#6.2 other laboratory assessments 
At 6-12 month intervals, patients with inactive disease should have: 
 CBC 
 ESR 
 CRP 
 Serum albumin 
 Serum creatinine (or GFR) 
 Urinalysis and urine protein/creatinine ratio 
If a patient is on a specific drug treatment, monitoring for that drug is required as well. 
 
Recommendation #7: Mucocutaneous involvement 
Characterization of mucocutaneous lesions, according to the existing classification systems, 
as to whether they may be: 
- Lupus erythematosus - specific. 
- LE-nonspecific. 
- LE mimickers. 
- Drug-related. 
Assessement of lesions, for activity and damage, with validated indices (i.e. Cutaneous Lupus 
Erythematosus Disease Area and Severity Index (CLASI)). 
 
 
Recommendation #8: Kidney 
- Patients with a persistently abnormal urinalysis or raised serum creatinine should have 
urine protein/creatinine ratio (or 24 h proteinuria), urine microscopy, renal ultrasound and be 
considered for referral for biopsy. 
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- Patients with established nephropathy should have protein/creatinine ratio (or 24 h 
proteinuria) and immunological tests (C3, C4, anti-dsDNA), urinary sediment microscopy 
and blood pressure at least every 3 months for the first 2-3 years.  
- Patients with established chronic renal disease (GFR < 60 ml or stable proteinuria > 0.5 
mg/24 hrs.) should be followed according to the National Kidney Foundation guidelines for 
chronic kidney disease. 
 
Recommendation #9: Neuropsychiatric manifestations 
- Monitoring of SLE patients for the presence of neuropsychological symptoms (seizures, 
paraesthesia, numbness, weakness, headache, epilepsy, depression, etc.) by focused 
history. 
- Evaluating attention, concentration, word finding and memory difficulties may be used to 
assess cognitive impairment (i.e. by asking the patient about problems with multitasking, 
with household tasks, or memory). If there is a suspicion of any cognitive impairment, the 
patient should be assessed in further detail then. 
 
Recommendation #10: Eye assessment 
In patients treated with glucocorticoids or antimalarials, a baseline eye examination is 
recommended according to standard guidelines.  
An eye examination during follow up is recommended:  
 in selected patients taking glucocorticoids (high risk of glaucoma or cataracts), 
 in patients on antimalarial drugs and  
o low risk -> no further testing is required until 5 years after baseline; after the 
first 5 years of treatment, eye assessment is recommended yearly, 
o High risk -> eye assessment is recommended yearly.  
 
 
 
1.2.3. Lupus treatment: treat to target in SLE 
Regarding SLE management, after steroid therapy in the 50ths and 
cyclophosphamide in the late 70ths, no other drug his approved. In the 21th century, 
Belimumab (anti-blys monoclonal antibody) was approved for severe SLE (Narain & 
Furie, 2016). 
However, a long road of off-label drugs his used in SLE. Despite these drugs, a 
state of the art therapy is not yet a reality. However, in the last years, more important 
than drug therapy is the treatment  strategy, which should target a low activity disease 
and a low long-term damage accrual. In this chapter, will be reviewed this new 
treatment strategies. 
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The concept of Treat to Target (T2T) has been successfully applied to many 
diseases including diabetes mellitus, hypertension and hypercholesterolemia, and 
more recently to rheumatoid arthritis (Smolen et al., 2010). 
In 2014, a task force of specialists involved in the care of SLE patients developed 
key recommendations for T2T in SLE (van Vollenhoven et al., 2014). Prominent 
features of the T2T/SLE recommendations include early identification of lupus 
nephritis, targeting remission, minimizing exposure to corticosteroids, optimal 
management of co-existent antiphospholipid syndrome, prevention of long-term 
damage accrual and improving quality of life in SLE patients. The T2T/SLE 
recommendations will led to improved care for SLE patients and provide useful 
guidance for those involved in their clinical management. However, targeting some 
SLE manifestations are easier to quantify than others, such as lupus nephritis 
compared with central nervous system (CNS) manifestations, which may make 
T2T/SLE challenging. Table 8 summarizes T2T in SLE. 
 
Table 8 - T2T recommendations in SLE (adapted fron Van Vollenhoven annals of Rheumatic 
diseases. April 17, 2014). 
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1.3. Etiopathogenesis 
Intense research of the cellular and molecular processes involved in SLE, 
allowed the design of specific and efficient therapies. However, its pathogenesis is still 
unknown. Genetic factors, contribute to the risk of SLE, and environmental factors 
(such as tobacco, Vitamin D…) also play an important role. Some of these genetic and 
environmental factors interact with each other, increasing the disease’s risk. 
AIDs are chronic conditions initiated by the loss of immunological tolerance to 
self-antigens. This heterogeneous group of disorders presents common genetic risk 
factors and shares several pathophysiological mechanisms leading to overlapping 
clinical manifestations targeting specific organs or multiple organ systems (Shoenfeld 
et al., 2008). Although they exhibit contrasting epidemiological features and clinical 
manifestations, there is evidence that they share similar immunogenetic mechanisms 
(Anaya, Gomez, & Castiblanco, 2006). Underlying these diverse clinical phenotypes 
may exist, a dysregulated immune system with an enhanced capacity to respond 
against self. The fact that AIDs share several clinical signs and symptoms (i.e. sub 
phenotypes), physiopathological mechanisms and genetic factors have been called 
autoimmune tautology and indicates that they have a common origin (Anaya, 2010). 
The function of the immune system is to defend the organism against foreign 
pathogens and self-altered elements. To complete these purpose, selected T and B-
lymphocytes and innate immune cell, activated by pathogen or damage associated 
molecular patterns, work together. These cells orchestrate a precise immune response 
through tightly regulated cell-cell interactions and secretion of cytokines and other 
inflammatory mediators. The body's defense against foreign pathogens must occur 
without causing unnecessary harm to self. To accomplish this, the elimination of the 
majority of self-reactive T and B-lymphocytes, in the thymus and bone marrow, through 
a process denominated negative selection his done. However, this process is 
imperfect, albeit purposely, and self-reactive lymphocytes that escape into the 
periphery must be kept under control by an array of peripheral tolerance mechanisms 
(Sprent & Kishimoto, 2001). When the balance of the effector and regulatory parts of 
an immune response is disturbed, self-reactive T and B cells become activated and 
promote autoimmunity (Bluestone, 2011).Discussion of regulatory cells and 
mechanisms his done, later on this chapter. 
Environmental factors combined with genetic and hormonal characteristics have 
been associated with SLE phenotype and with disease progression (J. Choi, Kim, & 
Craft, 2012; Kunz, 2013). 
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Vitamin D is one of the environmental factors likely related to SLE pathogenesis 
and its deficiency appears to be associated with immunomodulatory abnormalities in 
this disease (Schneider, Dos Santos, Santos, da Silva Chakr, & Monticielo, 2014). 
Later on in this chapter, will be reviewd the Vitamin D effect in the immune system, 
AIDs and SLE. 
 
 
 
1.3.1. SLE and Immune Response 
One or more mechanisms of B-cell tolerance are lost in SLE, allowing the 
production of ANAs by plasma cells (Figure 1). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Production of ANAs by plasma cells (adapted from (Gottschalk, 
Tsantikos, & Hibbs, 2015)). 
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Up to 90% of SLE patients have elevated titters of serum ANAs, up to 9.4 years 
and on average 3.3 years prior to clinical onset of SLE (Figure 2) (Arbuckle et al., 
2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The temporal delay between autoantibody development and disease onset 
coupled with incomplete penetrance of ANA-mediated disease suggests that 
pathogenesis is conditional upon other factors, such as antigen availability, a pre-
established inflammatory environment, and T-cell-mediated antibody isotope switching. 
Inadequate apoptosis can expose nuclear antigens allowing ANAs to extensively bind 
and form Immunocomplexes (ICs). Such ICs can deposit in organ and vessels resulting 
in activation of the alternative complement pathway and recruitment of proinflammatory 
macrophages and DCs via chemotactic signalling which upregulate inflammatory 
cytokine production and activate autoreactive T-cell subsets through antigen 
presentation and costimulation (Gottschalk et al., 2015).  
Endosomal Toll-Like Receptors (TLR)-7 and TLR-9 in activated B cells, 
plasmacytoid Dendritic Cells (DCs), and macrophages can respond to internalized self 
ICs containing nucleic acids, which can contribute to the initiation and perpetuation of 
the inflammatory cascade (Clancy, Markham, & Buyon, 2016). 
Disease-related autoantibodies in SLE focus on particular targets, including DNA-
containing antigens, such as dsDNA, and ribonucleic acid (RNA)-containing antigens, 
such as Sm/RNP. A variety of in vitro studies in mouse cells show that RNA- and DNA-
containing ICs, activate TLR7 and - 9, respectively, through B-Cell Receptor (BCR) -
mediated internalization in B cells or through Complement Fraction Gamma Receptor 
Family (FcγR)-mediated internalization in DCs. TLR engagement in B cells increases 
BCR signalling and antibody production, whereas, in peripheral DCs (pDCs), TLR 
Figure 2 - Cummulative antibodies in SLE (adapted from Arbuckle et al., 2003). 
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induces interferon (IFN)-α production, which causes myeloid DCs (mDCs) to release 
BAFF and further activates autoreactive B cells (Nundel et al., 2015). 
Additionally, upregulated TLR7 and TLR9 messenger RNA (mRNA) expression 
has been reported in Peripheral Blood Mononuclear Cells (PBMCs) from SLE patients, 
and the levels correlate with the expression of IFN-α (Wu, Tang, & Zuo, 2015). 
Regarding T-Cells, an aberrant T-Cell Receptor (TCR) signalling, has been 
reported, which leads to their hyperresponsiveness. There were describe alterations in 
the expression of TCRζ (zeta), the activation of intracellular Spleen Tyrosine Kinase 
(Syk), calcium signalling, and various other kinase pathways. Decreased in the 
expression levels of TCRζ, exists in the majority of patients with SLE. The 
downregulation of TCRζ expression and activity is, in contrast, with the 
hyperresponsiveness of T cells. However, it has been described that, in T cells of these 
patients, the more potent FCγR can replace the TCRζ (Yoshimoto, Setoyama, 
Tsuzaka, Abe, & Takeuchi, 2010). Furthermore, the inhibitory function of Cytotoxic T-
Lymphocyte Associated Protein 4 (CTLA-4) is impaired in T cells of lupus patients (Jury 
et al., 2010). Normally, CTLA-4 is associated with the Tyrosine Phosphatase 2 (SHP-
2), which dephosphorylates TCRζ, thereby disrupting TCR signalling (Barreto et al., 
2009). Due to the decreased expression of TCRζ in patients with SLE, the regulatory 
function of CTLA-4 may be impaired. Finally, it has been suggested that impaired TCRζ 
signalling interferes with T cell selection processes in the thymus, which results in 
increased numbers of autoreactive T cells; however, this phenomenon is not enough to 
induce autoimmunity (Hwang et al., 2012). 
 
1.3.1.1. Tregs and Th17 in SLE 
Regulatory T cells are specialized suppressor cells (Lahita et al., 2011; Mocanu, 
Oboroceanu, & Zugun-Eloae, 2013), with the phenotype 
CD4+FOXP3+CD25highCD127low (Lahita et al., 2011), that have the capacity to 
regulate the intensity and quality of the immune response (Mocanu, Oboroceanu, & 
Zugun-Eloae, 2013). They actively suppress effector cells, including those associated 
with autoimmune diseases (Jiang, 2011), thereby establishing and maintaining 
immunological self-tolerance (Daniel & von Boehmer, 2011). 
Some studies suggest that Treg cells are deficient in number and function in 
several autoimmune diseases including SLE (Sawla, Hossain, Hahn, & Singh, 2012). 
However, there are also reports of an enrichment of this cell type (Lin et al., 2007; 
Suarez, Lopez, Gomez, & Gutierrez, 2006). These contradictory observations may be 
either due to the lack of a well-defined specific Treg marker in humans or to the 
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heterogeneity of SLE phenotypes (Sawla et al., 2012). Concerning Treg population, the 
CD25 per se, was the initial marker, which could explain the reported contradictory 
results. The fact that FoxP3-expressing cells loses CD25 expression and consequently 
his suppressive functionality, can explain the disfunction of these cells (Bonelli et al., 
2009; Valencia, Yarboro, Illei, & Lipsky, 2007). 
Besides Th1 and Th2, identification of a third subset of CD4+ effector Th cells 
named Th17 was reported. These cells, because of its unique ability to produce IL-17 
(IL-17A and IL-17F),  play a critical role in the recruitment, activation and migration of 
neutrophils (Jiang, 2011). Beyond their protective role in the clearance of extracellular 
pathogens, its major role seems to be their involvement in the induction and 
maintenance of chronic inflammatory processes (Bansal, Henriquez, Sumar, & Patel, 
2012; Jiang, 2011). 
 The hypothesis that certain forms of autoimmunity may result from a conversion 
of Treg cells into a Th17 cell phenotype, has been suggested by some studies 
(Eisenstein & Williams, 2009).  
In SLE patients’ sera, the IL-17 levels are abnormally high when compared to 
healthy individuals. IL-17 is also produced by neutrophils, Innate Lymphoid Cells, and 
other T cell types including CD4+, CD8+, double negative (CD4-CD8-) and TCR-γδ 
(Jiang, 2011). This phenomenon could promote the autoimmune process by increasing 
the activation of immune cells itself. Release of IL-17 by infiltrating T cells in specific 
organs may also contribute to local tissue injury by instigating the inflammatory 
response (Jiang, 2011).  
 
Th17 and SLE 
The Signal Transducer and Activator of Transcription (STAT) 3 are 
overexpressed and hyperactivated in T cells from SLE patients. STAT3 plays a central 
role in T cell differentiation into Th17 and T follicular helper cells, two subsets that 
orchestrate autoimmune responses in SLE. Moreover, STAT3 is important in 
chemokine-mediated T cell migration. Expression of STAT3 is increased in T cells in 
SLE, whereas inhibition of STAT3 leads to decreased T cell migration and delayed 
onset of autoimmunity in lupus prone mice (Edwards, Mizui, & Kyttaris, 2015). 
Increased IL-17 production in Lupus, may also be explained by overactive 
costimulation via Signalling Lymphocyte Activation Molecules (SLAMs). Evidence 
suggests a crucial role for SLAMs in the expression of autoimmunity. SLAM Family 
(SLAMF) 3 and SLAMF6 expression is increased on the surface of SLE 
T cells compared with normal cells.                  
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SLAM coengagement with CD3 under Th17 polarizing conditions results in 
increased IL-17 production. On the other hand, naïve and memory CD4+ 
T cells produce more IL-17 in response to SLAMs costimulation as compared with 
CD28 costimulation. Engagement of SLAMF3 and SLAMF6 along with antigen (Ag)-
mediated CD3/TCR stimulation represents an important source of IL-17 production. 
Disruption of this interaction with decoy receptors or blocking antibodies should 
mitigate disease expression in SLE and other autoimmune conditions (Chatterjee et al., 
2012). 
IL-17A, a member of IL-17 family, amplifies the immune response by inducing the 
local production of chemokines and cytokines, recruiting neutrophils and monocytes, 
augmenting the production of autoantibodies, and aggravating the inflammation and 
damage of target organs such as the kidney in SLE (D. Li et al., 2015). 
 
Regulatory T-cells in SLE 
Above, we defined the nature and properties of regulatory T-Cells. Regarding the 
suppressive function of Tregs in SLE, different explanations have been published. 
Several reports demonstrate that the suppressive function of Tregs in SLE is impaired 
(Sawla et al., 2012).  Other reports claim that the suppressive function of Tregs in SLE 
is not impaired, but that autoreactive effector T cells in SLE are less susceptible to 
suppression by Tregs (Mercadante & Lorenz, 2016). However, it has also been 
demonstrated that Tregs from healthy controls are able to suppress effector T cells of 
patients with SLE (Valencia et al., 2007). Taken together, Tregs seem to play a role in 
the pathogenesis of SLE. 
 
Disturbed balance between Tregs and Th 17 Cells 
In SLE has been suggested, a disturbed balance between Th17 cells and Tregs. 
However, we only understand partially, the mechanisms underlying alterations in 
numbers and/or function of Th17 and Tregs in SLE, but may involve the overall 
cytokine milieu. 
For the development of Th17 cells, the combined action of Transforming Growth 
Factor Beta (TGFβ) and IL-6 is required, whereas Treg development depends on IL-2 
and TGFβ (X. Li et al., 2011). In SLE increased in IFN type I has been suggested, and 
it also promotes the development of Th17 cells, and an Interferon alfa monoclonal 
antibody is a nearby promising therapy (Khamashta et al., 2016). It has been shown 
that IFN-α triggers the production of IL-6 by mDCs, whereas IL-6 is required for the 
development of Th17 cells (Biswas, Aggarwal, Levesque, Maers, & Ramani, 2015). 
However, IFN-α impairs the suppressive function of Tregs in SLE. Importantly, in the 
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presence of IFN-α producing DCs, Tregs of SLE patients as well as Tregs of healthy 
controls were not capable to suppress T effector cells (Becker, Bopp, & Steinbrink, 
2013). In summary, immune response involving SLE pathogenesis is complex and 
includes defective removal of opsonized immune complexes and a complex cytokine 
milieu favouring B and T autoreactive cells as well as defective function or number of 
regulatory cells. 
 
 
1.3.2. Genetic factors and Immune Response 
Genetics and epigenetic studies have led to the exploration of the pathogenesis 
of SLE. Identification of differentially expressed genes and their regulatory 
mechanism(s) at whole-genome level may contribute to a comprehensive 
understanding of the development of SLE. 
Most of the genes identified as susceptibility risk factors for SLE are involved in 
the pathways of innate and adaptive immune system (Teruel & Alarcon-Riquelme, 
2016). Numerous studies reported an association with susceptibility, phenotype and 
even with monogenic rare presentations. This chapter is divided in immune system 
components and summarizes the most important genetic findings in this subject. 
 
 
 
1.3.2.1. Innate immune system 
Complement  
It is well known that complement deficiency, primary or secondary (anti-c1q 
antibodies for example), is related to disease susceptibility and phenotype (Orbai et al., 
2015). There is also a relation of anti-c1q antibodies to lupus nephritis (Orbai et al., 
2015) and C2 deficiency to cutaneous lupus and arthritis (Macedo & Isaac, 2016).   
Impaired “cleaning” of nucleic acid-containing auto-antigens is a very important 
mechanism for the development of autoantibodies, and the cumulative effect of new 
autoantibodies along many years is important to disease beginning (Macedo & Isaac, 
2016). Figure 3 presents the normal mechanism of efficient complement-mediated 
opsonisation of ICs. 
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Integrin Subunit Alpha M (ITGAM) gene is clearly associated with the disease in 
all populations (Teruel & Alarcon-Riquelme, 2016). The Gapaid consortium studied the 
genetic evidence for altered complement system functionality in SLE. This consortium 
genetic analysis revealed that the non-synonymous variant rs1143679 in complement 
receptor type 3 is associated with an increased production of anti-dsDNA IgG 
antibodies. They also found out that secondary complement deficiency in SLE does not 
impair opsonisation of nucleic acid-containing autoantigens. It is the dysfunction of the 
receptor which recognizes complement opsonized ICs that promote the development of 
class-switched autoantibodies targeting nucleic acids (Figure 4) (Prechl et al., 2016). 
 
 
 
 
 
 
 
 
 
 
Figure 3 - Normal opsonisation of Nucleic acids (NA) (adapted from (Prechl 
et al., 2016). 
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One of the main recent findings is that opsonisation is not impaired in SLE 
but complement receptors SNPs are important, and some of them have impaired 
efficacy in recognizing opsonized ICs. 
 
 
 
Mononuclear cells and interferon signature 
 Increased surface expression of class II molecules is an essential event in the 
maturation of DCs, in that higher surface expression is crucial to the increased capacity 
of mature DCs to effectively present antigens to naïve T cells (Banchereau & 
Steinman, 1998). 
The HLA class II genes, especially HLADRB1*03:01 and HLA-DRB1*15:01 
alleles are consistently associated with SLE susceptibility (Bettencourt et al., 2015; 
Vasconcelos et al., 2009). However, several genes within the HLA region contribute 
independently to SLE genetic susceptibility. Most interestingly has been the targeted 
next-generation sequencing of the MHC region, where a haplotype with regulatory 
polymorphisms was associated with changes in gene expression of the HLA class II 
molecules (Raj et al., 2016). Individuals homozygous for XL9 Polymorphism Haplotype 
3 (XL9 HAP3) (risk) variations have more than two-fold higher surface expression for 
HLA-DR and DQ molecules at baseline which increases to four (4)-fold after stimulation 
Figure 4 - Mechanism of impaired opsonisation in SLE (adapted from (Prechl et al., 2016). 
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with TLR-ligand on monocyte-derived DCs than haplotype (HAP) 1 (protective) 
homozygote’s (Raj et al., 2016). 
Among non-HLA genes, the Interferon Regulatory Factor 5 Transportin 3 (IRF5-
TNPO3) region shows the strongest and most consistent association signals with odds 
ratios (ORs) of 2.0 in all populations studied. IRF5 is a transcription factor involved both 
in the type I interferon and the toll-like receptor signalling pathways. In fact, a recent 
study in Hispanics with enriched Native American ancestry revealed IRF5 as the major 
locus in SLE, whereas the HLA association was secondary  (Alarcon-Riquelme et al., 
2016). DNA debris with aberrant methylation, like virus, can activate TLR7, 8 and 9 and 
stimulate intracellular pathways that conclude in IRF5 activation and finally Interferon-I 
secretion (Ouyang et al., 2007). 
This may explain why pathway analysis on the differential genes in SLE revealed 
significant enrichment in interferon signalling and toll-like receptor signalling pathways 
with consequent elevated serum levels of inflammatory cytokines, including IL-17A, 
Interferon-Gamma Induced Protein 10 (IP)-10, bFGF, TNF-α, IL-6, IL-15, Granulocyte 
Macrophage–Colony Stimulating Factor (GM-CSF), IL-1RA, IL-5, and IL-12p70 (Zhu et 
al., 2016). 
 
 
1.3.2.2. Adaptive immune system 
T-Cells 
T cells regulate the adaptive immune response and present themselves with an 
altered function in autoimmunity. 
The mRNA analysis identified new genes related to T cell dysfunction and 
confirmed induction of interferon signature genes; including Oligoadenylate Synthetase 
2 (OAS2) which was showed to be specific to SLE autoimmunity (Bradley, Suarez-
Fueyo, Moss, Kyttaris, & Tsokos, 2015). 
Among highly-expressed and significantly upregulated genes was Interleukin-2 
Receptor subunit Gamma (IL-2RG), encoding CD132, the common subunit of 
receptors for IL-2, -4, -7, -9, -15 and -21 (Bradley et al., 2015). 
Originally identified as the third subunit of the high-affinity IL-2 receptor complex, 
the common γ-chain also acts as a non-redundant receptor subunit for a series of other 
cytokines, collectively known as γ-chain family cytokines. ϒ-chain plays essential role 
in T cell development and differentiation, so that understanding the molecular basis of 
its signalling and regulation is a critical issue in T cell immunology. Unlike most other 
cytokine receptors, the γ-chain receptor is thought to be constitutively expressed and 
limited in its function to the assembly of high-affinity cytokine receptors. Recent studies 
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reported a series of findings that refute γ-chain as a simple housekeeping gene, and 
unveiled it as a new regulatory molecule in activation and differentiation of T-cells. 
Cytokine-independent binding of γ-chain to other cytokine receptor subunits suggested 
a pre-association model of γ-chain with proprietary cytokine receptors. In addition, 
identification of a γ-chain splice isoform revealed expression of Soluble Form of 
Gamma Chain (Sγc). Sγc directly interacted with surface IL-2R subunit Beta (IL2Rβ) to 
suppress IL-2 signalling and to promote pro-inflammatory Th17 cell differentiation. As a 
result, endogenously produced Sγc exacerbated autoimmune inflammatory disease, 
while the removal of endogenous Sγc significantly ameliorated disease outcome. 
These data provide new insights into the role of both membrane and soluble γ-chain in 
cytokine signalling, and open new venues to interfere and modulate γ-chain signalling 
during immune activation. These unexpected discoveries further underscore the 
perspective that γ-chain biology remains a largely uncharted territory that invites further 
exploration (Waickman et al., 2016). Figure 5 explains this activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recently, a defined subset of T helper cells, Th9 cells has been identified by the 
potent production of IL-9. The critical role of IL-9 in promoting cellular and humoral 
immune responses makes it an important focus of potential therapeutic interventions. 
IL-9 is a 28-30 Kilo Dalton (kDa) monomeric glycosylated polypeptide belonging to the 
IL-7/IL-9 family of proteins that bind to a composite receptor consisting of the private 
receptor IL-9R and IL2RG (Ciccia et al., 2016). 
Figure 5 - Th17 activation via Syc (adapted from (Waickman, Park, & Park, 2016). 
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B-Cells 
B-Cell survival is also crucial in SLE disease. B-Cell activating Factor (BAFF) is a 
cytokine critical for development and proper selection of B cells, and the targeting of 
BAFF has emerged as a successful treatment strategy for SLE (Hahn, 2013). Previous 
reports have suggested that BAFF expression is directly induced by type I IFNs, but the 
precise mechanism for this remains unknown. In fact, it seems that IRFs control the 
expression of BAFF. IRF1 and IRF2 were identified as positive regulators of BAFF 
transcription and IRF4 and IRF8 as potent repressors. These data suggest that type I 
IFN blockade in SLE patients will lead to downregulation of BAFF and a consequential 
reduction of autoreactive B cell clones and autoantibodies (Sjostrand et al., 2016). 
There is a progressive selection against ANA+ B cells as they mature from 
transitional to naïve to CD27+IgD- and CD27+IgD+ memory cells in both healthy 
subjects and SLE patients; however, SLE patients failed to anergize ANA+ naïve B 
cells to the same extent as healthy individuals. It has also been shown that anergy 
induction is restored in SLE patients treated with belimumab, an inhibitor of BAFF 
(Malkiel et al., 2016). 
In summary, for individual patients a unique profound combination of genetic 
factors modulating innate and adaptive immune responses is necessary to induce SLE 
(Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.3. Environmental factors and Immune Response 
 
Various environmental exposures have been implicated in the induction, 
acceleration or promotion of flares in SLE. Nevertheless, there is no definitive data 
Figure 6 - Genetic influence in SLE susceptibility 
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quantifying the relative contributions of these environmental risk factors to disease 
development, onset or flare. 
 
Among the environmental agents studied in SLE (M. Y. Choi, Barber, Barber, 
Clarke, & Fritzler, 2016), the followings are described: 
- Diet and microbiota. 
- Pesticides, chemical and industrial exposures. 
- Cigarette smoking, alcohol consumption. 
- Drugs and vaccines. 
- Ultraviolet radiation. 
 
Diet and microbiota 
The capacity of the intestinal microbiota to shape immune responses outside the 
intestine will be highlighted with examples from one potent immunomodulatory species; 
the unculturable, Gram-positive, spore-forming segmented filamentous bacteria, which 
are influenced by a single micronutrient, vitamin A. These bacteria support the 
development of autoimmune arthritis. In this model, the immunologic phenotypes 
induced by these microorganisms have been linked to excessive Th17 cell responses. 
However, cellular and molecular mechanisms by which intestinal commensals 
influence autoimmune responses at distal sites remain poorly understood.  
In some instances, progress has been made in defining specific molecules that 
mediate immunomodulatory effects. Oral administration of the capsular polysaccharide 
A of the human gut commensal Bacteroides fragilis protects against experimental 
autoimmune encephalomyelitis in mice, via conversion of naïve CD4+ T cells into IL-10-
producing Treg cells.  
 
The evidence that the intestinal microbiota is involved in the development of SLE 
is less clear than for other autoimmune diseases. More recent discoveries of an 
important role for TLR7/9 in the pathogenesis of lupus suggest that bacterial or viral 
commensal triggers might also contribute to SLE pathogenesis.  
 
In addition, several dietary manipulations can alter the course of SLE, which may 
be partly mediated by effects on the gut microbiota. Dietary interventions or factors, 
such as polyunsaturated fatty acids, vitamins A, D, and E, and phytoestrogens also 
lead to improved outcome in animal models of SLE, mostly via reduction in proteinuria 
and glomerulonephritis (Vieira, Pagovich, & Kriegel, 2014). 
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On the other hand, the gut microbiota interacts not only with the host but also 
with other organisms and environmental factors. Exogenous viruses and the virome – 
the genomes of all the viruses that inhabit a host – are interacting with the gut 
microbiota. The common “IFN-α signature” in the peripheral blood of SLE patients 
suggests a potential viral trigger of flares. While exogenous viruses have been 
implicated as potential contributors (e.g. Epstein-Barr virus), a chronic trigger within the 
gastrointestinal virome or endogenous retroviruses seems at least as likely, especially 
since retroelements have been shown to drive autoimmunity (Vieira et al., 2014). 
 
Pesticides, chemical and industrial exposures 
Very large, population-based studies reported increased SLE patients death or 
hospitalization in association with high level of silica and other ambiental toxics, 
including mining machine operators, miners and quarry workers, other construction 
workers, glass ceramic and tile workers and chimney sweepers (Parks & De Roos, 
2014). 
Data on pesticides are inconsistent and no specific pesticide or product has been 
identified as a likely causative agent. The most convincing data on specific pesticides 
come from animal studies of organochlorine insecticides; the fact that most of these 
pesticides are banned or highly restricted diminishes the opportunities for continued 
research of these compounds (Parks & De Roos, 2014). 
Mineral oils are broadly classified mixtures of alkanes and cyclic paraffins, 
typically by-products of petroleum distillation or production from crude oil. Mineral oils 
have diverse industrial pesticides, chemical and industrial exposures related to SLE 
(Parks & De Roos, 2014).  
Studies have shown elevated risk of SLE associated with self-reported exposure 
to mercury. Endotoxins are another important class of immune adjuvants, present in 
organic dusts across a variety of industries. An association with SLE is suggested by 
one large study showing SLE mortality was associated with work as a textile machine 
operator (Parks & De Roos, 2014). 
 
Cigarette smoking, alcohol consumption 
It is well known that current smokers have more serious cutaneous 
manifestations than former or never smokers.  It is also likely that smoking decreases 
the efficacy of antimalarials in patients with cutaneous lupus erythematosus (Takvorian, 
Merola, & Costenbader, 2014). 
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Smoking has also been linked with more severe SLE with larger organ system 
involvement. Among patients with lupus nephritis, those who smoked had accelerated 
development of end-stage renal disease. Smoking is also associated with higher odds 
of thrombotic events and avascular necrosis (Takvorian et al., 2014). 
On the other hand, alcohol consumption in moderate doses may have a 
protective effect against the development of SLE, although this is still debated 
(Takvorian et al., 2014). 
 
 
Drugs and vaccines 
Drug-induced SLE is also a recognized entity. However, drug induced SLE is 
usually a mild disease, recovering after drugs withdraw. Despite this information, some 
patients can develop severe lupus. Many drugs have been proposed but only few were 
definitively associated with SLE. Table 9, summarizes this information (Araujo-
Fernandez et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9 – Drugs that can induce SLE (adapted from (Araujo-Fernandez, Ahijon-Lana, & 
Isenberg, 2014). 
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The vaccines-autoimmunity interplay is very similar to the established association 
between infections and autoimmunity. Infectious agents can cause or trigger 
autoimmunity through several mechanisms such as molecular mimicry, polyclonal 
activation, bystander activation and the presence of superantigens. Vaccines, as well 
as infections, activate immune-mediated mechanisms that can induce protective 
immunity. SLE induced by vaccination is not very well recognized and many vaccines 
are recommended to overpass the risk of immunosuppressive therapy. Immune 
Thrombocytopenia (ITP) is the most studied model and most probably related to 
vaccination (Rinaldi, Perricone, Ortega-Hernandez, Perricone, & Shoenfeld, 2014). 
 
 
Ultraviolet radiation 
While the link between Ultraviolet (UV) radiation exposure and SLE exacerbation 
is more firmly well established, only few studies suggest an association between UV 
radiation and the development of incident SLE. Given that photosensitivity due to SLE 
could be present for several years before diagnosis, this association may be due to 
reverse causation. 
One of the major unanswered questions related to a potential role of UV radiation 
in the development of SLE is when the relevant susceptibility window for UV-B 
exposure happens: in utero, at birth, in childhood, adolescence or adulthood. It is also 
not known whether UV-B exposure acts as an instantaneous hazard, triggering SLE 
onset very soon after exposure, or whether SLE risk is more related to cumulative 
lifetime exposure. Accurate assessment and quantification of individual exposure to UV 
radiation is critical for understanding its potential role in the etiology of SLE. However, 
studies to date have largely relied on subject recall or occupational categories to 
quantify past solar UV radiation exposure (Barbhaiya & Costenbader, 2014). 
On the other hand, Vitamin D, mainly synthetized after sun exposure, will be one 
of the main important environmental factors to SLE susceptibility and severity. Thus, 
this is a paradox. Vitamin D will be addressed later because is one of the main links 
between genetic and environment. 
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1.4. Vitamin D 
1.4.1. The Physiology of Vitamin D  
Vitamin D is unique among vitamins, since it works as a hormone and can be 
synthesized on the skin, as a result of exposure to sunlight. It is well known the Vitamin 
D role on the phosphorus and calcium metabolism regulation, ensuring the normal 
bone mineralization, among other functions (Alves et al., 2013). This hormone is 
responsible for the maintenance of calcium serum levels by promoting calcium and 
phosphorus absorption from the intestine and calcium bone reabsorption ("Declaração 
Portuguesa da Vitamina D," 2009). 
Vitamin D is acquired both through nutritional means (10-20%) and by the 
cutaneous synthesis under the action of sunlight. Dietary sources of Vitamin D are 
scarce, but the main ones are fish oils and fortified food products (dairy and bread 
products) that exist in some countries (USA and Northern Europe). In Portugal, several 
vitamin supplements containing Vitamin D exist in the market. However, the main 
source of Vitamin D results from the cutaneous synthesis after sun exposure and is 
dependent on various factors such as the geographical area latitude, season, time of 
day, the body surface exposed to the sun and exposure duration, use of sunscreens, 
skin pigmentation, obesity and age ("Declaração Portuguesa da Vitamina D," 2009). 
Vitamin D3 or cholecalciferol, after formation in the skin, and Vitamin D2 or D3, from 
dietary sources, are hydroxylated in the liver, resulting in the formation of 25-
hydroxyvitamin D or 25(OH)D, the main circulating form. 25(OH)D subsequently 
undergoes hydroxylation in the kidney to generate the biologically active, 
dihydroxylated form of Vitamin D, calcitriol or 1,25(OH)2D, which acts through specific 
Vitamin D receptors to regulate not only calcium metabolism, but also differentiation 
and division of several cell types (Mithal et al., 2009). The identification of Vitamin D 
receptors in immune system cells and the discovery that DCs can produce the 
metabolically active form of Vitamin D have led to the suggestion that Vitamin D is an 
immune modulator (Carvalho et al., 2015b). Recent evidence correlate insufficient 
Vitamin D levels with an increased risk of developing other non-bone-related disorders: 
cardiovascular diseases, hypertension, malignant neoplasia, type I diabetes mellitus, 
MS, dementia, RA and infectious disease (Alves et al., 2013; Cutolo, 2009; 
"Declaração Portuguesa da Vitamina D," 2009; Pludowski et al., 2013; L. Silva et al., 
2010). 
The high prevalence of inadequate Vitamin D is nowadays seen as a public 
health problem affecting several countries in Europe and the USA, particularly those at 
risk for developing osteoporosis and its consequences ("Declaração Portuguesa da 
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Vitamina D," 2009). In chronic Vitamin D deficiency, secondary hyperparathyroidism 
occurs, with a consequent increase in bone turnover, loss of bone mass and increased 
risk of low impact fractures. This vitamin has also relevant extra-osseous functions, 
namely in muscle function and balance, and activation of receptors located in these 
tissues allows the improvement of these parameters ("Declaração Portuguesa da 
Vitamina D," 2009; L. Silva et al., 2010). 
 
 
1.4.2. Vitamin D deficiency 
The environmental, hormonal, genetic and nutritional conditions will influence the 
serum levels of Vitamin D. Vitamin D deficiency screening is accomplished through 
measurement of 25(OH)D, which is the best index for assessing Vitamin D store in the 
body ("Declaração Portuguesa da Vitamina D," 2009), due to its greater half-life 
comparing with the metabolically active form. Routinely only at-risk populations should 
be screened, including the elderly, institutionalized, pregnant women and post-
menopausal women (increased risk of fractures) (Alves et al., 2013). 
Much debate has taken place over the definition of Vitamin D deficiency. Most 
agree that a 25(OH)D concentration <50 nmol/L, or 20 ng/mL, is an indication of 
Vitamin D deficiency, whereas a 25(OH)D concentration of 51–74 nmol/L, or 21–29 
ng/mL, is considered to indicate insufficiency; concentrations >75 nmol/L, or 30 ng/mL, 
are considered to be adequate (Dawson-Hughes et al., 2005; Holick, 2007, 2009; 
Souberbielle et al., 2010). The optimal serum 25(OH)D levels are those for which 
calcium absorption is optimized, Parathyroid Hormone (PTH) levels are reduced and 
the greatest benefit to the bone and muscle function are obtained. Currently levels 
above 75 nmol/L (30 ng/mL) are recommended. 
 
Several studies have described inadequacy of Vitamin D levels all over the 
Europe, although the Vitamin D status within different European countries shows a high 
variation (Cashman et al., 2016; Pludowski et al., 2014; Quraishi, Camargo, & Manson, 
2016). 25(OH)D levels lower than 25 nmol/L were found in 2% to 30% of adults, but 
this percentage may increase to 75% or more in older individuals in institutions. An 
international study, the European Action on Nutrition and Health-Survey on 
independent older subjects showed mean serum 25(OH)D levels of 20 to 30 nmol/L in 
Southern European centers and 40 to 50 nmol/L in Northern Europe. The strong 
positive correlation between serum 25(OH)D and latitude in this survey was much 
unexpected because UV irradiation is more effective in Southern than in Northern 
European countries (McKenna, 1992; Mithal et al., 2009; van der Wielen et al., 1995). 
INTRODUCTION 
 
34 
 
This inadequacy was also observed for younger subjects (Braegger et al., 2013; 
Gonzalez-Gross et al., 2012; Pludowski et al., 2014) and for pregnant women 
(Eggemoen et al., 2016; O'Riordan, Kiely, Higgins, & Cashman, 2008). 
In fact, when Northern European countries are considered, mean values of 
25(OH)D range from 45±35 nmol/L in men to 47±34nmol/L in women in studies from 
Finland (Lamberg-Allardt, Outila, Karkkainen, Rita, & Valsta, 2001), and are dependent 
on season (82.5±34.1 nmol/L in July-August vs 36.3±30.5 nmol/L in  January-February) 
(p<0.001) (Savolainen, Maenpaa, Alhava, & Kettunen, 1980). In Danish population, 
mean values are about 55.5 nmol/L (Christiansen, Christensen, McNair, Nielsen, & 
Madsbad, 1982). In the same way, Norwegians have constant values during winter (50-
55 nmol/L), being different from July to September (p<0.0006) (Vik, Try, & Stromme, 
1980). Regarding different age groups, younger adults have mean values of 63.0 
nmol/L (30.3-95.5), while active elderly living at home have lower levels (46.8 nmol/L 
(18.4-110.6)) (Aksnes, Rodland, Odegaard, Bakke, & Aarskog, 1989). In United 
Kingdom, a study has demonstrated that 29% of the population was 25(OH)D 
profoundly deficient (<25 nmol/L) and 32% insufficient (25-50 nmol/L) (Hayden, Sandle, 
& Berry, 2015). In Ireland, this issue was subject of further studies, which have 
demonstrated that 40 to 51% of the population has 25(OH)D insufficiency (<50 nmol/L) 
(Cashman et al., 2013; T. Hill et al., 2005; Lardner, Fitzgibbon, Wilson, Griffin, & 
Mulkerrin, 2011), reaching 58% in winter (O'Sullivan, Nic Suibhne, Cox, Healy, & 
O'Morain, 2008). Also, 7 to 10% has 25(OH)D deficiency (<25 nmol/L) (T. R. Hill et al., 
2006; Lardner et al., 2011) and in the elderly this percentage rises to 79% (McKenna, 
Freaney, Meade, & Muldowney, 1985). Overall, 75.6% of the Irish population had 
inadequate levels of 25(OH)D (<75 nmol/L) (Cashman et al., 2013). 
Considering Southern Europe, some groups are interested in learning more 
about the prevalence of the 25(OH)D in those populations. Three studies from Italy 
demonstrated hypovitaminosis D. In postmenopausal women (n=570; 41-80 years) 
mean values of serum 25(OH)D were 18.3±8.3 ng/mL (45.75±20.75 nmol/L) and 28% 
of the subjects presented hypovitaminosis D (<30 nmol/L), with a significant (p<0.001) 
seasonal variation (Bettica, Bevilacqua, Vago, & Norbiato, 1999). This evidence was 
confirmed few years later in a larger cohort (n=700; 60-80 years), where values of 
25(OH)D lower than 5 ng/mL (12.5 nmol/L) were found in 27% of the women and lower 
than 12 ng/mL (30 nmol/L) in 76% (Isaia et al., 2003). In an Italian Single-Center Study, 
with 478 subjects with diagnosis of acute myocardial infarction, it was possible to 
observe a high prevalence of Vitamin D deficiency among these subjects. Mean serum 
25(OH)D levels was 14.5 (7.8-22.7) ng/mL [36.25 (19.5-56.75) nmol/L], with 324 
(67.78%) of the subjects presenting deficiency (≤20 ng/mL) and 107 (22.38%) 
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insufficiency (21-30 ng/mL) (Aleksova et al., 2015). Mean serum 25(OH)D was about 
25 nmol/L in breastfed children and about 30 nmol/L in their mothers in Greece (Challa 
et al., 2005). In Greek adolescents, serum 25(OH)D was lower than 25 nmol/L in 47% 
during winter (Lapatsanis et al., 2005). Very low levels were also found in Spanish 
elderly and institutionalized persons, confirming the prevalence of poor Vitamin D 
status in this social group (Gonzalez-Clemente et al., 1999; Larrosa et al., 2001; Perez-
Llamas et al., 2008; Quesada, Jans, Benito, Jimenez, & Bouillon, 1989; Vaqueiro, 
Bare, Anton, Andreu, & Gimeno, 2006), as well as in postmenopausal women (Aguado 
et al., 2000; Mezquita-Raya et al., 2001; Quesada-Gomez et al., 2013) and children 
(Docio et al., 1998). 
Studies in other European countries were also published. The SUVIMAX study in 
French adult men and women between 35 and 65 years showed a mean serum 
25(OH)D of 43 nmol/L in the North and 94 nmol/L in the Southwest of France (Chapuy 
et al., 1997). In this study, the correlation between serum 25(OH)D and latitude was 
negative as expected. In the Netherlands, the Longitudinal Ageing Study in Amsterdam 
showed a serum 25(OH)D lower than 25 nmol/L in 8% of men and 14% of women, and 
lower than 50 nmol/L in 45% of men and 56% of women (Snijder et al., 2005). Similar 
data were found in the population-based Hoorn study (van Dam et al., 2007) and the 
Swiss MONICA project (Burnand et al., 1992). A study of Swiss elderly persons living 
in nursing homes observed that 90% of the elderly women had serum 25(OH)D levels 
below 50 nmol/L compared to 57% in non-institutionalized elderly women (Krieg, 
Cornuz, Jacquet, Thiebaud, & Burckhardt, 1998). In Belgium, the mean serum 
25(OH)D levels of 126 subjects (21-65 years) was 19.4±7.7 ng/mL, where 34% of the 
population exhibited insufficiency (<15 ng/mL, or 37.5 nmol/L), predominantly males 
(MacFarlane et al., 2004). 
 
In Portugal, the prevalence of inadequate Vitamin D levels is not known yet, since 
there are no epidemiological studies of this prevalence in a national healthy adult 
population, but it is expected that the Portuguese population follows the same trend of 
other European countries. However, several studies in specific hospital populations, 
and pediatric healthy population, have been published. 
In 2005, 1456 adult women (18-92 years) from Porto were studied. Data about 
dietary habits were obtained, through a semi-quantitative questionnaire, validated for 
the Portuguese population, and compared with the daily reference values 
recommended by the European Union. The proportion of women with calcium ingestion 
below the recommendations varied from 41% (<30 years) to 58.1% (≥70 years); 
ingestion of inadequate values of Vitamin D varied from 70,5% (<30 years) to 96% (60-
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69 years), showing a trend to increase linearly with age (p<0.001) (Lucas, Costa, & 
Barros, 2005). 
Few years later (2009), a study in a healthy pediatric population from Porto was 
published. A group of 45 children (33F, 12M; 2.5-16 years) was evaluated in winter and 
spring of 2007/2008. None of them was had been on supplementation after the first 
year of life. Values above 100 nmol/L were considered optimal, 75-100 nmol/L 
sufficient, 50-74 nmol/L relative insufficient and <50 nmol/L deficient. Nine (20%) had 
optimal levels and 24 (53%) had sufficient levels, while 6 (13%) and 6 (13%) presented 
relative insufficiency and deficiency, respectively. Thus, a lack of Vitamin D was found 
in 26% of the studied population during the months with less sunlight. According to 
these cut off values, 80% of the children did not achieve optimal levels (Monteiro, 
2009). 
In the same year, 233 prevalent hemodialysis (HD) patients (107F, 116M; 27% 
diabetics and 32% hypertensive; mean age=62.7±15.3 years; mean HD 
time=42.9±39.3 months) from the Hospital of Vila Franca de Xira were investigated. 
Almost half (47%) of the patients were taking active forms of Vitamin D. Deficiency was 
considered for values below 15 ng/mL, insufficiency for values below 30 ng/mL and 
normal values above 30 ng/mL. Serum levels of 25(OH)D were found to be low 
(21.6±12.2 ng/mL) and negatively correlated with age, diabetes mellitus, C-reactive 
protein and vascular calcifications; levels of 25(OH)D were positively correlated with 
1,25(OH)2D3 and albumin. These results suggested that lower levels of 25(OH)D are a 
cardiovascular risk marker in HD patients (Matias et al., 2009).  
Since Vitamin D deficiency is highly prevalent in chronic kidney disease (due to 
inhibition of renal 1α-hydroxylase), 158 HD patients (84F, 74M; mean age=62.8±14.8 
years), 25% with diabetes and 34% with hypertension, with a 1-year follow-up, were 
studied in Hospital of Vila Franca de Xira. Baseline 25(OH)D and 1,25(OH)2D levels 
were measured twice (end of winter and of summer, respectively) and at the end of the 
study, after 6 months of supplementation. At baseline, both 25(OH)D and 1,25(OH)2D 
serum levels were low and positively correlated (p<0.001). The authors observed that 
80% of the patients had 25(OH)D below sufficiency values (<30 ng/mL), and there was 
an increase in serum 25(OH)D and 1,25(OH)2D after supplementation. Oral 
cholecalciferol supplementation in HD patients seems to be an easy and cost-effective 
therapeutic measure; it allows reduction of Vitamin D deficiency, a better control of 
mineral metabolism with less use of active Vitamin D, attenuation of inflammation, and 
possibly improvement of cardiac dysfunction (Matias et al., 2010). 
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In 42 adult individuals (39F, 3M; mean age=64±10.2 years (35-85 years)) 
admitted to the Orthopedic Service of Hospital de São João (Porto) with wrist fragility 
fracture, serum 25(OH)D levels were quantified between July and October 2009. 
25(OH)D mean value was 25.6 ng/mL. Only 26.2% of these patients had levels above 
30 ng/mL, whilst 45.2% had insufficiency (20-29 ng/mL), 23.8% had deficiency (8-20 
ng/mL) and 4.8% had severe deficiency (<8 ng/mL). The values are similar to those 
registered in the Nordic countries. The findings reveal worrying factors that should alert 
to specificities of the Portuguese elderly: high rate of hyperparathyroidism, nutritional 
deficits reported to their youth, and high rate of untreated early menopause (L. Silva et 
al., 2010). 
It has been described that low levels of Vitamin D are associated with CVD, 
including myocardial infarction. In a case-study, a male patient with 70 years and 
myocardial infarction was observed. He had vitiligo diagnosed for 20 years and clinical 
instructions to avoid sun exposure, which led to hypovitaminosis D. Serum 25(OH)D 
levels were 12 ng/mL (optimal, 30-80 ng/mL). Thus, an association between 
myocardial infarction, hypovitaminosis D and vitiligo was established (Nunes & Martins, 
2010). 
In another pediatric study, 73 children (37F, 36M), aged 12 months to 17 years, 
from the outpatient clinic of Centro Hospitalar do Porto, were studied. The study 
occurred between March 2008 and July 2010. The children were divided in pre-school 
age (12 months to 5 years; 23.3% (17/73)) and school age (6 to 17 years; 76.7% 
(56/73)). Normal 25(OH)D levels (>75 nmol/L) were observed in 17.8% of the children 
(11% with optimal values, >100nmol/L; and 6.8% with sufficient values, 75-100 
nmol/L). On the other hand, 82.2% presented lack of Vitamin D (42.5% with relative 
insufficiency, 50-74 nmol/L; and 39.7% with deficiency, <50 nmol/L). Gender, 
residential area, BMI and season were not related to 25(OH)D levels. It was observed 
that children in school age had higher Vitamin D deficiency (p=0.013), thus establishing 
a correlation with age (Rocha, 2012). 
Another study, a cohort of 122 healthy children and adolescents (5-18 years) 
from Porto evaluated in the pediatric outpatient clinic during the winter and spring of 
2011/2012. Vitamin D status was observed to be of insufficiency (≥20 and <30 ng/mL) 
in 92.5% of the cases, from which 47.8% presented deficiency (≥10 and <20 ng/mL) 
and 6% severe deficiency (<10 ng/mL). Only 7.5% of the sample had an adequate 
status (≥30 ng/mL) (Ferreira et al., 2012). 
In a group of 123 patients (64F, 59M; mean age 71±17.2 years) admitted to an 
internal medicine ward in Coimbra, it was observed a high prevalence (67.5%) of 
hypovitaminosis D (<20 ng/mL), 25.2% of which had moderate hypovitaminosis D (10-
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20 ng/mL). Differences between ages were found: patients with severe hypovitaminosis 
D (<10 ng/mL) were older (p=0.027) (Santiago et al., 2012). 
From the outpatient clinic of Rheumatology in Hospital de Ponte de Lima, a group 
of 39 patients with Juvenile Idiopathic Arthritis (28F, 11M; mean age=17.8 years (4-28 
years); disease duration=9.5±5.1 years) was studied. Serum 25(OH)D levels between 
20 and 30 ng/mL were considered as insufficiency and levels below 20 ng/mL as 
deficiency. Low levels of 25(OH)D were observed in 74.4% (29/39) of the patients, 
46.2% (18/39) with insufficiency and 28.2% (11/39) with deficiency (Peixoto, Teixeira, 
Costa, & Araújo, 2013). 
Between September and December 2010, 25(OH)D levels were measured in 
2071 patients (61.3% F, 38.7% M; mean age=54 years) at Hospitais Universitários de 
Coimbra laboratory. The majority of the requisitions were from the internal medicine 
ward (38.2%) and endocrinology service (21.3%). Values below 30 ng/mL were 
observed in 88.1% of the evaluated patients, and 65% of whole cohort had values 
below 20 ng/mL (mean 11.3 ng/mL). PTH levels were increased in 55.3% of the 
requests (mean=221.3 pg/mL). The findings showed a high prevalence of Vitamin D 
deficiency (Alves et al., 2013). 
In Lisbon, from 2012 to January 2014, plasma samples from 518 HIV-infected 
patients (197F, 321M; mean age 46±11 years) were collected to determine 25(OH)D 
levels. Levels below 20 ng/mL were considered as deficiency, 20-30 ng/mL as 
insufficiency and above 30 ng/mL as optimal. The 25(OH)D levels median was 20 
ng/mL (4.1 to 99.7 ng/mL) with differences between winter (median 16.7 ng/mL) and 
summer (median 24.9 ng/mL) (p<0.0001). Levels below 30 ng/mL were present in 
80.1% of the patients (30.9% insufficiency and 49.2% deficiency). An association 
between antiretroviral therapy regimens with Efavirenz and low levels of 25(OH)D was 
found (Boura et al., 2014). 
In 2015, at Guimarães hospital, 76 patients (55F, 21M; mean age 33.8±10.2 
years), with inflammatory bowel disease, were enrolled, 19 of which with ulcerative 
colitis and 57 with Crohn’s disease. Mean serum 25(OH)D levels were low (26.0±10.0 
ng/mL), but in Crohn’s patient’s levels were lower than in those with ulcerative colitis 
(24.6±8.0 ng/mL vs. 30.0±12.5 ng/mL; p=0.032). Sixty-eight percent of all patients had 
insufficient levels of Vitamin D (≥20 ng/mL and <30 ng/mL) and Vitamin D deficiency 
(<20 ng/mL) was found in 30% of the patients (Castro et al., 2015). 
In a hospital-based population study from Braga, 5439 25(OH)D measurements 
were performed between 6 June 2012 and 13 November 2014, corresponding to 3257 
different individuals. Women were the majority fraction, 55% (2.992/5439), with median 
age of 64 years. Deficiency (≤20 ng/mL) was observed in 60% of the cases, 
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insufficiency (21-29 ng/mL) in 20.7% and only 18.9% had sufficient levels (≥30 ng/mL). 
It was observed a negative correlation between age and Vitamin D levels (p<0.001; r=-
0.054) and no differences between genders were observed. Vitamin D levels were 
variable throughout the year (p<0.001): higher in summer (July to September; 14-31 
ng/mL), followed by autumn (October to December; 11-27 ng/mL), spring (April to 
June; 10-25 ng/mL) and winter (January to March; 7-20 ng/mL). During summer, 
sufficient levels of Vitamin D were present in 27.8% of the cases, while this was 
observed in only 9.2% during winter (Santos, Fernandes, & Garcia, 2015). 
 
 
1.4.3. Vitamin D and Autoimmune Diseases 
The importance of Vitamin D in several autoimmune disorders has been reported 
and Vitamin D deficiency has been associated with the pathogenesis and severity of 
MS, RA, SSc and SLE, among others (Cutolo, 2009). In SLE patients, serum Vitamin D 
levels seem to correlate inversely with SLEDAI scores (Mandal et al., 2014). 
It has been found that one of the consequences of 1,25(OH)2D3 on the immune 
response is the stimulation of innate immunity and suppression of adaptive immunity 
(Hart & Gorman, 2013). Studies on the immunomodulatory properties of 1,25(OH)2D3 
confirmed the inhibition of Th1 cell development via an inhibition of IL-12 production by 
Antigen Presenting Cells (APCs). Further work documented its ability to drive CD4+T 
lymphocytes to a Th2 phenotype with a reduction in Th1 type activity (Bansal et al., 
2012), by increasing the production of IL-5 and IL-10. Vitamin D, indirectly, reduces the 
production of IFNγ (Guillot, Semerano, Saidenberg-Kermanac'h, Falgarone, & Boissier, 
2010). It also affects B cells causing induction of B cell apoptosis, inhibition of B cell 
proliferation, and generation of memory B cells, plasma cell differentiation and 
immunoglobulin production/secretion (Antico, Tampoia, Tozzoli, & Bizzaro, 2012; 
Baeke, Takiishi, Korf, Gysemans, & Mathieu, 2010; Guillot et al., 2010; D. Kamen & 
Aranow, 2008). In human epidermal and dermal cells, it was demonstrated that 
1,25(OH)2D3 modulates regulatory T cell numbers and their suppressive abilities 
through DCs (Hart & Gorman, 2013). The effect of Vitamin D on DCs include the 
differentiation of monocytes into immature dendritic cells, the maturation of dendritic 
cells and dendritic cell survival (D. Kamen & Aranow, 2008).  
Local Vitamin D metabolism allows immune cells to modulate immune responses 
in an independent way when regulation is required, but the optimization of this 
autocrine and/or paracrine circuit is strictly dependent of the circulating 25(OH)D 
availability. The levels of circulating 25(OH)D needed to meet the requirements of 
Vitamin D sufficiency are still a matter of debate, especially in light of the non-classical 
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effects of Vitamin D (Baeke et al., 2010). These evidences justify the motivation to 
consider Vitamin D supplementation as an immunomodulatory intervention in SLE.  
The FOXP3 gene has a VDRE in its promoter region, being important for its 
cellular expression (Kang et al., 2012). The immunomodulatory effect assessed by the 
imbalance of FoxP3+/IL-17A CD4+ T lymphocytes is widely recognized  (Astry, 
Venkatesha, & Moudgil, 2015). 
 
 
1.5. Vitamin D and SLE: the evidence 
1.5.1. Vitamin D and SLE susceptibility 
Vitamin D insufficiency may be an important factor in SLE susceptibility during 
early life, based on Vitamin D effect in autorreactive T-lymphocytes central deletion 
(Cocco et al., 2012; Ramagopalan et al., 2009). We can look for autoimmune 
susceptibility as an “early-life” condition in which Vitamin D insufficiency is also a 
determining factor for an autorreactive profile. VDREs have been found in the promoter 
region of the MS associated allele HLA-DRB1*15:01 (Cocco et al., 2012; Ramagopalan 
et al., 2009), suggesting that with low Vitamin D availability, VDREs are incapable of 
inducing DRB1*15:01 expression, allowing early life autorreactive T-cells to escape 
central thymic deletion. These findings have been found in MS; in SLE, no data is 
available. 
We thus postulate that the preventive role of Vitamin D in SLE (and other 
autoimmune diseases) could be limited in time, during the development of the immune 
system. Later on, its role should be essentially a modulating one. 
With these ideas in mind, retrospective genetic susceptibility studies, that do not 
have controlled Vitamin D levels in childhood, may yeld no valid results. The 
susceptibility studies related with polymorphisms of Vitamin D receptor are such an 
example, with different susceptibility profiles in different populations, but without 
controlled Vitamin D levels in the studied population (Mao & Huang, 2014; Xiong, He, 
Zeng, Zhang, & Hu, 2014). In this chapter, we will review the evidence of Vitamin D 
effect on SLE. 
Usually, patients with established SLE lack Vitamin D. The reduced sun 
exposure, the use of sunscreens, the gut malabsorption (example: secondary to drugs 
such as corticosteroids), among others, are all significant factors for this steroid 
hormone insufficiency (Holick, 2012). However, sun exposure, the most important 
factor for Vitamin D precursor synthesis at the skin level, is also one of the strong 
activators of SLE flares. This is thought to result from the UV wavelengths of sunlight 
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potentiating the stimulator of interferon genes (STING)-dependent activation of the 
IRF3 in response to cytosolic DNA and cyclic dinucleotides in keratinocytes and other 
human cells (Kemp, Lindsey-Boltz, & Sancar, 2015). 
This paradoxical phenomenon, being well recognized, is also ignored in the 
supplementation strategies, which are based on the general population guidelines. SLE 
patients need treatment strategies based on serum levels of 25(OH)D and not standard 
supplementation strategies. Serum levels of 30 ng/ml are validated for metabolic bone 
disease but not for immunological effects (Antico et al., 2012). 
 
1.5.2. The emerging role of Vitamin D in immunomodulation 
 Vitamin D has a nuclear receptor, the VDR, which is present in all immune 
system cells. Many key genes involved in immune regulation have VDREs (Kang et al., 
2012), implying a Vitamin D effect in immune modulation. This Vitamin exercises its 
role, both, at the innate immunity and adaptive immunity levels. During immune 
response, it modulates the activation of DCs and their ability to present antigens, and 
polarizes the adaptive immune response to a Th2 response (Holick, 2007). Finally, it is 
essential for the expression of the FoxP3, via VDRE present in the promoter region of 
its gene and therefore essential to the normal expression of regulatory T cells (Kang et 
al., 2012). 
In view of these properties, an inflammatory profile in patients with Vitamin D 
deficiency must be considered. However, the benefit and efficacy of Vitamin D 
supplementation are very heterogeneous among patients and diseases. Many 
questions about dosage and patients’ optimization are still in debate. 
 
1.5.2.1. Vitamin D and APC in SLE 
Lerman et al. studied the ability of 1,25(OH)2D3 to affect human monocyte 
phenotype. This phenotype was assessed by incubating cells with sera from 15 
patients with SLE and from 5 healthy volunteers. Addition of 1,25(OH)2D3 resulted in 
significant reductions in the expression of MHC Class II, CD40, and CD86 and 
increases in expression of CD14 in both types of sera. Overall, 1,25(OH)2D3 limited 
human APC activation via IFNα-induced and independent mechanisms. 1,25(OH)2D3 
inhibited APC activation by SLE sera, suggesting that it may be possible for 
1,25(OH)2D3 to reduce the immunostimulatory effects of the SLE milieu by interfering 
with the soluble cytokine mediators in the sera of these patients (Lerman, Burnham, & 
Behrens, 2011). 
Ben-Zvi et al. studied 19 SLE patients stratified by 25(OH)D. There were no 
differences between circulating DCs number and phenotype. Monocyte Derived 
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Dendritic Cells (MDDCs) of the patients were normally responsive to the regulatory 
effects of Vitamin D in vitro as evidenced by decreased activation in response to 
Lipopolysaccharide (LPS) stimulation in the presence of 1,25(OH)2D3. Additionally, 
Vitamin D supplementation reduced expression of IFN-α regulated genes by healthy 
donors and SLE MDDCs in response to factors in activating SLE plasma (Ben-Zvi et 
al., 2010). 
Wu HJ et al. showed that “tolerogenic” DCs are a potential cell-based therapy in 
SLE by treating monocyte-derived DCs from SLE patients and healthy subjects with 
combination of 1,25(OH)2D3 and dexamethasone followed by LPS-induced maturation. 
Lupus activated DCs were found to acquire semi-mature phenotype that remained 
maturation-resistant to immunostimulants and was also found to acquire enhancing 
Regulatory-T Cells phenotype (H. J. Wu et al., 2015). 
Finally, Cynthia Aranow et al. published a Randomized Control Trial (RCT) trying 
to prove the effect of Vitamin D supplementation in interferon signature. The studied 
failed the primary outcome (Aranow et al., 2015). 
 
 We learned with Aranow’s RCT that we still do not know the in vivo behaviour of 
this effect on interferon signature and human studies with tolerogenic DCs in SLE are 
not yet available. We also do not know if the effect on APC is identical in the various 
body compartments with different cytokine expression, for example in lupus nephritis, 
which can be the only manifestation of SLE. On the other hand, we do not know the 
role of MHC Class II down-regulation in APC in patients with only positive antinuclear 
antibodies, in serological active quiescent Lupus or during severe flares. It is necessary 
to replicate the effect in vivo and to know in which stage of the disease this adjustment 
brings more benefit. DCs induced tolerance may be essential in the early stages of the 
disease and less important in severe flares. 
 
1.5.2.2. Vitamin D, Regulatory T-Cells and T-Helper 17 Cells 
Terrier et al. showed the safety and efficacy of 25(OH)D high doses 
supplementation on restoration of regulatory and effector T cell balance and B cell 
homeostasis in 24 SLE patients (Terrier et al., 2012). However, several limitations were 
found in this study. The time established for new flares (6 months) is too short to 
evaluate this effect. On the other hand, there is no control group with evaluation of 
regulatory T cells, Th17 cells and IL-17A expression in a healthy population. We only 
know that Vitamin D changes the profile of immune deregulation, but its meaning is 
completely unknown. We also do not know if numerical changes correct functional 
INTRODUCTION 
43 
 
changes (Ohl & Tenbrock, 2015). However, one can say that Vitamin D high doses are 
a safe therapy.  
Viviane de Souza et al., in a small open-label study from Brazil, also found that 
Vitamin D deficiency was more prevalent in patients with SLE and was associated with 
higher levels of IL-6 (de Souza et al., 2014). 
Banica LM et al. showed in vitro that rapamicin and Vitamin D together were able 
to induce regulatory properties in CD4+ T-Cells. However, this sustained effect was 
observed only in the rapamycin group (Banica et al., 2014). 
Piantoni S et al. also showed an enhancement of Treg cells and the production of 
Th2 cytokines after a long-term of monthly treatment with Vitamin D in SLE patients. 
These numeric differences were only significant after 2 years of treatment (Piantoni et 
al., 2015). 
Wahono CS et al. and Drozdenko et al. observed that the effect of Vitamin D 
therapy was mainly on IL-17A cytokine expression and less on regulatory T-Cells 
(Drozdenko, Heine, & Worm, 2014; Wahono et al., 2014). 
In summary, we found a universal trend to Vitamin D immune regulation based 
on regulatory T-Cell properties and IL-17A expression. However, we need controlled 
trials with a large number of SLE patients, controlled methodology, especially functional 
studies with micro-RNA of inducible regulatory T-Cell genes and time dependent 
studies. Maja Vukić et al. made the first trials with this concept. They studied 71 
patients from the VitDmet study (ClinicalTrials.gov Identifier: NCT01479933) and 10 
from VitDbol (ClinicalTrials.gov Identifier: NCT02063334). In an interventional 
prospective study, they correlated the changes in mRNA expression with serum 
25(OH)D levels in primary human cells. In peripheral blood mononuclear cells, direct 
transcriptional effects were observed on selected VDR target genes, such as an up to 
2.1-fold increase, after one day only of supplementation onset. This allows us to infer 
that both long-term and short-term Vitamin D supplementation studies allow monitoring 
of the Vitamin D responsiveness in human individuals and represent a new kind of 
human in vivo investigations  about Vitamin D in humans (Vukic et al., 2015). 
 
 
1.5.3. Vitamin D Inflammation and atherosclerosis 
Vascular protective effects of Vitamin D have been postulated due to modulation 
of inflammatory cytokines. However, the effects of Vitamin D supplementation on 
inflammatory cytokines in trials have been inconsistent. 
Petri’s investigation group studied 200 patients enrolled in the Lupus 
Atherosclerosis Prevention Study and found that 25(OH)D was not associated with any 
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measure of subclinical atherosclerosis. 25(OH)D deficiency was associated with higher 
high sensitivity (hs)CRP at baseline, but did not predict a change in hsCRP over 2 
years (Kiani, Fang, Magder, & Petri, 2013). 
However, in pediatric Lupus patients enrolled in the Atherosclerosis Prevention in 
Pediatric Lupus Erythematosus substudy (Robinson, Tangpricha, Yow, Gurion, 
McComsey, et al., 2014; Robinson, Tangpricha, Yow, Gurion, Schanberg, et al., 2014) 
the same data were not consistent with the adults’ study. They also found that Vitamin 
D deficiency is independently associated with elevated hsCRP, a marker of 
inflammation that predicts cardiovascular disease risk. Although, association is not 
proof of causation and they did not study the impact of Vitamin D supplementation in 
the follow-up of these patients’ hsCRP. By chance, the same study found that Vitamin 
D status is a determinant of atorvastatin effect on carotid intima medial thickening 
progression rate in children with lupus at 3 years, and it was significant. 
Lertratanakul et al. reported a retrospective study from a large international 
inception cohort; they studied the risk of cardiovascular (CV) event incidence. Patients 
in the higher quartiles of 25(OH)D were less likely to have hypertension and 
hyperlipidemia and were more likely to have lower C-reactive protein levels and lower 
SLEDAI 2K scores at baseline when compared with the first quartile. Vitamin D levels 
were not associated with CV event incidence; however, hazard ratios for CV event 
incidence decreased with successively higher quartiles (Lertratanakul et al., 2014). 
Reynolds et al. studied 75 SLE patients in a cross-sectional retrospective study to 
correlate Vitamin D levels with disease and markers of subclinical vascular disease. 
Their results were significant and correlated Vitamin D deficiency with increased aortic 
stiffness in SLE, independent of cardiovascular disease (CVD) risk factors and insulin 
resistance. They concluded that Increased inflammatory disease activity may be the 
mechanism by which Vitamin D deficiency mediates vascular stiffness in this patients’ 
group (Reynolds et al., 2012). Sabio et al. showed the same results in a RCT (Sabio et 
al., 2015). 
Reynolds et al. also made a prospective study with Vitamin D deficient SLE 
patients and described the effectiveness of calcitriol to restore angiogenic capacity of 
SLE myeloid angiogenic cells and to positively modulate the paracrine regulation of 
endothelial nitric oxide synthase (Reynolds et al., 2016). 
Abou-Raya et al. have done a randomized placebo-controlled trial with 206 
patients showing that high dose cholecalciferol was effective in disease activity control 
and in the improvement of hemostatic and inflammatory markers: IL-1, IL-6, IL-18, 
Tumour Necrosis Factor (TNF-α), Von Willebrand factor and fibrinogen (Abou-Raya, 
Abou-Raya, & Helmii, 2013).  
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In essence, there is enough evidence to affirm that Vitamin D deficiency parallels 
hsCRP as an inflammatory biomarker for atherosclerosis and this effect is independent 
of insulin resistance. This observation could be because the effect is more significant 
on endothelium dysfunction rather than an improvement of metabolic syndrome. SLE, 
like RA, is an independent risk factor for accelerated atherosclerosis and Vitamin D 
deficiency may be one modifying risk factor. 
The different data between the adult and pediatric patients are explained by 
different study designs, by the lack of a follow-up on the hsCRP after Vitamin D 
supplementation and by the fact that the adult study screening of the carotid intima 
medial thickening progression rate was not an association study with statins. 
It would be rather important to repeat the analysis of both groups with the statin 
effect and following-up the hsCRP in pediatric patients. 
 
 
1.5.4. Vitamin D resistant state and SLE 
SLE could be a conceptual form of resistance to Vitamin D effect. This resistant 
state has multiple steps including the epigenetic mechanisms (also regulation of 
metabolic pathways), gene regulation in different cell types and Vitamin D receptor 
polymorphisms (the transcriptome). 
The following summarizes the concept of resistance: 
 
1.5.4.1 Epigenetic mechanisms 
Epigenetic mechanisms play a crucial role in regulating gene expression as we 
showed above with the VDRE in non-coding sequences of MHC Class II (Cocco et al., 
2012; Ramagopalan et al., 2009). The main mechanisms involve methylation of DNA 
and covalent modifications of histones by methylation, acetylation, phosphorylation, or 
ubiquitination. Mainly DNA methyltransferases and ten-eleven translocation proteins, 
while a plethora of enzymes, such as histone acetyltransferases, histone deacetylases, 
histone methyltransferases, perform modifications in DNA methylation and histone 
demethylases regulate covalent histone modifications. 
In many diseases, such as cancer, the epigenetic regulatory system is often 
disturbed. Vitamin D interacts with the epigenome on multiple levels. Firstly, critical 
genes in the Vitamin D signalling system, such as those coding for VDR and the 
enzymes 25-hydroxylase (CYP2R1), 1α-hydroxylase (CYP27B1), and 24-hydroxylase 
(CYP24A1) have large 5'-C-phosphate-G-3' (CpG) islands in their promoter regions 
and therefore can be silenced by DNA methylation. Secondly, VDR protein physically 
interacts with coactivator and corepressor proteins, which in turn are in contact with 
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chromatin modifiers, such as histone acetyltransferases, histone deacetylases, histone 
methyltransferases, and histone demethylases, and with chromatin remodelers. 
Thirdly, a number of genes encoding for chromatin modifiers and remodelers, such as 
histone demethylases of the Jumonji C-domain containing proteins and lysine-specific 
demethylase families, are primary targets of VDR and its ligands. Finally, there is 
evidence that certain VDR ligands (1,25-dihydroxyvitamin D3) have DNA demethylating 
effects (Fetahu, Hobaus, & Kallay, 2014).  
 
This is the first resistance mechanism. SLE, like cancer, is a state of DNA 
hypermethylation. The disease itself can mute key enzymes of its metabolism and 
create a state of 25(OH)D deficiency. Conversely, the “DNA demethylating” effect can 
be important to the maintenance of key enzymes and their target genes, maintaining 
immune system homeostasis. Once again, the replacement of cholecalciferol is not 
established and is likely to need very high levels or greater affinity analogues to 
overpass this resistance. This particular field lacks evidence. Other resistance 
mechanism will be addressed in the chapter dedicated to VDR. 
 
 
1.5.4.2 VDR related mechanisms  
Vitamin D acts via binding to an intranuclear receptor, VDR, present in target 
tissues and cells. This receptor belongs to the superfamily of transacting transcriptional 
regulatory factors (Kostner et al., 2009). In humans, VDR gene is located on 
chromosome 12q13.1, extends over 100 kb and includes eight protein-coding exons, 
six untranslated exons, eight introns and two promoter regions (de Azevedo Silva et al., 
2013).  
 
VDR function in transcriptomic era 
Genome-wide overview does not involve additional signal transduction steps, as 
they are known for hydrophilic signalling molecules, such as peptide hormones, growth 
factors and cytokines. VDR shares the main structural characteristics of nuclear 
receptors, which is a highly conserved DNA-binding domain and a structurally 
conserved ligand binding domain VDRs. DNA-binding domain specifically contacts the 
hexameric consensus sequence RGKTSA (R=A or G, K=G or T, S=C or G) within the 
major groove of genomic DNA. However, like most other transcription factors, VDR 
uses a partner DNA-binding protein, in order to bind efficiently to its target sites. More 
than 20 years ago, this heterodimeric partner turned out to be the nuclear receptor 
Retinoid X Receptor (RXR). Steric constraints of the dimerizing DNA-binding domains 
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of VDR and RXR determine the optimal binding site of the VDR-RXR complex as a 
direct repeat of two hexameric nuclear receptor binding motifs spaced by three 
nucleotides (DR3). Within VDRs ligand-binding domain, a network of some 40 mostly 
non-polar amino acids forms a ligand-binding pocket in which 1,25(OH)2D3 and its 
synthetic analogues are specifically fixed with high affinity. This ligand binding process 
induces a conformational change in the surface of VDRs ligand-binding domain, which 
results in a significant change of VDRs protein-protein interaction profile: from a 
suprepressor it is turned into an activator (Carlberg, 2014). 
The genome-wide location of VDR is an essential information for understanding 
the pleiotropic physiological action of 1,25(OH)2D3. 
Probably, B cells have accessible VDR binding sites. Nevertheless, it can be 
questioned whether the regulation of a few hundred primary VDR target genes per 
tissue requires a far higher number of high quality genomic VDR binding sites. For the 
23,409 non-overlapping, VDR binding sites a full 75% of them are observed only in one 
cell type. These unique VDR binding sites may be the mediators of cell-type specific 
actions of the receptor and its ligand. In fact, on the level of VDR target gene 
expression, as measured by microarrays, it is already known that in most tissues a 
rather different set of genes respond to stimulation with 1,25(OH)2D3. On the other 
hand, VDR locations that overlap between two or more tissues represent independent 
confirmations of the validity of a VDR binding site. Moreover, genomic regions that are 
recognized in multiple cell types by VDR may have a more generalized, and therefore 
likely higher, impact on the physiological actions of the receptor and its ligand than the 
cell type specific sites (Tuoresmaki, Vaisanen, Neme, Heikkinen, & Carlberg, 2014). 
In turn, and in light of the renewed understanding of the distribution of 
transcriptional binding patterns and the diversity of RNA species, it is also timely to 
consider how these relationships illuminate VDR function (Long, Sucheston-Campbell, 
& Campbell, 2015). 
Hossein-nezhad et al. published a RCT showing that Vitamin D supplementation 
caused at least a 1.5-fold change in the expression of 291 genes that are involved in 
apoptosis, immune function, transcriptional regulation, and epigenetic modification, 
response to stress, cell cycle activity and differentiation. They identified 66 genes, that 
were most significantly affected by the subjects' Vitamin D status, i.e. those who were 
Vitamin D deficient with 25(OH)D of 16.2±4.2 ng/ml compared to adults who had a 
25(OH)D of 27.5±8.4 ng/ml at baseline. Of these 66 genes, 17 genes whose 
expression significantly changed after Vitamin D3 supplementation, in both deficient 
and insufficient/sufficient groups, were found to have novel VDREs (Hossein-nezhad, 
Spira, & Holick, 2013). 
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The VDR Transcriptome regulation 
With the emergence of comprehensive transcriptomic approaches including 
microarray technologies, an understanding was developed concerning the VDR 
transcriptome in different cell types and treatment conditions. In many ways, these 
studies also highlighted the heterogeneity of VDR actions. This heterogeneity may in 
part reflect experimental conditions (e.g., growth conditions, ligand exposures) with 
very different cell lines, but also genuine tissue-specific differences of co-factor 
expression that alter the amplitude and periodicity of VDR transcriptional actions. 
These transcriptomic direct actions can regulate cell cycle, activate key enzymes (like 
kinases), perform chromatin remodelling and have event demethylation effects, very 
important in cancer and autoimmune diseases as showed above (Long et al., 2015). 
 
VDR Regulation of Non-Coding RNA Species 
Many researchers have considered roles for non-coding RNA in the regulation of 
cell function and have begun to examine the interplay between the at least 20 different 
types of different non-coding RNA. Many of these RNA species are gene regulatory 
RNA and include microRNA (miRNA) and long noncoding RNA (long crane), whereas 
others are involved in the post-transcriptional modification of RNA, for example small 
nucleolar RNA (snoRNA). The data is still sparse, but non-coding sequences regulation 
is an important mechanism regarding Vitamin D/VDR interaction and immune 
regulation. An important example is the VDREs in non-coding sequences of MHC-class 
II (Cocco et al., 2012). It is likely that the increased application and integration of 
microarray and next generation sequencing approaches will identify the key networks 
downstream of the VDR transcriptome, pertaining to both protein coding and non-
coding RNA (Long et al., 2015). 
 
The Repertoire of VDR-Protein Interactions and Genomic Binding Sites 
Microarray studies showed that VDR combines with other proteins in a network of 
interactions, quite likely in a cell type specific manner, to participate in diverse gene 
regulatory networks. It remains to be established how targeted this is. The variation 
observed in both the type and position of binding sites for the VDR, depending on cell 
phenotype and disease state, suggests it is a directed process. At the very least, this 
will establish a paradigm for hypothesis testing, regarding what directs the VDR to bind 
and participate in gene transcription. The specificity of VDR signalling may arise due to 
integration with other, perhaps more dominant, transcription factors (Carlberg, 2014). 
Again, for other nuclear receptors, the concept has emerged that receptor binding 
is guided by the actions of more dominant, so-called pioneer, factors including the 
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Forkhead family members. However, efforts to define the major pioneer factors for the 
VDR have proven to be less consistent between the different VDR microarray studies. 
This may reflect the biology of the VDR, given its existance in the nucleus both in the 
presence and absence of ligand, such that a single pioneer dominant factor is not as 
deterministic (Long et al., 2015).  
 
 
Genetic Variation in VDR Binding – The VDR Polymorphisms 
Four common SNPs in the VDR gene have been extensively investigated: FokI 
C>T (rs2228570), BsmI A>G (rs1544410), ApaI G>T (rs7975232), and TaqI C>T 
(rs731236). BsmI and ApaI SNPs are both located in intron 8, and the TaqI is a silent 
SNP in exon 9. Although three of these polymorphisms do not produce any structural 
change on the VDR protein, they are in strong linkage disequilibrium. On the other 
hand, the T allele of the FokI SNP creates an alternative ATG initiation codon in exon 
2, leading to a VDR protein that is three amino acids longer, suggesting a potential 
functional consequence (Yang, Leung, Adamopoulos, & Gershwin, 2013). The 
combination of this data allows the use of phenotype-driven data to identify what VDR 
binding sites, and interactions, are important.  
There are few studies regarding transcriptomic alterations in real life patients and 
all with indirect results and no microarrays essays for microRNA or others. 
Barry EL et al. investigated whether 41 candidate SNPs in Vitamin D and calcium 
pathway genes (Vitamin D Binding Protein, 7-dehydrocholesterol reductase, CYP2R1, 
CYP27B1, CYP24A1, VDR, and calcium-sensing receptor) are associated with 
25(OH)D or modify the increase in 25(OH)D from Vitamin D3 supplementation. They 
studied 1878 healthy persons and showed that the increase in 25(OH)D due to Vitamin 
D3 supplementation was modified by genotypes at rs10766197 near CYP2R1, 
rs6013897 near CYP24A1, and rs7968585 near VDR (Barry et al., 2014). 
Monticielo et al. studied 195 SLE patients and 201 healthy controls and, 
according to genotype distribution, 25(OH)D concentrations were significantly higher in 
patients carrying the FokI f/f genotype in comparison with patients carrying the F/F 
genotype (31.6±14.1 ng/ml vs. 23.0±9.2 ng/ml, p=0.004), reinforcing its role in the 
functional activity of VDR (Monticielo, Brenol, et al., 2012). 
In summary, a number of resistance mechanisms can be postulated with this 
overview. One of the potential Vitamin D resistance mechanisms in SLE is the fact that 
different cells require different concentrations of active hormone, and we do not know 
the targets nor the concentrations required for each cells at the various stages of the 
disease. 
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On the other hand, there seems to be 1000–10,000 genomic VDR binding sites 
per cell type. This is far more than the number of primary 1,25(OH)2D3 target genes, 
which is in the order of 100-500 per tissue. This indicates that some genes are 
controlled by more than one VDR binding site, i.e., they may have a higher potential to 
be regulated by 1,25(OH)2D3 rather than target genes with only one active VDR locus. 
 
Finally, the VDR receptor has polymorphisms, which interfere with their 
conformation, as the FokI. Furthermore, the remaining key enzymes in the synthesis of 
25(OH)D, as well as its carrier (the VDR binding-protein) also have polymorphisms, 
which alter its enzyme activity and transport. As such, the state of resistance to Vitamin 
D is complex and the analysis of the VDR polymorphisms only evaluates one of the key 
steps of the problem. 
 
 
1.5.5. Vitamin D in SLE: real practice 
Many studies address Vitamin D therapy in real practice. There are some 
considerations that we have made, which are important for real practice: 
- Can Vitamin D supplementation prevent SLE flares? 
- Can Vitamin D levels predict flares? 
- What is the optimal dosage in SLE? 
- Is there a window of opportunity? 
 
There are a large number of studies addressing this issue, but, the evidence is 
sparse. 
Birmingham et al. made a study with 46 SLE patients from the specimen bank 
and database of the Ohio SLE Study. They studied the Vitamin D seasonal variation 
levels and their correlation with flares. The major finding of this study was that in non-
African-Americans SLE patients, there was a highly significant decrease in 25-
hydroxyvitamin D serum levels at the time of flare, for those flares occurring during low 
daytime sun exposure season. This was observed in both non-renal and renal flares 
(Birmingham et al., 2012). 
Schoindre Y et al. prospectively studied the relationship between 25(OH)D levels 
and SLEDAI score, in 170 SLE patients, and assessed the role of Vitamin D in 
predicting SLE flare-ups. There was no association between baseline 25(OH)D levels 
and relapse-free survival rate (Schoindre et al., 2014). 
Finally, Susmita Roy et al. published a complex paper, developing a general 
kinetic model in an attempt to capture the role of Vitamin D in immunomodulatory 
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responses. This kinetic model, developed using the ideas of chemical network theory, 
leads to a system of nine coupled equations that were solved both by direct and by 
stochastic (Gillespie) methods. They found that although Vitamin D plays a negligible 
role in the initial immune response, it exerts a profound influence in the long term, 
especially in helping the system to achieve a new, stable steady state. They also found 
that the optimal Vitamin D level lies in the 50–100 nmol/L range, where both pathogen 
and effector T-cell levels remain at reasonably low risk range (Roy, Shrinivas, & 
Bagchi, 2014). 
 
This is a difficult issue. Despite the general idea that low Vitamin D levels are 
related to higher disease activity, proofs are needed in RCT. It seems that SLE flares 
can relate to large variations of Vitamin D, but, the hormone levels themselves cannot 
predict flares. This statement does not exclude that Vitamin D basal therapy, at least in 
stable SLE patients, cannot prevent flares. Finally, in theory, immunomodulation can be 
achieved with optimal levels between 75-100 nmol/L, however it is shown that optimal 
individual levels need to be tailored. 
 
This important medical problem leads to the question of whether an insight into 
the genome-and transcriptome-wide actions of VDR and 1,25(OH)2D3 is helpful in a 
more accurate evaluation of the human individual’s responsiveness to, and needing for, 
Vitamin D. Interestingly, only for a subset of individuals, significant correlations 
between the up-regulation of both genes and the intervention-induced raise in serum 
25(OH)D concentrations were obtained. This suggests that, on a molecular level, not 
all study participants benefited from the Vitamin D3 supplementation because they had 
already reached their individual optimal Vitamin D status before the start of the 
intervention, or they carry a genetic polymorphism making them less responsive to 
Vitamin D3, or other undefined reasons. 
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2.1. Thesis framework  
This thesis was designed based on a cohort of patients with systemic 
autoimmune diseases that currently has between 3,000 and 4,000 patients in active 
follow-up. The Unidade de Imunologia Clínica (UIC) of the Centro Hospitalar do Porto 
(CHP) is a unique multidisciplinary service in Portugal, as it covers the whole are of 
what is now considered clinical immunology (primary immunodeficiencies, secondary 
immunodeficiencies, autoinflammatory syndromes and AIDs). UIC is an ambulatory 
service in essence, providing consulting services to hospitalizations and offering a 
multidisciplinary approach to difficult clinical cases. 
The personal contact with about 1000 patients with systemic autoimmune 
diseases was important to recognize a widespread symptomatic Vitamin D deficiency. 
Many findings such as fatigue, myalgia and arthralgia are common aspects in SLE but 
many patients improve solely with Vitamin D replacement. We also found that replenish 
Vitamin D guided by serum levels was by far more effective than empirical prescription 
and it was usual to need doses greater than 5,000 IU of cholecalciferol per day for 
effective treatment. 
Several issues were raised and addressed in this thesis. First, structured 
Portuguese studies to give a problem overview could not be found and secondly there 
was a lack of real-life data on patients with SLE. There are many reasons for patients 
with lupus to be potentially deficient in Vitamin D. Available data miss a lot of 
information: the effect of seasons of the year, sun exposure, diet variations, food 
supplements and latitude. Without these data, it is difficult to define whether this 
deficiency is multifactorial and substantially different from that found in the healthy 
population. This knowledge is crucial because no one could answer the question 
whether lack of Vitamin D is the cause or consequence of the disease. 
Then the question of whether Vitamin D was related to SLE susceptibility has 
surfaced. Many theoretical models were generated, but the one developed for MS, in 
which VDRE in noncoding sequences in the HLA-DRB1*15 plays a potential role in 
disease protection, interested us particularly.  
Finally, two equally fundamental questions were placed: what is the role of 
Vitamin D and its receptor in SLE progression and if Vitamin D-based therapeutic 
strategies will be equally effective in patients with stable as well as severe active 
disease. 
 
The hypotheses, aims, material and methods to answer these questions will be 
presented. 
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2.2. Hypotheses 
 Patients with SLE have significant Vitamin D insufficiency, which leads to an 
increased risk of disease flares, damage accrual and long-term cardiovascular disease. 
This dysfunction is likely due, at least in part, to failure of “immunomodulatory” 
effects of Vitamin D. 
 
The hypotheses of this work are: 
 
Hypothesis 1: Vitamin D levels in our SLE patients are lower than in a healthy 
population with the same demographic characteristics (age and sex). 
Hypothesis 2: Vitamin D status is related to SLE susceptibility. 
Hypothesis 3: SLE severity is related to VDR SNPs 
Hypothesis 4: Vitamin D deficiency is associated with SLE severity. 
Hypothesis 5: Supplementation with Vitamin D alters the clinical expression and 
immunological deregulation of SLE patients (T-CD4+ cells expressing FoxP3 and T-
CD4+ cells producing IL-17A). 
Hypothesis 6: Clinical and Immunological response to Vitamin D supplementation is 
limited by SLE disease activity.  
 
 
2.3. Aims 
With respect to the first hypothesis is to: 
- Develop two epidemiological studies in Portuguese SLE patients and 
healthy controls to prove deficiency of Vitamin D in both populations and 
their different characteristics. 
 
 With respect to the second hypothesis is to: 
- Develop a retrospective longitudinal/ genetic study with more than 1000 
patients proving a protective effect of different alleles of MHC class II to AID 
susceptibility, in an attempt to theorize on VDRE in MHC class II genes as 
being such as important as in MS. 
 
With respect to third and fourth hypotheses is to: 
- Develop two retrospective longitudinal/ immunogenetic studies with 170 SLE 
patients (DNA databank) from a well-characterized cohort, to correlate VDR 
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polymorphisms and longitudinal and baseline levels of Vitamin D with 
disease different aspects (activity, flares and damage accrual).  
 
With respect to the fifth and sixth hypotheses is to: 
- Develop two interventional studies with Vitamin D supplementation: 
 To study the effect of Vitamin D supplementation (despite baseline 
levels) in 24 stable SLE patients, regarding disease severity, T-CD4+ 
cells expressing FoxP3 and T-CD4+ cells producing IL-17A. 
 To study the effect of Vitamin D supplementation (despite baseline 
levels) in 4 severely SLE patients, regarding Tregs, T-CD4+ cells 
producing IL-17A and miR-146a expression. 
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2.4. Thesis Design 
  The design of the thesis was based in a large national cohort with more than 
3,000 patients with AIDs and SLE patients of UIC from Centro Hospitalar do Porto. In 
order to prove our hypotheses and answer the questions raised, we have made two 
epidemiological studies, three retrospective/ immunogenetic studies and finally two 
interventional studies. The table above shows the distribution of these studies (table 
10). 
 
 
 
 
 
 
 
 
 
 
Table 10 - Thesis design. 
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3.1. Subjects 
Patients 
A population of one thousand and two hundred twenty-eight (1228) patients that 
had collected DNA in our databank, with six autoimmune different diseases, including 
213 SLE patients, were selected, by convenience, from the cohorts of the Neurology, 
Dermatology and Clinical Immunology of Centro Hospitalar do Porto - Hospital de 
Santo António for HLA genetic studies. 
Regarding Vitamin D studies in lupus patients, diagnosed according to the 1997 
and 2012 revised ACR criteria for SLE, they were selected, again by convenience, from 
the described cohort: 
 
One hundred and twenty-four (124) SLE patients participated in Vitamin D levels 
epidemiologic studies,  
One hundred and seventy (170) SLE patients with at least five years of disease, 
was selected for VDR polymorphisms study,  
Concerning Vitamin D relation with disease severity, one hundred and twelve 
(112) patients were selected, from the described database of 170 SLE patients, and  
Twenty-four (24) stable and four (4) severely active SLE patients, were recruited for the 
interventional studies of Vitamin D in SLE patients.  
 
Healthy controls 
Healthy unrelated individuals were recruited from the same region of SLE 
patients, with a total of 674 analyses. 
Two hundred (200) blood donors voluntarily participated in the Vitamin D levels 
epidemiologic study.  
Two hundred and eighty-two (282) individuals were used as control group for 
HLA genetic study. 
On hundred and ninety-two (192), were used as controls for VDR polymorphisms 
studies.  
 
 
3.2. Data collection 
SLE disease characterization 
Disease severity was assessed using number of affected organs, number of 
severe flares (defined by the SELENA-SLEDAI flare composite) and the need of 
steroids or immunosuppressive therapy during disease duration (assumed as those 
who still were on these therapeutics at the time of data collection). Disease activity was 
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assessed by the SLEDAI 2-K and by the BILAG score. Cumulative damage was 
evaluated with the SLICC/ACR Damage Index. Flares were defined by the SELENA-
SLEDAI flare composite index. 
Clinical manifestations (kidney involvement, Central Nervous System 
involvement, Peripheral Nervous System involvement, articular, malar rash, 
photosensitivity, dsDNA, leukopenia, lymphopenia, pericarditis, pleuritis, lung 
involvement, myositis, ascitis, serositis, haematological and skin involvements) were 
established using a standard protocol accordingly to ACR glossaries for SLE 
classification criteria and EULAR recommendations for neuropsiquiatric, nephritis and 
SLE management.  
Considering kidney involvement, we took into account the response to treatment: 
complete response, partial response, no-response, chronic renal failure (CRF) and 
CRF in dialysis.  
 
Questionnaires 
A questionnaire about age, gender, weight, height, ethnicity, nationality, place of 
birth, occupation, sun exposure, sunscreens use, eating habits, smoking habits, 
physical activity, diagnosed pathologies, use of medicines and food supplements, was 
answered during blood donation, by healthy controls selected for the Vitamin D 
epidemiological studies.   
 
 
3.3. Laboratory assessments 
Vitamin D measurement 
Blood was collected in Vacuette® Z Serum Clot Activator tubes for the 
measurement of PTH and in Vacuette® Z Serum Separator Clot Activator tubes for the 
other measurements. Serum was obtained by centrifugation and stored in several 
aliquots at -20°C until analysed. Serum 25(OH)D was chosen as a reliable marker of 
individual Vitamin D status as it reflects Vitamin D obtained from food sources and 
cutaneous synthesis, and it is not prone to diurnal variation. 
Serum 25(OH)D was measured using an electro-chemiluminescence binding 
assay (ECLIA) for the in vitro determination of total 25-hydroxyvitamin D (Elecsys® 
Vitamin D total, Cobas, Roche©). The reference range for 25(OH)D was >75 nmol/L 
(measurement range: 7.50-175 nmol/L). The serum PTH concentration was assessed 
using an electro-chemiluminescence assay with 15-65 pg/mL as a reference range. 
Serum total calcium, phosphate and creatinine concentrations were measured by 
routine laboratory methods in a Cobas Integra 800. 
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DNA Samples and Genotyping  
Peripheral blood samples (10 mL) were collected in EDTA. Genomic DNA was 
obtained from Proteinase-K–treated peripheral blood leukocytes by using a Salting-Out 
procedure. 
 
HLA-DRB1 genotyping 
DNA was amplified using polymerase chain reaction and sequence-specific 
primers. Primers and probes were validated by the Twelfth International 
Histocompatibility Workshop. Polymerase Chain Reaction (PCR) products were 
visualized under ultraviolet light after running in a 1.5% agarose gel containing ethidium 
bromide. 
 
VDR Genotyping  
The single nucleotide polymorphisms (SNP) were genotyped using pre-designed 
TaqMan® allelic discrimination assays from Applied Biosystems (Foster City, CA, USA) 
in a Rotor Gene 6000 Real-Time PCR machine (Corbett Life Science). 
Genotyping of the BsmI (rs1544410), ApaI (rs7975232), TaqI (rs731236) and 
FokI (rs2228570) genetic variants, located within the 12q12-14 (VDR gene) region, was 
carried out. 
 
Flow Cytometry  
Peripheral blood lymphocyte’s subsets, including T, B, NK, TCD4+FoxP3+, 
TCD4+IL-17A+ were analysed by flow cytometry, in a Coulter Epics XL-MCL® 
cytometer. Cells counts (cells/μL) and proportions (%) were established from fresh 
blood samples using different protocols and monoclonal antibodies (mAbs), conjugated 
to fluorescein (FITC), phycoerythrin (PE), Phycoerythrin-Texas Red (ECD) and 
Phycoerythrin Cyanin 5.1 (PC5).  
T (CD3+/CD4+ and CD3+/CD8+), B (CD19+) and NK (CD56+) lymphocytes were 
analysed using a Beckman Coulter standard protocol with the following mAbs: anti-
CD45 FITC (clone B3821F4A), anti-CD3 PC5 (clone UCHT1), anti-CD4 RD1 (clone 
SFCI12T4D11), anti-CD8 ECD (clone SFCI21Thy2D3), anti-CD19 ECD (clone J4.119) 
and anti-CD56 FITC (clone N901/NKH-1); all from Beckman Coulter, Fullerton, 
California, USA).  
Effector CD4+ T cells producing IL-17 were quantified after four hour stimulation 
with phorbol 12-myristate 13-acetate (PMA) and ionomicin in the presence of brefeldin 
A. Cells were fixed and permeabilized using the IntraPrep Permeabilization Reagent 
(Beckman Coulter) buffer system and stained with anti-CD4 PC5 (clone 13B8.2; 
MATERIAL AND METHODS 
 
64 
 
Immunotech, Marseille, France) and anti-IL-17 PE (clone eBio64DEC17; eBioscience 
Inc, San Diego, CA).  
CD4+FoxP3+ T cells were quantified after cell fixation and permeabilization using 
the mAbs anti-CD4 PC5 (clone 13B8.2; Beckman Coulter - IOTest; Marseille, France), 
anti-CD25 FITC (clone B1.49.9; Immunotech, Marseille, France, only for severely 
active SLE interventional study), and anti-FoxP3 PE (clone PCH10; eBioscience Inc, 
San Diego, CA), according to the manufacturer's staining protocol. 
 
RNA Samples and Quantification 
Total RNA, including small RNAs, was extracted using a miRNeasy Mini Kit with 
a Qiacube (QIAGEN, Courtaboeuf, France) according to the manufacturer’s instruction. 
RNA concentration, purity, and quality were assessed using the NanoDrop® ND-1000 
(Thermo Fisher Scientific, Massachusetts, EUA). MiR-146a expression was analysed, 
using TaqMan microRNA pre-designed assay as recommended by manufacturer 
(Applied Biosystems, Inc., Foster City, CA). The assay includes two steps: generation 
of cDNA followed by TaqMan real time PCR. Briefly, total RNA was reverse-
transcribed, using TaqMan miRNA Reverse Transcription Kit following the 
manufacturer's protocol (Applied Biosystems, Inc., Foster City, CA). TaqMan miRNA 
assay included specific RT Primers and TaqMan Probes to quantify mature hsa-miR-
146a (P/N 4373132). For normalization, hsa-miR-RNU48 (P/N 4373883) was used. All 
reactions were incubated at 95°C for 10 min followed by 50 cycles of 92°C for 15 sec 
followed by 72°C for 20 sec. in ROTOR GENE 6000 (Corbett Life Science). Melt curve 
analysis was performed at the end of each qPCR run. No-template and no-reverse 
transcriptase controls were included. A threshold cycle (CT) was observed in the 
exponential phase amplification, and quantification of relative expression levels was 
performed, using standard curve for target genes and endogenous control. An 
efficiency of 90-100% of PCR was only taken into consideration and mean ΔCT±SE 
(CT value of target gene-CT value of normalizer) for each target was calculated as 
described previously (Dorak, 2006; Williams et al., 2007). Therefore, higher ΔCT 
indicates lower expression of target gene. 
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3.4. Studies design 
In this section, we present the studies design, which is explained in table 11. 
 
Table 11 - Studies design. 
Ref. 
Type of 
Study 
Name of Study 
Year of data 
collection 
Design of 
study 
N Objective  Outcome Measured Methods of Hypothesis Testing 
1 
E
P
ID
E
M
IO
L
O
G
IC
A
L
 
S
T
U
D
IE
S
 
Vitamin D levels in a healthy 
population from the North of 
Portugal 
Summer 2015 
and winter 
2016 
Prevalence 
study  
198 healthy 
controls 
Prevalence of Vitamin D 
deficiency in non-supplemented 
healthy population in different 
seasons of the year. 
Vitamin D levels in winter 
and summer time 
Kolmogorov-Smirnov test, Student’s t-test or one-way ANOVA 
(continuous variables) and χ2 test (dichotomous variables). Pearson’s 
or Spearman’s correlation coefficients. Multiple linear regression 
analysis. A p-value < 0.05 statistically significant. Statistical analyses:  
Statistical Package for the Social Sciences software (version 23, IBM 
SPSS Statistics, NY, USA). 
2 
Vitamin D levels in a SLE 
population from the North of 
Portugal 2015 
Prevalence 
case–control 
study 
124 SLE 
patients and 
198 healthy 
controls 
Prevalence of Vitamin D 
deficiency in non-supplemented 
SLE patients, in different 
seasons of the year, comparing 
with healthy controls. 
Vitamin D levels in winter 
and summer time 
Kolmogorov-Smirnov test, Student’s t-test or one-way ANOVA 
(continuous variables) and χ2 test (dichotomous variables). Pearson’s 
or Spearman’s correlation coefficients. A p-value < 0.05 statistically 
significant. Statistical analyses:  Statistical Package for the Social 
Sciences software (version 23, IBM SPSS Statistics, NY, USA). 
1 
IM
M
U
N
O
G
E
N
E
T
IC
 S
T
U
D
IE
S
  The Protective Role of HLA-DRB1 
(∗) 13 in Autoimmune Diseases. 
2015 
Retrospective 
cohort study 
1228 patients 
with AIDs and 
281 healthy 
controls 
HLA-DRB1 genes association 
with AIDs risk and protection. 
HLA-DRB1 alleles 
frequency 
 Stepwise logistic regression on an allelic level. ORs obtained in a 
multivariable logistic regression analysis adjusted for all the other 
genes. A p-value < 0.05 statistically significant. Statistical analyses:  
Statistical Package for the Social Sciences software (version 23, IBM 
SPSS Statistics, NY, USA). 
2 
Association between Vitamin D 
Receptor (VDR) gene 
polymorphisms and systemic lupus 
erythematosus in Portuguese 
patients.  
2014 
Retrospective 
cohort study 
170 SLE 
patients and 
192 healthy 
patients 
Correlation of VDR SNPs to 
SLE severity and damage. 
Number of severe flares, 
number of involved organs, 
concomitant therapy, 
SLICC, VDR 
polymorphisms. 
Allele and genotype frequencies obtained by direct counting. Chi-
square test, Mann-Whitney test. Uni and then multivariate analysis 
(logistic regression with the significant variables in univariate analysis). 
Odds Ratio calculated with a binary logistic regression. Statistical 
analyses:  Statistical Package for the Social Sciences software (version 
23, IBM SPSS Statistics, NY, USA). 
3 
Relation of Vitamin D levels with 
SLE number of severe flares. 
2016 
Retrospective 
cohort study 
112 SLE 
patients 
Correlation of baseline and 
mean Vitamin D levels during 
10 years with SLE severity. 
Number of severe flares, 
Vitamin D levels. 
Kolmogorov-Smirnov test, Student’s t-test or one-way ANOVA 
(continuous variables) and χ2 test (dichotomous variables). Pearson’s 
or Spearman’s correlation coefficients. A p-value < 0.05 statistically 
significant. Statistical analyses:  Statistical Package for the Social 
Sciences software (version 23, IBM SPSS Statistics, NY, USA). 
1 
IN
T
E
R
V
E
N
T
IO
N
A
L
 S
T
U
D
IE
S
  Vitamin D supplementation effects 
on FoxP3 expression in T cells and 
FoxP3+/IL-17A ratio and clinical 
course in systemic lupus 
erythematosus patients: a study in a 
Portuguese cohort.  
2013 
Interventional 
cross-
sectional 
24 SLE 
patients 
To evaluate the effect of a 6 -
month escalating dose of 
Vitamin D supplementation on 
FoxP3 TCD4+ cells and IL-17A 
TCD4+ cells expression, and 
FoxP3+/IL-17A ratio 
Vitamin D levels, SLEDAI, 
SLICC, FoxP3 TCD4+ 
cells, IL-17A TCD4+ cells 
expression, and 
FoxP3+/IL-17A ratio 
Wilcoxon signed-rank test.  Statistical analyses:  Statistical Package for 
the Social Sciences software (version 23, IBM SPSS Statistics, NY, 
USA). 
2 
Effect of high dose cholecalciferol 
during SLE flares in miR-146a 
expression, regulatory T-Cells and 
IL-17A expression. 
2016 
Interventional 
cross-
sectional 
4 SLE patients 
To evaluate the effect of a 3- 
week high dose Vitamin D 
supplementation in severely 
active SLE patients, on FoxP3 
TCD4+ cells, IL-17A TCD4+ 
cells, FoxP3+/IL-17A ratio and 
miR-146a expression. 
Vitamin D levels, SLEDAI, 
BILAG, FoxP3 TCD4+ 
cells, IL-17A TCD4+ cells 
expression, and 
FoxP3+/IL-17A ratio. and 
miR-146a expression. 
Relative expression values were calculated using the 2-ΔΔCt method. 
Differences in ΔCt were evaluated using two-tailed Student’s t-test. 
Statistical analyses:  Statistical Package for the Social Sciences 
software (version 23, IBM SPSS Statistics, NY, USA). 
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3.5. Statistical Analyses 
In our studies, continuous data were checked for normality using the 
Kolmogorov-Smirnov test and natural logarithm (ln) transformations were used for 
skewed variables previously to the statistical analysis. Differences between groups 
were tested using the Student’s t-test or one-way ANOVA (continuous variables) and 
χ2 test (dichotomous variables). Pearson’s or Spearman’s correlation coefficients were 
calculated to test relationships between continuous variables. 
Multiple linear regression analysis was used to consider potential determinants of 
25(OH)D levels (dependent variable). The following independent variables: age and 
BMI (as continuous variables), season and gender (as categorical variables) were 
included in the model. 
   A stepwise logistic regression on an allelic level was applied, using forward 
selection which involves starting with all HLA-DRB1 alleles, testing the deletion of each 
allele using a chosen model comparison criterion, deleting the allele (if any) that 
improves the model the most by being deleted, and repeating this process until no 
further improvement is possible. It should be noted that odds ratios (ORs) obtained in a 
multivariable logistic regression analysis are adjusted for all the other genes included in 
the model, and therefore differ from those obtained when a given gene is compared 
with all other genes, in order to identify the HLA-DRB1 genes contributing to the six 
different AIDs. 
 Allele and genotype frequencies were obtained by direct counting, for VDR 
polymorphisms study. Chi-square test was used to determine the differences of 
genotypic and allelic frequencies between patients and control groups. The same test 
was also conducted for the study of the association of the different genotypes or alleles 
with SLE clinical symptoms. Clinical and laboratory features associated with SLE were 
analysed by both uni and then multivariate analysis (logistic regression with the 
significant variables in univariate analysis). Mann-Whitney test was used to compare 
SLICC distributions and Odds Ratio was calculated with a binary logistic regression. 
The prevalence of genotypes in healthy controls was examined for deviation from 
Hardy–Weinberg equilibrium by using exact Chi-square test. 
 
Paired Wilcoxon Signed Ranked Test, because the data did not follow a 
Gaussian distribution, was used to compare Vitamin D levels taken at baseline (before 
Vitamin D supplementation, D0) with those taken at the end of the studies (M6 and 
D21). The miR-146a relative expression values were calculated using the 2-ΔΔCt 
method. Differences in ΔCt were evaluated using two-tailed Student’s t-test (severely 
active SLE patients study). 
MATERIAL AND METHODS 
 
67 
 
 
A p-value below 0.05 was considered to be statistically significant. Statistical 
analyses were performed using Statistical Package for the Social Sciences software 
(version 23, IBM SPSS Statistics, NY, USA). 
 
 
3.6. Ethical approval 
Written informed consent was obtained for each volunteer, and the study was 
approved by the Ethics Committee of Centro Hospitalar do Porto, according to 
Declaration of Helsinki. Studies using DNA databank and data storage, were approved 
by National Commission of Data Security 
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4.1. EPIDEMIOLOGIC STUDIES 
4.1.1. Vitamin D levels in a healthy population from the North of Portugal 
(Submitted to The Journal of Steroid Biochemistry and Molecular Biology 2016) 
 
The study was conducted in Porto (~41° N), in July and August 2015 (summer 
time) and April 2016 (winter time). The average age of these individuals was 43.1±12.1 
years. Subjects were stratified in three groups according to age. Two men were 
excluded because they were under multivitamin supplementation. In order to analyse 
the influence of BMI on the 25(OH)D levels, the subjects were categorized into two 
groups based on BMI values: BMI<30 kg/m2 (non-obese) or BMI≥30 kg/m2 (obese).  
The characteristics of the study population are shown in Table1. Approximately 
48% were women, and the mean age (±SD) of the study population was 43.1±12.1 
years. No statistically significant differences were observed between genders. The 
frequency of obesity was significantly higher in this population compared with the 
general Portuguese population (22.7% vs. 14.2%, p=0.001, OR=1.77, 95%CI=1.26-
2.50) (do Carmo et al., 2008). 
The mean serum 25(OH)D concentration was 55.4±23.4 nmol/L in all 
participants (median 50.9 nmol/L) with no significant differences between men and 
women (57.4±23.9 vs. 53.3±22.8 nmol/L; p=0.219). Fifty women (52.6%) and 45 men 
(43.7%) were deficient in 25(OH)D (Table 12). 
No statistically significant correlation was found between age and 25(OH)D 
levels (p=0.349). When subjects were categorized in groups according to age (Figure 
7), no differences in 25(OH)D levels between the three groups (p=0.311) were 
observed. 
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Table 12 - Characteristics of the study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI was negatively correlated with 25(OH)D levels (p=0.001, r=-0.237) (Figure 
9). In conformity, 25(OH)D levels were significantly lower in obese compared to non-
obese subjects (46.6±17.6 vs. 57.7±24.2 nmol/L, p=0.012) (Figure 8).  
Characteristics Total 
(n=198) 
Women 
(n=95) 
Men 
(n=103) 
Sociodemographics    
Age, years, mean ± SD 43.1±12.1 41.9±12.5 44.2±11.7 
Season    
Summer, n (%) 101 (51.1) 44 (46.3) 57 (55.3) 
Winter, n (%) 97 (49.0) 51 (53.7) 46 (44.7) 
BMI, mean ± SD 27.0±4.3 26.9±4.4 27.2±4.2 
Laboratory measurements    
PTH levels (pg/mL), mean ± SD 44.9±14.7 45.6±12.6 44.3±16.5 
Creatinine levels (mg/dL), mean ± SD 0.8±0.2 0.8±0.1 0.8±0.2 
Total calcium levels (mmol/L), mean ± SD 2.4±0.1 2.4±0.1 2.4±0.1 
Phosphorus levels (mmol/L), mean ± SD 1.0±0.2 1.0±0.2 1.0±0.2 
25(OH)D levels (nmol/L)    
Mean ± SD 55.4±23.4 53.3±22.8 57.4±23.9 
<50 nmol/L (deficiency), n (%) 95 (48.0) 50 (52.6) 45 (43.7) 
50-75 nmol/L (insufficiency), n (%) 60 (30.3) 27 (28.4) 33 (32.0) 
>75 nmol/L (optimal), n (%) 43 (21.7) 18 (18.9) 25 (24.3) 
Figure 7 - Prevalence of Vitamin D deficiency and insuficiency by age. 
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In the winter period, 74.2% of the studied population had a 25(OH)D 
concentration below 50.0 nmol/L compared with 22.8% in the summer period 
(p<0.0001). Only five individuals (5.2%) presented optimal levels of 25(OH)D in winter, 
and 38 (37.6%) in summer (Table 13). 
 
Table 13 – Differences in 25(OH)D concentrations according to season. 
25(OH)D levels (nmol/L) Winter (n=97) Summer (n=101) p 
Mean ± SD 42.2±16.9 68.2±21.5 <0.0001 
<50 nmol/L (deficiency), n (%) 72 (74.2) 23 (22.8) 
<0.0001 50-75 nmol/L (insufficiency), n (%) 20 (20.6) 40 (39.6) 
>75 nmol/L (optimal), n (%) 5 (5.2) 38 (37.6) 
 
In multiple linear regression analysis, controlling for age and gender, significant 
associations between 25(OH)D levels and season and BMI were found. Winter and 
higher BMI were significantly associated with lower serum 25(OH)D levels (Table 14). 
 
Table 14 - Results of a multiple linear regression analysis on determinants of 25(OH)D levels. 
Variable B SE p 
Intercept 4.224 0.189 <0.0001 
Age -0.002 0.002 0.499 
Season 0.482 0.054 <0.0001 
Gender -0.40 0.054 0.456 
Body Mass Index (kg/m
2
) -0.17 0.007 0.010 
Corr .r
2
=0.341    
Figure 8 - Comparison of serum 25(OH)D levels 
between obese (BMI≥30) and non-obese (BMI<30) 
individuals. 
Figure 9 - Correlation between 25(OH)D 
and BMI. 
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4.1.2. Vitamin D levels in a SLE population from the North of Portugal 
(Unpublished results) 
 
The study was conducted in Porto (~41° N), for the last 10 years. Subjects were 
stratified in two groups according to winter and summer Vitamin D levels. Data were 
compared with 198 healthy blood donors. Patients taking Vitamin D supplements were 
excluded. 
The characteristics of the study population are shown in Table 15. In SLE 
patients, 85% had Vitamin D deficiency. The mean Vitamin D levels were 48.9±27.2 
and there were no significant differences between summer and winter (p=0.117). 
Comparing with the control group, a significant difference was only observed during the 
summer time (p=0.0003). 
 
 Table 15 - Vitamin D levels in SLE patients vs. Control Population. 
 
 
 
Conclusions  
Hypothesis 1: Vitamin D levels in our SLE patients are lower than in a healthy 
population with the same demographic characteristics (age and sex).  
 
 Vitamin D is insufficient in at least two thirds of Portuguese healthy adult 
population and 85% of SLE patients. 
 
 SLE patients’ mean levels are lower than in general population, but only during 
the summertime.  
 
  Hypovitaminosis D in SLE population may differ from the observed in healthy 
population, due to deficient sun exposure during summer time, and not due to 
the disease effect on Vitamin D metabolism. 
 SLE Patients (n=124) Control Population (n=198) p 
25(OH)D levels (nmol/L) Total 
Winter 
(n=54) 
Summer 
(n=70) 
Total 
Winter 
(n=97) 
Summer 
(n=101) 
Winter Summer 
Mean ± SD 48.9±27.2 43.0±21.4 53.5±30.2 55.4±23.4 42.2±16.9 68.2±21.5 0.799 0.0003 
<50 nmol/L (deficiency), n (%) 72 (58.1) 38 (70.4) 34 (48.6) 95 (48.0) 72 (74.2) 23 (22.8) 
0.621 
 
50-75 nmol/L (insufficiency), n (%) 34 (27.4) 11 (20.4) 23 (32.8) 60 (30.3) 20 (20.6) 40 (39.6) 0.001 
>75 nmol/L (optimal), n (%) 18 (14.5) 5 (9.2) 13 (18.6) 43 (21.7) 5 (5.2) 38 (37.6)  
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4.2. IMMUNOGENETIC STUDIES 
4.2.1. The Protective Role of HLA-DRB1*13 in Autoimmune Diseases 
(J Immunol Res. 2015; 2015:948723. doi: 10.1155/2015/948723) 
 
The HLA-DRB1 frequencies in all the patients were compared with the ones of 
a control group consisting of 282 unrelated individuals without disease and with the 
same geographic origin: Portugal. With this methodology, different types of association 
between alleles and AIDs were found (Table 16). These included three risk alleles for 
two or more AIDs, two protective alleles for two or more AIDs and three risk alleles for 
a particular AID. 
HLA-DRB1*13 was a protective allele for four AIDs: SLE (OR=0.58, p=0.016), 
Psoriasis and Psoriatic Arthritis (OR=0.621, p=0.050), RA (OR=0.58, p=0.044) and 
SSc (OR=0.42, p=0.035).  
There was one risk allele associated with three AIDs. HLA-DRB1*03 was found 
to be a risk factor for SLE (OR=2.49, p=4.2x10-5), MS (OR=1.81, p=0.003) and MG 
(OR=2.98, p=6.1x10-5). There were two risk alleles associated with two AIDs: HLA-
DRB1*08 were positively associated with MS (OR=1.73, p=0.033) and SSc (OR=3.01, 
p=0.004) and HLA-DRB1*01 was found to be a risk factor for RA (OR=1.79, p=0.017) 
and SSc (OR=2.28, p=0.006). 
HLA-DRB1*09 was negatively associated with SLE (OR=0.18, p=0.027) and 
MS (OR=0.22, p=0.004). 
Three risk disease-specific alleles were found. HLA-DRB1*04 for RA (OR=2.81, 
p=6x10-6), HLA-DRB1*07 for Psoriasis and Psoriatic Arthritis (OR=1.79, p=0.006) and 
HLA-DRB1*15 for MS (OR=2.17, p=2x10-5). 
Considering the total of AIDs, HLA-DRB1*03 frequencies were significantly 
higher (p=0.026, OR=1.49) in the total of patients compared with controls; conversely 
HLA-DRB1*13 (p=0.003, OR=0.64) and HLA-DRB1*09 (p=0.001, OR=0.31) 
frequencies were significantly lower. 
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 Controls 
(n=282) 
SLE 
(n=213) 
Ps+PsA 
(n=166) 
RA 
(n=153) 
SSc 
(n=67) 
MS 
(n=536) 
MG 
(n=93) 
TOTAL 
(n=1228) 
HLA-DRB1*01 
66 
(23.4%) 
40 (18.8%) 39 (23.5%) 
50 (32.7%) 
OR=1.79 
p=0.017 
28 (41.8%) 
OR=2.28 
p=0.006 
100 (18.7%) 23 (24.7%) 280 (22.8%) 
HLA-DRB1*03 
44 
(15.6%) 
73 (34.3%) 
OR=2.49 
p=4.2X10
-5
 
25 (15.1%) 28 (18.3%) 11 (16.4%) 
123 (22.9%) 
OR= 1.81 
p=0.003 
33 (35.5%) 
OR=2.98 
p=6.1X10
-5
 
293 (23.9%) 
OR=1.51 
p=0.022 
HLA-DRB1*04 
69 
(24.5%) 
42 (19.7%) 46 (27.7%) 
73 (47.7%) 
OR=2.81 
p=6X10
-6
 
13 (19.4%) 128 (23.9%) 23 (24.7%) 325 (26.5%) 
HLA-DRB1*07 
72 
(25.5%) 
55 (25.8%) 
66 (39.8%) 
OR=1.79 
p=0.006 
38 (24.8%) 14 (20.9%) 147 (27.4%) 23 (24.7%) 343 (27.9%) 
HLA-DRB1*08 24 (8.5%) 21 (10.0%) 10 (6.0%) 
3 (2.0%) 
OR=0.24 
p=0.026 
15 (22.4%) 
OR=3.01 
p=0.004 
65 (12.1%) 
OR=1.73 
p=0.033 
7 (7.5%) 121 (9.9%) 
HLA-DRB1*09 14 (5.0%) 
2 (1.0%) 
OR=0.18 
p=0.027 
5 (3.0%) 0 (0.0%) 3 (4.5%) 
5 (1.0%) 
OR=0.22 
p=0.004 
2 (2.2%) 
17 (1.4%) 
OR=0.23 
p=1x10
-4
 
HLA-DRB1*13 
84 
(29.8%) 
39 (18.3%) 
OR=0.58 
p=0.016 
32 (19.3%) 
OR=0.62 
p=0.050 
25 (16.3%) 
OR=0.58 
p=0.044 
8 (11.9%) 
OR=0.42 
p=0.035 
124 (23.1%) 17 (18.3%) 
245 (20.0%) 
OR=0.58 
p=0.004 
HLA-DRB1*15 
56 
(19.9%) 
55 (25.8%) 22 (13.3%) 17 (11.1%) 12 (17.9%) 
175 (32.7%) 
OR=2.17 
p=2X10
-5
 
15 (16.1%) 296 (24.1%) 
Table 16 - Associations between HLA class II and six AIDs: SLE, Psoriasis (Ps) and Psoriatic Arthritis (PsA), 
RA, SSc, MS, and MG. 
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4.2.2. Association between VDR gene polymorphisms and Systemic Lupus 
Erythematosus in Portuguese Patients. 
(Lupus. 2015 Jul;24(8):846-53.doi:10.1177/0961203314566636) 
  
The demographic and clinical features of the 170 (15 M and 155 F) patients with 
SLE are presented in Table 17.  Patients with less than 5 years of disease where not 
considered. 
The average age of the SLE patients was 45 ± 13.4 years and the mean disease 
duration was 14.5 ± 6.5 (7 – 43) years.  The subjects without known autoimmune 
disease had an average age of 47 ± 12.8 years.  
Phenotypic and genotypic frequencies for VDR SNPs were in Hardy-Weinberg 
equilibrium.  
No statistically significant differences were observed between frequencies of the 
VDR polymorphisms in the patients group when compared with controls as shown in 
Table 18. 
The relationship between VDR polymorphisms and disease expression was 
analysed in patients, with complete clinical data compiled, according to the clinical 
manifestations listed in table 17 and malar rash, photosensitivity, leukopenia, 
lymphopenia, pericarditis, pleuritis, lung involvement, myositis, ascitis, serositis as well 
as SLICC scores, number of affected organs, number of severe flares and the need of 
steroids or immunosuppressive therapy during disease duration. No associations were 
found between VDR SNPs and all the previously referred clinical features, except with 
skin involvement where the ApaI TC genotype frequency was higher in the patient 
group (p=0.038). 
No significant differences were observed in number of affected organs, number of 
severe flares and the probability of long-term need of steroids or immunosuppressive 
therapy during disease duration. 
The only exception was the association of different polymorphisms with damage 
accrual, namely, the significantly higher frequencies of VDR genotypes TaqI TT and 
FokI CT found in patients with SLICC>0 (Table 19). 
 
SLICC values were higher in SLE patients with FokI CT and TaqI TT genotypes 
(p=0.031 and p=0.046 respectively, Figure 10). 
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Table 17 – Demographic and clinical/laboratory features of SLE patients. 
 
Patients Features 
 
n / n total (%) 
Male 
 
15/170 (9) 
Female 
 
155/170 (91) 
Age (years) 
 
45 (±13.4) 
 
> 10 years of disease 
 
118/170 (69) 
    
ANA+ 
 
170/170 (100) 
ANTI ds-DNA 
 
90/170 (56) 
Haematological abnormalities 101/170 (59) 
Arthritis 
 
120/170 (71) 
Skin involvement 
 
140/170 (82) 
Nephritis 
 
48/170 (28) 
Type III  4/48 (8) 
Type IV  31/48 (65) 
Type V  8/48 (17) 
Type VI  2/48 (4) 
NS involvement 
 
13/170 (8) 
    
Immunosuppressors/steroids * 161/170 (95) 
Severe Flares 
 
147/170 (86) 
>3 affected organs or systems 42/170 (25) 
* Patients with immunosuppressors or steroids at the time of 
clinical evaluation. 
Figure 10 - Box-whisker plots of SLICC distribution according to FokI and TaqI genotype, in SLE patients. 
SLICC: Systemic Lupus International Collaborative Clinics; SLE: systemic lupus erythematosus. 
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Polymorphism 
SLE patients 
n (%) 
Control Population 
n (%) 
Odds Ratio 
(95% CI) 
p-value 
rs1544410 (BsmI) 161 186 
   
Allele 
       
A 105 (65.2%) 131 (70.4%) 0.89 (0.65-1.22) 0.47 
G 133 (82.6%) 148 (79.6%) 1.06 (0.79-1.44) 0.68 
Genotype 
       
AA 28 (17.4%) 38 (20.4%) 0.11 (0.10-1.36) 0.09 
AG 77 (47.8%) 93 (50.0%) 0.59 (0.18-1.88) 0.37 
GG 56 (34.8%) 55 (29.6%) 1 
  
rs7975232 (ApaI) 167 187 
   
Allele 
       
T 132 (79.0%) 159 (85.0%) 0.88 (0.65-1.19) 0.42 
G 117 (70.1%) 129 (68.9%) 1.02 (0.75-1.40) 0.88 
Genotype 
       
TT 50 (29.9%) 58 (31.0%) 0.97 (0.36-2.57) 0.95 
TG 82 (49.1%) 101 (54.0%) 0.78 (0.37-1.63) 0.5 
GG 35 (21.0%) 28 (15.0%) 1 
  
rs731236 (TaqI) 169 179 
   
Allele 
       
C 107 (63.3%) 127 (70.9%) 0.84 (0.61-1.15) 0.29 
T 142 (84.0%) 145 (81.0%) 1.06 (0.79-1.44) 0.69 
Genotype 
       
CC 27 (16.0%) 34 (19.0%) 5.6 (0.46-67.9) 0.17 
CT 80 (47.3%) 93 (52.0%) 1.39 (0.43-4.51) 0.58 
TT 62 (36.7%) 52 (29.1%) 1 
  
rs2228570 (FokI) 164 192 
   
Allele 
       
T 85 (51.8%) 102 (53.1%) 0.97 (0.69-1.35) 0.84 
C 147 (88.0%) 174 (90.6%) 0.98 (0.73-1.32) 0.89 
Genotype 
       
TT 17 (10.4%) 18 (9.4%) 1.08 (0.50-2.31) 0.85 
CT 68 (41.5%) 84 (43.8%) 0.86 (0.54-1.37) 0.53 
CC 79 (48.2%) 90 (46.9%) 1 
  
 
 
 
 VDR polymorphism 
SLICC=0 
n (%) 
 
SLICC>0 
n (%) 
 rs731236 (TaqI) 98 
 
63 
Allele 
C 68 (69.4%) 
 
34 (54.0%) 
T 81 (82.7%) 
 
55 (87.3%) 
 CC 17 (17.3%) 
 
8 (12.7%) 
Genotype CT 51 (52.0%) 
 
26 (41.3%) 
 TT 30 (30.6%) 
 
29 (46.0%) 
 rs2228570 (FokI) 93 
 
63 
Allele 
T 44 (47.3%) 
 
39 (61.9%) 
C 81 (87.1%) 
 
58 (92.1%) 
 TT 12 (13.3%) 
 
5 (7.9%) 
Genotype CT 32 (35.6%) 
 
34 (54.0%) 
 CC 40 (51.1%) 
 
24 (38.1%) 
Table 18 - Genotype and phenotype frequencies of VDR polymorphisms in SLE 
patients and Control Population. 
Table 19 - Genotype and phenotype frequencies of VDR 
polymorphisms in SLE patients with SLICC=0 and SLICC>0. 
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4.2.3. Relation of Vitamin D levels with SLE number of severe flares 
(Unpublished results) 
 
For this study, we correlated the baseline Vitamin D levels with severe flare 
number and with patients with three or more and less than three severe flares. We also 
correlated severe flares with mean Vitamin D value in the last 10-years follow-up. 
We compared baseline Vitamin D levels of 112 SLE patients with the number of 
severe flares.  
We observed a higher number of flares in patients with low baseline Vitamin D 
levels (p=0.045) (Figure 11). We also observed that patients with three or more flares 
have significant lower baseline Vitamin D levels (p=0.004) (table 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 20 - Relation between less than and more or equal to three severe flares and baseline 
25(OH)D levels. 
 
<3 Flares 
(n=101) 
≥3 Flares 
(n=11) 
p 
Baseline 25(OH)D 
levels (nmol/L) 
51.34 ± 28.24 25.74±14.09 0.004 
 
 
Figure 11 - Inverse correlation between baseline 25(OH)D levels and number of severe 
flares (p=0.045). 
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The mean Vitamin D levels in the previous 10 years of disease in 68 patients, 
were lower in patients with higher number of severe flares, although not significant 
(p=0.178) (Figure 12). However, if we categorized them in two subgroups (patients with 
three or more and less than three severe flares), the difference is significant (p=0.044) 
(table 21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 21 - Relation between less than and more or equal to 3 severe flares and mean 25(OH)D 
levels over the past 10 years. 
 
<3 Flares 
(n=60) 
≥3 Flares 
(n=8) 
p 
Mean 25(OH)D 
levels (nmol/L) 
64.3 ± 23.0 46.6±20.6 0.044 
 
 
 
 
 
Figure 12 - Inverse correlation between mean 25(OH)D levels over the last 10 years and 
number of severe flares (p=0.178). 
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Conclusions  
Hypothesis 2: Vitamin D status is related to SLE susceptibility. 
 
 We cannot answer this question with this study. However, we confirm genetic 
data that can allow new studies able to determine Vitamin D effect in SLE 
susceptibility. 
 
 We confirmed the HLA-DRB1*03 risk and the HLA-DRB1*13 protective effect to 
SLE. The possibility of this effect to be mediated by the canonical VDRE 
presence in HLA-DRB1 genes should be explored. Low Vitamin D levels in 
mothers during pregnancy and in early childhood could enhance this effect. 
 
 The effect of HLA-DRB1 alleles (*01 and *13 in Lupus) should be studied in 
different latitudes to prove that optimal sun exposure (and Vitamin D levels) could 
be one of the causes of lower incidence of AIDs. 
 
 
 
 
Conclusions  
Hypothesis 3: SLE severity is related to VDR SNPs. 
 
 VDR polymorphisms (TaqI and FokI variants) are related to damage accrual in 
SLE patients. 
 
 These effects seem to be unrelated to Vitamin D levels. 
 
 VDR polymorphisms are not related to flares or specific organ involvement. 
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Conclusions  
Hypothesis 4: Vitamin D deficiency is associated with SLE severity. 
 
 Baseline Vitamin D levels at SLE diagnosis (before supplementation) correlate 
with the number of severe flares and specifically in patients with three or more 
severe flares during follow-up. 
 
 Mean Vitamin D levels in a 10-year follow-up of SLE patients are related to the 
number severe flares (p= 0.178), but especially in those who had three or 
more severe flares (p=0.044). 
 
 Vitamin D levels at the beginning of the disease and the Vitamin D burden 
during disease are related to the number of severe flares, leading to 
phenotypes that are more aggressive. 
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4.3. INTERVENTIONAL STUDIES 
4.3.1. Vitamin D supplementation effects on FoxP3 expression in T cells and 
FoxP3+/IL-17A ratio and clinical course in systemic lupus erythematosus 
patients: a study in a Portuguese cohort. 
(Immunol Res. 2016 Jul 16. [Epub ahead of print]. doi: 10.1007/s12026-016-8829-3) 
 
Patients were recruited between 1 November 2012 and 31 January 2013. By 
protocol, all these patients should have more than 5 years of disease duration, and 
should be in a stable phase of disease and without major flares for at least 1 year. 
Stability was defined as no new major organ involvement in the last year independently 
of the SLEDAI-2K score and no changes in steroid dose or immunosuppressive 
therapy in the last 12 months.  Baseline 25(OH)D serum level was measured. 
Hypovitaminosis D was defined as serum 25(OH)D <75 nmol/L and patients were 
selected irrespectively of their baseline 25(OH)D levels. 
Demographic, clinical and laboratorial features of SLE patients at baseline are 
described in Table 22. Serum 25(OH)D levels significantly increased under Vitamin D 
supplementation from 59.32 ± 29.59 nmol/L at Day 0 to 80.39 ± 24.57 nmol/L at Month 
3 (p=0.030) and to 85.25 ± 30.92 nmol/L at Month 6 (p=0.001) (Figure 13). 
Treatment was safe, with no significant increase of serum phosphorus or calcium 
levels. Serum calcium significantly decreased from 2.34 ± 0.10 mmol/L at Day 0 to 2.27 
± 0.10 mmol/L at Month 6 (p=0.026) but all in the normal range. 
Disease activity, assessed by SLEDAI-2K, significantly decreased from 2.75 ± 
4.76 at Day 0 to 1.67 ± 2.79 at Month 6 (p=0.026) (Figure 14). 
Serum anti-dsDNA levels (evaluated by immunofluorescence) remained stable 
during follow-up, while C3 complement fraction significantly decreased from 101.5 ± 
23.57 mg/dL at Day 0 to 95.46 ± 21.71 mg/dL at Month 6 (p=0.013), but no new 
hypocomplementemia occurred (reference values: 88-201 mg/dL). 
None of the patients required modification of the prednisone and 
immunosuppressive dosage or initiation of new immunosuppressive agents. We did not 
observe SLE flares during the 6 months’ follow-up period. 
The impact of Vitamin D supplementation on the proportions of CD3+ T cells, 
CD4+ and CD8+ T cells is shown in Figure 15.  
The mean proportions at baseline were 80.05 ± 5.64% for CD3+ T cells (Figure 
15A), 47.8 ± 7.58% for CD4+ T cells (Figure 15B), and 30.56 ± 7.73% for CD8+ T cells 
(Figure 15C). At Month 6, the proportion of CD3+ T cells, CD4+ and CD8+ T cells 
remained stable.  
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The impact of Vitamin D supplementation on CD3+CD4+FoxP3+ T cells was 
evaluated. The percentage of CD4+FoxP3+ cells at baseline was 7.27 ± 5.92%. The 
percentage of CD4+FoxP3+ cells was increased at 11.42 ± 6.54% at Month 6 (p<0.001) 
(Figure 16A). A decrease was observed in CD4+IL-17A from 3.89 ± 1.76% at Day 0 to 
2.82 ± 1.03% at Month 6 (p=0.001) after Vitamin D supplementation (Figure 16B). 
Accordingly, the FoxP3+/IL-17A ratio in patients with SLE after 6 months of 
Vitamin D supplementation was higher than that in the baseline (p<0.001) (Figure 17).  
Considering patients with 25(OH)D levels at baseline ≥75 nmol/L, the increase of 
FoxP3+/IL-17A ratio observed for the entire group after 6 months of Vitamin D 
supplementation was also valid (p=0.043) (Figure 18).  
The relationship between CD4+FoxP3+ and CD4+IL-17A cells and 25(OH)D 
levels, serum calcium, serum phosphorus and serum PTH levels was also analysed. 
No associations were found between these features and CD4+FoxP3+ and CD4+IL-17A 
proportions. 
No significant differences were observed for the other laboratory and clinical 
parameters, such as SLICC score. 
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Table 22 – Demographic, clinical and laboratorial features of SLE patients at baseline. All 
patients completed the 6 months’ follow-up period. 
   
Characteristics N=24 
Epidemiology  
Age, years, mean ± SD 47 ± 11 
Female gender, n (%) 23 (95.83%) 
Previous SLE manifestations  
Skin, n (%) 19 (79,2%) 
Joints, n (%) 18 (75%) 
Serositis, n (%) 4 (16.7%) 
Kidney, n (%) 7 (29.2%) 
Nervous system, n (%) 3 (12.5%) 
Flares, n (%) 10 (41.7%) 
Flares, mean (range) 0.66 (0-3) 
SLEDAI/SLICC and analytical studies  
SLEDAI at Day 0, mean (range) 2.71 (0-21) 
SLICC at Day 0, mean (range) 1.04 (0-5) 
Calcium levels, mean (range), mmol/L 2.34 (2.12-2.52) 
Phosphorus levels, mean (range), mmol/L 1.02 (0.65-1.4) 
C3 levels at Day 0, mean (range), mg/dL 101.5 (51-147) 
C4 levels at Day 0, mean (range), mg/dL 16.5 (6-35) 
Anti-dsDNA levels at Day 0, mean (range), IU/mL 34.15 (0.2-302) 
% CD3
+
 levels at Day 0, mean (range) 80.05 (69.1-90.5) 
% CD3
+
CD4
+
 levels at Day 0, mean (range) 47.8 (39-62.5) 
% CD3
+
CD8
+
 levels at Day 0, mean (range) 30.55 (18.2-44.9) 
%T CD4
+
 FoxP3
+
 at Day 0, mean (range) 7.27 (0.48-15.57) 
%T CD4
+
IL17
+
 at Day 0, mean (range) 3.89 (1.19-8.58) 
%T CD4
+
 FoxP3
+
/%T CD4
+
 IL17
+
 ratio at Day 0, mean (range) 2.23 (0.16-8.9) 
25-hydroxyvitamin D levels  
Mean ± SD, nmol/L 59.3 ± 29.6 
25(OH)D ≤ 25 nmol/L, n (%) 2 (8.3%) 
25 < 25(OH)D ≤ 50 nmol/L, n (%) 8 (33.3%) 
50 < 25(OH)D ≤ 75 nmol/L, n (%) 7 (29.2%) 
25(OH)D > 75 nmol/L, n (%) 7 (29.2%) 
Associated treatments*  
Prednisone, n (%) 15 (62.5%) 
Prednisone <10 mg 11 
Prednisone 10-20 mg 3 
Prednisone >20 mg 1 
Hydroxychloroquine, n (%) 17 (70.8%) 
Azathioprine, n (%) 2 (8.3%) 
Mycophenolate mofetil, n (%) 3 (12.5%) 
     *At the time of the study. 
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Figure 13 - Time evolution of serum 25(OH)D levels (M3 – month 3; M6 – month 6); 
*p<0.05, **p<0.01. 
Figure 14 - Disease activity assessed by SLEDAI-2K scores. 
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Figure 15 - Evolution of peripheral blood lymphocytes proportions with Vitamin D supplementation. CD3
+
 (A), 
CD3
+
CD4
+
 (B) and CD3
+
CD8
+
 (C) proportions at Day 0 and M6. 
Figure 16 - Variation of the proportions of CD4
+
FoxP3
+
 T cells (A) and CD4
+
IL-17A T cells (B) after Vitamin 
D supplementation. 
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Figure 17 - Variation of FoxP3
+
/IL-17A ratio after Vitamin D supplementation. 
Figure 18 - Variation of FoxP3
+
/IL-17A ratio in patients group with ≥75 nmol/L 
25(OH)D levels (at baseline) after Vitamin D supplementation. 
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4.3.2. Effect of high dose cholecalciferol during SLE flares in miR-146a 
expression, regulatory T-Cells and IL-17A expression. 
(Unpublished results) 
 
The characteristics of the studied patients and Vitamin D levels before and after 
high-dose supplementation are presented in table 23.  
Four (4) SLE patients with severely active disease were selected. Severely active 
disease was defined as having a SLEDAI2-K score > 6 and a least one BILAG A for 
organ or system.  
Regarding Vitamin D levels, even with Vitamin D high-doses, no significant 
differences were observed before and after supplementation. 
 
 
 
 
 
 
 
 
 
 
 
Considering IL-17A T CD4+ producing cells, Tregs and Tregs/IL-17A ratio before 
and after supplementation, no enhancement of Tregs or Tregs/IL-17A was observed 
(table 24). 
 
 
 
Table 24 - CD25
+
FoxP3
+
CD4
+ 
T-cells and IL-17A
+
CD4
+ 
T-cells proportions in 4 SLE patients 
after Vitamin D therapy. 
 
 Baseline After Vitamin D Shot 
p 
Ratio Patients 
%CD25
+
 
FoxP3
+
CD4
+ 
%IL-17A
+ 
CD4
+
  
Ratio 
(Treg/IL-17A) 
%CD25
+
 
FoxP3
+
 CD4
+
 
%IL-17A
+
 
CD4
+
 
Ratio 
(Treg/IL-17A) 
1 13.88 5.31 2.61 9.41 4.29 2.19 
0.054 
2 8.88 2.02 4.40 5.11 2.37 2.16 
3 8.46 5.87 1.44 1.51 5.57 0.27 
4 5.04 3.4 1.48 1.79 3.17 0.56 
Table 23 - Baseline disease characteristics and vitamin D levels before and after 
supplementation. 
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No significant differences were found in miR-146a expression between SLE 
patients (before and after Vitamin D supplementation) and controls (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusions  
Hypothesis 5: Supplementation with Vitamin D alters the clinical expression and 
immunological deregulation of SLE patients (T-CD4+ cells expressing FoxP3 and T-
CD4+ cells producing IL-17A). 
 
 Vitamin D supplementation seems to provide favourable immunological 
effects in SLE patients with stable and low disease activity;  
 
 This effect is probably independent of the 25(OH)D patient’s status. 
 
 
 
Conclusions  
Hypothesis 6: Clinical and Immunological response to Vitamin D supplementation is 
limited by SLE disease activity. 
 
 Severe SLE activity may cause resistance to Vitamin D therapeutical effects, 
including enhancing of Vitamin D levels and immunogenetic effects. 
Figure 19 – miR-146a expression before and after Vitamin D supplementation. 
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5.1. Epidemiologic studies 
5.1.1. Discussion of hypothesis 1: Vitamin D levels in our SLE patients are lower 
than in a healthy population with the same demographic characteristics (age and sex). 
 
The first issue of this thesis was to prove that healthy Portuguese population is 
Vitamin D deficient. 
There is ongoing debate related to the optimal levels of 25(OH)D, but all available 
evidences suggest that children and adults should maintain a 25(OH)D blood level 
above 50 nmol/L to prevent rickets and osteomalacia, respectively. However, to 
maximize Vitamin D effect on calcium, bone and muscle metabolism, the 25(OH)D 
blood level should be above 75 nmol/L. Numerous epidemiological studies have 
suggested that a 25(OH)D blood level above 75 nmol/L may have additional health 
benefits in reducing the risk of common cancers, autoimmune diseases, type 2 
diabetes, cardiovascular disease, and infectious diseases (Grober, Spitz, Reichrath, 
Kisters, & Holick, 2013). 
Deficient Vitamin D status of the general population in the USA, Canada, Asia 
Pacific, Middle East, Africa and across Europe (Hilger et al., 2014) is well documented, 
being more prevalent in winter, in women, in older age groups, in individuals with dark 
skin, and at higher latitudes (Nair & Maseeh, 2012). 
To the best of our knowledge, we conducted the first epidemiologic study in a 
Portuguese healthy population. In our study we also observed that almost half of the 
healthy non-supplemented individuals presented significant Vitamin D deficiency, 
reaching 74% during the winter period, confirming the well-known seasonal fluctuation 
in 25(OH)D concentrations. No association between Vitamin D levels and gender was 
observed, although women presented slightly lower levels of 25(OH)D. Moreover, we 
did not find any association between Vitamin D status and age. These observations are 
in line with a recent study suggesting the widespread hypovitaminosis D across 
Europe, even in countries with abundant sunlight, and with prevalence rates meeting 
the criteria of a pandemic (Cashman et al., 2016).  
Concerning SLE patients, although the common idea that patients with lupus 
have more Vitamin D deficiency than the normal population, this is only evident in the 
summer time. Theoretically, SLE severe disease activity would block the effect of the 
key enzymes for Vitamin D metabolism (D. L. Kamen, 2010). However, our data shows 
that this effect may not be important, as Vitamin D levels in SLE population during 
winter time are similar to those observed in the control population. Therefore, our 
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results suggest that Vitamin D deficiency in patients with lupus may be only related to 
the performance of solar eviction and not to SLE disease activity. 
 This is the first time that this approach was accomplished in patients with SLE. 
Literature data, though extensive and covering the dates or times of the year on which 
blood collections are made, have important limitations. These limitations are related to 
study methodologies,  being restricted to the study of seasonal hypovitaminosis D 
effect in flares rate or to Vitamin D deficiency prevalence in non-supplemented SLE 
patients without a healthy controlled population (Dall'Ara et al., 2015; Munoz-Ortego, 
Torrente-Segarra, Prieto-Alhambra, Salman-Monte, & Carbonell-Abello, 2012). In 
summary, to study the prevalence of Vitamin D deficiency in SLE patients, we need to 
compare them with healthy controls and it is obvious the concomitant need of a non-
supplemented SLE cohort.  
The negative association of Vitamin D status with obesity is well documented in                                                                                                                                                                                                          
different studies (Peterson, Tosh, & Belenchia, 2014; Vogt, Baumert, Peters, Thorand, 
& Scragg, 2016). Concerning our study with healthy blood donors, an inverse 
correlation was observed between 25(OH)D levels and BMI. This is probably due to the 
decreased bioavailability of Vitamin D from cutaneous and dietary sources as a result 
of its sequestration in body fat compartments (Pourshahidi, 2015).  
In conclusion, season and BMI are predictors for Vitamin D deficiency in healthy 
population. As expected, season is also a predictor for lower levels in lupus patients. 
More significant is the fact that 74% of healthy adults are Vitamin D deficient and that 
this effect is similar in SLE patients. The fact that levels are identical in wintertime, 
points to that the main cause of Vitamin D deficiency is not SLE severity. 
The strengths of our epidemiologic studies comprise a detailed questionnaire 
documenting demographic data, blood sampling taking place through summer as well 
as winter times and a selection of a Vitamin D non-supplemented patients and controls. 
On the other hand, although the questionnaire in healthy population included data 
about sun exposure, sunscreens use, eating and smoking habits, physical activity, 
diagnosed pathologies, and use of medicines and/or food supplements, these 
parameters were only used to exclude confounding factors that could bias our results, 
and were not used in the analysis of the results, as that was beyond the scope of the 
study.  
These new data allowed the understanding that hypovitaminosis D is essentially 
iatrogenic in SLE patients and Vitamin D should be measured and given as 
supplement, not only to patients but also to populations at risk for AIDs. 
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5.2. Immunogenetic studies 
5.2.1. Discussion of hypothesis 2: Vitamin D status is related to SLE susceptibility. 
 
No SLE cohort exists in the world with extensive data on Vitamin D levels since 
the diagnosis. For this reason, studies relating SLE susceptibility and low Vitamin D 
levels are not available. On the other hand, it seemed challenging for many 
investigators the study of the importance of VDR polymorphisms in disease 
susceptibility (Mao & Huang, 2014; Xiong et al., 2014). 
Many studies have been published in different populations, but with inconsistent 
data and weak statistical correlations (Mao & Huang, 2014; Xiong et al., 2014). 
However, these populations need controlled Vitamin D levels since childhood, in order 
to remove the hypovitaminosis D effect in disease susceptibility.  Why this need? 
Because Vitamin D seems essential in central clonal selection, as described in the 
“introduction” section of this thesis (Ramagopalan et al., 2009). 
In our study, different, already described, associations of HLA-DRB1 alleles with 
different AIDs were observed. We confirmed the positive associations of HLA-
DRB1*03, HLA-DRB1*08 and HLA-DRB1*15 with MS in a large population of 
Portuguese MS patients (Cree, 2014; A. M. Silva et al., 2007) and SLE was positively 
associated with HLA-DRB1*03 and negatively associated with HLA-DRB1*09 and HLA-
DRB1*13. These observations are also important in other Rheumatic diseases. 
When AIDs were considered, the frequency of HLA-DRB1*03 was significantly 
overrepresented in the total of patients. This allele is associated with a wide range of 
AIDs (Bilbao et al., 2003), has low affinity for CLIP (class II-associated invariant chain 
peptide) and may not require HLA-DM to ensure peptide presentation, avoiding 
efficient peptide selection and allowing the binding of low stability peptides (Collado, 
Guitart, Ciudad, Alvarez, & Jaraquemada, 2013). Our observations suggest that the 
HLA-DRB1*13 allele may confer protection for AIDs. HLA-DRB1*13 is a high frequency 
allele in the general population and its frequency in this sample of the Portuguese 
population is similar to the ones observed worldwide (Bruno & Lima, 2013). This 
sustains that the lower frequency of HLA-DRB1*13 in every individual AIDs groups is 
not secondary to the deviations granted by the concurrent positive associations. 
When the data obtained from previous studies are taken into consideration, HLA-
DRB1*13 seems to be an almost universal protective allele for RA (Jun et al., 2007; 
Oka et al., 2014; Ucar et al., 2012; van der Helm-van Mil et al., 2005; van der Woude et 
al., 2010). Recently, this allele was also described to be protective in SLE in the 
Japanese population (Furukawa et al., 2014). Subtle structural differences in the HLA 
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molecule have functional implications at the protein level. Specific amino acid patterns 
at the peptide binding cleft are involved in disease susceptibility, such as the well 
known shared epitope first described in the RA susceptibility alleles HLA-DRB1*01 and 
HLA-DRB1*04 (Michou et al., 2006). In a recent study, Van Heemst and collaborators 
identified (citrullinated) vinculin, present in the joints of Anti-Citrulinnated Protein 
Antibodies (ACPA)+ RA patients, as an autoantigen targeted by ACPA and CD4+ T 
cells. These T cells recognize an epitope with the core sequence HLA-DR Rheumatoid 
Arthritis Protective Epitope (DERAA), which is also found in many microbes and in 
protective HLA-DRB1*13 molecules, presented by predisposing HLA-DQ molecules. 
Intriguingly, DERAA-directed T cells are not detected in HLA-DRB1*13+ donors, 
indicating that the DERAA epitope from HLA-DRB1*13 mediates (thymic) tolerance in 
these donors, thus explaining the protective effects associated with HLA-DRB1*13. The 
authors suggest that subjects HLA-DRB1*13+ will present the HLA-DRB1*13-derived 
DERAA-peptide in the thymus, leading to tolerization of the DERAA-reactive T cell 
response (van Heemst et al., 2015). The negative association we describe here 
supports the idea that the HLA-DRB1*13 allele, possibly by its specific structural 
features, may as well influence disease status by conferring resistance to AIDs. The 
protective effect of HLA-DRB1*13 could be explained by a more proficient antigen 
presentation by these molecules, favouring an appropriate immune response 
(Diepolder et al., 1998; Ramezani et al., 2008). As a result, negative selection and 
development of HLA-DR-driven autoreactive regulatory T cells are promoted (Tsai & 
Santamaria, 2013). 
 
A different model would relate HLA molecules with the presence of specific 
endophenotypes indirectly associated with autoimmunity. Fesel C. suggested in 2012 
that the HLA genotype may primarily influence the general activation state of CD4 T-
cells, instead of disease outcome (Fesel et al., 2012). The apparent protective effect of 
HLA-DRB1*13 could also be explained by this effect. Curiously, several reports have 
suggested an association of HLA-DRB1*13 and/or HLA-DQB1*06 with slow disease 
progression in human immunodeficiency virus-infected individuals, meaning that 
among HIV controllers there is an association between the presence of certain class II 
HLA alleles and strong CD4 T-cell responses (Ferre et al., 2010; Malhotra et al., 2001). 
Low sunlight exposure is postulated to be the major latitude-linked component in 
MS risk (Acheson, Bachrach, & Wright, 1960). The HLA-DRB1*0301 allele, like 
the HLA-DRB1*1501 allele, harbours a putative VDRE in its promoter region 
(Ramagopalan et al., 2009). Alleles without the putative VDRE were associated with 
disease resistance. These parallel results suggest an influence of UV light and Vitamin 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
99 
 
D on HLA-DRB1 gene expression and presentation to CD4+ T lymphocytes of peptides 
relevant to Type 1 Diabetes and MS etiology. The nature of the peptides as well as the 
timing and outcome of the presentation event are unknown. These could be related to 
thymic tolerance or peripheral T-cell responses to peptides from infectious agents 
(Hayes et al., 2015). 
The genetic data obtained in this work cannot allow us to assume any 
relationship between SLE susceptibility and Vitamin D. However, we found the same 
risk allele HLA-DRB1*03 for SLE, which has the functional canonical VDRE in its 
noncoding sequence, and the same protective HLA-DRB1*13, which has a mutant non-
effective VDRE. The answer to our question needs studies out of this thesis scope, but 
it would be interesting to study the mother-child effect of Vitamin D deficiency and 
relate them to this risk and protective alleles. Does this effect may explain the low 
incidence of autoimmune diseases in the African population? May the phenotypic 
change that is seen in this population when they migrate to other latitudes be explained 
by this effect? These questions should be answered with maternal and child 
population-based studies in different world latitudes. This seems to be the way Vitamin 
D could be related to SLE susceptibility. 
The association of UV radiation and Vitamin D with autoimmune disease risk is 
strong and consistent, shows a dose–response relationship, is temporally plausible and 
appears to be universal with respect to genotypes, dietary and smoking habits, and 
exposure to infectious and commensal organisms. Thus, it is reasonable to suggest 
that Vitamin D is probably the environmental factor with the greatest influence on the 
emergence of an autoimmune disease phenotype given a disease-susceptible 
genotype. What remains to be done is to rigorously test this correlation in humans 
experimentally, and to uncover plausible biological mechanisms that coexist with 
known facts of autoimmune disease. 
  
 
5.2.2. Discussion of Hypotheses 3 and 4 
Hypothesis 3:  SLE severity is related to VDR Polymorphisms. 
Hypothesis 4: Vitamin D deficiency is associated with SLE severity. 
These studies, to the best of our knowledge, established, for the first time, an 
association between VDR polymorphisms (TaqI and FokI) and a higher long-term 
cumulative damage in SLE patients. 
The Vitamin D receptor is a pleiotropic gene associated with multiple autoimmune 
diseases. ApaI, BsmI and TaqI polymorphisms do not affect directly VDR protein 
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structure, but differences in stability and/or translation efficiency of the RNA have been 
reported. The FokI polymorphism seems to have consequences for both VDR protein 
structure and transcriptional activity (van Etten et al., 2007). Thus, VDR gene 
polymorphisms can modify the immunomodulatory action of Vitamin D and may have 
an effect on the clinical manifestations of SLE, namely autoantibody production 
(Ritterhouse et al., 2011). 
Four previous studies in Asian populations reported a positive association 
between BsmI and FokI VDR polymorphisms and susceptibility to SLE (Huang, Wu, 
Wu, & Tsai, 2002; Luo et al., 2012; Luo et al., 2011; Ozaki et al., 2000). It has also 
been observed that VDR polymorphisms may influence clinical manifestations. 
Concerning nephropathy, an association with the bb genotype of BsmI was described 
in a Japanese cohort by Ozaki et al. On a Han Chinese population, Luo et al. 
associated this nephropathy with the B allele of the same polymorphism. Emerah et al. 
replicated this result in an Egyptian female population, observing that AA (ApaI) and FF 
(FokI) genotypes were also risk factors for the development of nephropathy in SLE 
patients. In a study of Polish females, Mostowska et al. compared patients with and 
without renal symptoms and observed that the FF and Ff genotypes of FokI had higher 
frequencies in patients with clinical manifestations. Additional research associated VDR 
polymorphisms with other SLE features such as serositis, ANA, anti-dsDNA, anti-Sm 
and anti-histone antibodies (Luo et al., 2012; Luo et al., 2011). In other studies, no 
association between VDR polymorphisms and SLE was reported (Abbasi et al., 2010; 
Kaleta et al., 2013; Monticielo, Teixeira Tde, Chies, Brenol, & Xavier, 2012; 
Sakulpipatsin et al., 2006). 
In summary, the association between Vitamin D receptor polymorphisms and 
SLE has been extensively studied, but the results described are widely dissonant so 
far. The comparison of data present in the literature is difficult, due either to study 
design or ethnic differences. Up to date, the role of VDR polymorphisms in this disease 
remains uncertain and limited by the lack of controlled Vitamin D populations.  
These studies suggest a role for VDR gene polymorphisms in SLE long-term 
outcome. A positive association was found between VDR polymorphisms and SLE 
damage accrual. The presence of CT genotype of FokI and TT genotype of TaqI 
seems to confer risk for a worse prognosis, being a risk factor for a higher long-term 
cumulative damage. Several hypotheses may explain these results. 
It is known that VDR polymorphisms may alter VDR expression, transcription and 
function, and thus these modifications may interfere with Vitamin D activity. In fact, 
Vitamin D has an important role in the control of inflammatory responses with a switch 
from Th1 to Th2 cytokine profile, enhancing Th17 pathway via transcriptional 
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modulation of interleukin-17A, as well as facilitating an induction of regulatory T cells 
(Joshi et al., 2011; Peelen et al., 2011). 
Additionally, VDR polymorphisms may also be in linkage disequilibrium within 
HLA-DRB1 alleles that are central players in several autoimmune diseases (Israni, 
Goswami, Kumar, & Rani, 2009). 
Furthermore, VDR signalling may influence the transcriptional activity of genes 
involved in the pathophysiological mechanisms of autoimmune diseases. The promoter 
region of HLA-DRB1 locus has a Vitamin D responsive element that controls/regulates 
HLA-DRB1 expression (Israni et al., 2009; Ramagopalan et al., 2009). Binding of 
1,25(OH)2D3 originates conformational changes in VDR, which promote its hetero-
dimerization with RXR and translocation of this complex into the nucleus. The RXR-
VDR heterodimer binds to the Vitamin D responsive elements in promoter regions of 
1,25(OH)2D3 responsive genes, such as HLA-DRB1 gene. It has been described that 
Vitamin D deficiency in early childhood may lead to lower HLA-DRB1 expression, 
impairing thymic selection and promoting autoimmune disease development (Israni et 
al., 2009). 
Despite the positive association observed between CT genotype of FokI and TT 
genotype of TaqI and SLE damage accrual, there is a lack of clear association with the 
number of affected organs, number of severe flares and pharmacological therapy. This 
can be explained by the small number of individuals in each subgroup, nevertheless 
the main explanation is that damage in SLE is multifactorial and not only related to 
disease activity itself. For example, a more inflammatory profile could be found in 
Lupus patients, which could explain a worse long-term prognosis. This is not 
necessarily related to disease activity, but with other factors, as already described in 
larger cohorts, like cardiovascular disease (Perez-Hernandez et al., 2016). 
These results provide a support to the hypothesis that Vitamin D polymorphisms 
are associated with SLE disease activity, although the number of subjects studied was 
relatively small. Therefore, this finding requires independent replication in larger 
cohorts (Liberman, 2007). 
Furthermore, we did not find a correlation between VDR polymorphisms and low 
Vitamin D levels at disease onset, neither with Vitamin D average levels over 10 years. 
Moreover, the effect found on disease damage with diverse VDR SNPs was unrelated 
to Vitamin D levels (data not presented). 
In the same cohort, we also analysed baseline Vitamin D levels and correlated 
them with the number of severe flares. We observed a significant inverse correlation 
between these two variables, specifically in patients with three or more severe flares. 
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Finally, we studied patients with available mean Vitamin D levels in the previous 
10 years of disease and correlated them with the number of severe flares. Once again, 
we observed a negative correlation but it was not significant; on the other hand, 
statistical significance was obtained for patients with ≥3 severe flares.  
In conclusion, in Lupus patients with VDR risk genotypes, Vitamin D 
supplementation could be a useful strategy for prevention of long-term cumulative 
damage, compensating VDR dysfunction. Vitamin D daily dose should be adapted to 
the concept of “Vitamin D Resistant State” and the optimal dose should be tailored for 
each patient. Individual genotype cannot be changed; however, Vitamin D deficiency 
can be searched and addressed accordingly. 
We propose that patients with Vitamin D deficiency, and heterozygotes for FokI 
and TT for TaqI polymorphisms of VDR, have more severe disease and damage. 
 
 
 
5.3. Interventional studies 
5.3.1. Discussion of hypotheses 5 and 6. 
Hypothesis 5: Supplementation with Vitamin D alters the clinical expression and 
immunological deregulation of SLE patients (T-CD4+ cells expressing FoxP3 and T-
CD4+ cells producing IL-17A. 
Hypothesis 6: Clinical and Immunological response to Vitamin D supplementation is 
limited by SLE disease activity.  
In these studies, for the first time, we assessed the safety, the clinical and 
immunological effects of Vitamin D supplementation in patients with SLE in a 
Portuguese population. We addressed 24 stable patients, with stable therapy, and 
supplemented them during 6 months guided by levels and aiming more than >75 
nmol/L. The protocol comprised the registry of flares, new damage and, more 
important, the FoxP3 expression and IL-17A in T CD4+ cells. We also created a 
concept of FoxP3/IL-17A ratio to use as a biomarker of immunologic imbalance. We 
confirmed the high frequency of hypovitaminosis D in SLE patients (70.8%) already 
described in some studies, and we have also demonstrated that Vitamin D 
supplementation significantly increased serum 25(OH)D levels, at 3 and 6 months after 
the beginning of the study. Furthermore, it was shown that this therapy was safe, since 
no alterations on phosphorus or calcium levels and no side effects were reported. 
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After 6 months of Vitamin D supplementation, it was observed an increase of 
FoxP3 expression in CD4+ T cells and a decrease in IL-17A cells. The FoxP3+/IL-17A 
ratio was found to be significantly higher at the end of the treatment. This effect was 
also observed in patients with elevated Vitamin D levels at baseline, showing that 
immunological effects were unrelated to the standard cut-offs used for metabolic bone 
disease. These results suggest that Vitamin D supplementation may improve 
FoxP3+/IL-17A ratio (and indirectly the Treg/Th17 ratio), an effect described for the first 
time in SLE patients. Vitamin D supplementation was shown to be a safe and efficient 
treatment to improve clinical and immunological stability in SLE patients, as well as for 
flare prevention. Since none of the patients exhibited complications resulting from 
Vitamin D supplementation, perhaps the administered doses could be increased, 
maintaining the safety profile and leading to even better results. 
 MicroRNAs (miRNA) have gene expression regulatory roles in innate immunity 
(Chan, Ceribelli, & Satoh, 2013). The miR-146a, an NFkB regulated transcript, is 
activated during LPS stimulation of monocytes and is critical in endotoxin tolerance to 
prevent cellular overstimulation when in excess of the TLR4 ligand. So, miR-146a act 
as a negative regulator of innate immunity (Ma, Becker Buscaglia, Barker, & Li, 2011). 
Interestingly, miR-146a has been reported to be upregulated in PBMCs and synovial 
tissue in rheumatoid arthritis patients, but reported to be downregulated in PBMCs of 
SLE patients (Qu et al., 2015). Further analysis showed that underexpression of miR-
146a negatively correlated with clinical disease activity and with IFN scores in patients 
with SLE (Tang et al., 2009).   
Of note, miR-146a directly repressed the downstream transactivation of type I 
IFN. At the molecular level, miR-146a targeted IFN regulatory factor 5 and STAT-1 
(Saba, Sorensen, & Booth, 2014). The ability of Vitamin D to regulate miRs and their 
emerging relationship have been proposed through several experimental and clinical 
approaches; however, the implications of their impact in inflammatory responses have 
only been studied in in vitro models (Arboleda & Urcuqui-Inchima, 2016). The aim of 
this study was to determine the Vitamin D effect in miR-146a expression as well as in T 
CD4+CD25+FoxP3+ (Treg) and TCD4+ IL-17A producing cells, in active SLE.   
Furthermore, we have treated 4 patients with severely active SLE (with clinical 
SLEDAI >6 and at least one BILAG A for an organ or system) with high doses of 
Vitamin D. These patients had previous supplementation and only one had a mild 
deficiency. It was shown here that even with high dose therapy there was no effect on 
Vitamin D levels. Two patients were treated with 50,000 IU of cholecalciferol for 3 
weeks and the remaining 2 with 100,000 IU weekly for 3 weeks. Interestingly, it was not 
demonstrated a significant increase in Vitamin D levels in these patients and much less 
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a change (decrease) in miR-146a expression, which has already been described in 
other studies. The miR-146a expression is described to be low in SLE and its 
expression down-regulates IFN-α production (Ma et al., 2011). We also did not found 
any enhancement in CD4+CD25+FoxP3+ T-cells and CD4+IL-17A+T-cells ratio (Treg/IL-
17A ratio), as it was observed in the stable SLE patients study. 
 It was shown earlier that disease activity may not be important in patients’ 
Vitamin D status, but in this open-label study, we found that disease activity may 
prevent its increase and hence truncate its immunomodulatory effect. As such, it 
appears to be resistance to treatment with Vitamin D (even without hypovitaminosis) 
and this is associated with very active disease. However, this effect does not seem to 
occur in stable patients and low activity SLE patients. 
 
In conclusion, these studies demonstrated that Vitamin D supplementation seems 
to provide favourable immunological effects in patients with SLE, independently of the 
25(OH)D patients’ status. Nevertheless, these results should be interpreted with 
caution since previous studies evaluating the supplementation of 25(OH)D in SLE 
disease have had inconsistent results.  
It is important to consider every existing variable and their specific outcomes in 
each patient. Using the FoxP3+/IL-17A ratio, it may be possible to tailor Vitamin D 
therapy for each patient. An individualized therapy should be undertaken, since some 
patients will need very high doses of supplementation whereas others will need only 
modest doses to achieve the same outcome. In these stable patients we showed, 
indirectly, that the general guidelines (>75 nmol/L) are probably not enough to achieve 
a better immunological tolerance state. 
Finally, we are closing the gate of the resistant state to Vitamin D in SLE. It 
seems that cholecalciferol regulatory effects are dependent of SLE disease activity, 
and there seems to be a window of opportunity to supplement these patients with 
higher doses of Vitamin D. During severe flares, a resistant state to Vitamin D 
supplementation and benefits may exist. 
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5.4. Main Conclusions 
 
 
 
Table 25 - Main conclusions. 
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5.5. Future directions 
Theoretically, Vitamin D should have relevant effects on musculoskeletal health, 
immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia 
and even mortality. However, many of these effects are theoretical and it is necessary 
to demonstrate these in vivo cellular effects, detected in vitro, in a large group of 
patients followed in a systematic and controlled manner. These studies are needed to 
identify the optimal dose of Vitamin D for each patient, based on their clinical, genetic 
and physiopathological state. On a quick observation of the factors that modulate the 
response to Vitamin D, it would be tempting to use very high doses, because they 
seem safe and could surpass any therapeutic resistance. However, secure scientific 
evidence only applies to calcium metabolism, and other deleterious effects of the 
hormone when used massively are essentially unknown.  
As such, the great challenge is to recognize all factors involved in the 
modulation of Vitamin D, such as transcriptomic and epigenetic factors, polymorphisms 
of various enzymes, key receptors of its metabolism, specific cellular targets and the 
expression of cytokines. This is the only way we can develop tailored therapies for 
each disease and each patient using an individualized treatment plan. 
 
 Vitamin D levels in SLE patients are needed to be addressed further. It is 
necessary to study the difference between summer and winter in a larger cohort 
and in different populations, which could allow us to confirm that SLE activity is not 
a determinant for lower Vitamin D levels. 
 
 We should study further VDRE in protective and risk HLA alleles, the effect of 
different latitudes and start to study mothers and newborns. 
 
 VDR polymorphisms can be biomarkers for damage in SLE and their identification 
in these patients should be studied. 
 
 Vitamin D supplementation may have a window of opportunity for 
immunomodulation, during SLE low disease activity phases. 
 
 We need new guidelines for Vitamin D supplementation in SLE. 
 
 An RCT study should be done using better Vitamin D analogues or in combination 
with immunosuppression during severe disease flares. 
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Abstract 
 
 
 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease 
with multi-organ inflammation, linked to the loss of immune tolerance to self-
antigens and the production of a diversity of autoantibodies. The phenotype and 
progression of SLE have been linked to a combination of environmental, genetic 
and hormonal factors. One such environmental factor is Vitamin D, a vital 
hormone with well-established effects on mineral metabolism, skeletal health 
and effects on cardiovascular system. The purpose of this article is to make the 
analysis of evidence and literature review of the pleomorphic effects of Vitamin 
D in SLE. The article is structured in topics of interest based in the authors’ 
opinion and summarizes the evidence of studies and trials of Vitamin D in SLE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease 
with multi-organ inflammation, linked to the loss of immune tolerance to self-
antigens and the production of a diversity of autoantibodies. 
In adults, the female to male ratio, is approximately 9:1, the peak age of SLE 
diagnosis is between 15 and 44 years, affecting mainly women of childbearing 
age [1]. There is evidence of strong genetic contribution to the development of 
SLE: familiar prevalence was found to be 5.6% if one first degree relative is 
affected; disease concordance in dizygotic twins is 2-5% and in monozygotic 
twins 29-57% [2]. 
The phenotype and progression of SLE have been linked to a combination of 
environmental, genetic and hormonal factors [1, 3]. One such environmental 
factor is Vitamin D, a vital hormone with well-established effects on mineral 
metabolism, skeletal health and effects on cardiovascular system [4;5] The 
major source of vitamin D, at least in lower latitudes is sun exposure. Vitamin D 
is also available in some foods and supplements. 
The identification of vitamin D receptors in immune system cells and the 
discovery that dendritic cells can produce the metabolically active form of 
vitamin D, 1,25-dihydroxyvitamin D3 (calcitriol), have led to the suggestion that 
vitamin D is an immune modulator and also anti-infective agent [6,7,8,9] This 
can explain why vitamin D deficiency-related symptoms, such as fatigue, are 
frequently observed in patients with SLE [10]. Furthermore, SLE patients may 
be at increased risk of low vitamin D status as a result of both photosensitivity, 
with consequent sun avoidance, as well as chronic use of medications which 
interfere with vitamin D metabolism [11, 12]. Moreover, the existence of Vitamin 
D response elements in key promoter regions of HLA-DRB1 [13], 
polymorphisms in key enzymes and receptors of vitamin D metabolism, can 
explain why patients have different clinical responses during supplementation 
[14]. Vitamin D deficiency is categorized in different classifications, but it can be 
classified as optimal, insufficiency/inadequacy and deficiency (supplement 1) 
[15].  
The purpose of this article is to make the analysis of evidence and 
literature review of the pleomorphic effects of Vitamin D in SLE. The article is 
structured in topics of interest based in the authors’ opinion. In appendix 2 we 
present a summary of the trials and studies with Vitamin D intervention in SLE. 
 
 
 
 
 
 
 
1 - Vitamin D and SLE susceptibility  
 
 
 
 
Vitamin D insufficiency may be an important factor in SLE susceptibility 
during early life, based on Vitamin’s D effect in auto-reactive T-lymphocytes 
central deletion [13, 14]. We can look for autoimmune susceptibility as an 
“early-life” condition in which vitamin D insufficiency is also a determining factor 
for an auto-reactive profile. Vitamin D response elements (VDREs) have been 
found in the promoter region of the Multiple Sclerosis (MS) associated allele 
HLA-DRB1*15:01 [13, 14] suggesting that with low vitamin D availability, 
VDREs are incapable of inducing *15:01 expression allowing early life auto-
reactive T-cells to escape central thymic deletion. These findings have been 
found in MS, however in SLE that should also occur. 
In our epigenetic data we genotyped for HLA-DRB1 locus 1228 patients 
with autoimmune diseases (AIDs): 213 with Systemic Lupus Erythematosus 
(SLE), 166 with Psoriasis or Psoriatic Arthritis (Ps + PsA), 153 with Rheumatoid 
Arthritis (RA), 67 with Systemic Sclerosis (SSc), 536 with Multiple Sclerosis 
(MS), and 93 with Myasthenia Gravis (MG) and 282 unrelated controls. We 
confirmed previously established associations of HLA-DRB1(∗)15 (OR = 2.17) 
and HLA-DRB1(∗)03 (OR = 1.81) alleles with MS, HLA-DRB1(∗)03 with SLE 
(OR = 2.49), HLA-DRB1(∗)01 (OR = 1.79) and HLA-DRB1(∗)04 (OR = 2.81) 
with RA, HLA-DRB1(∗)07 with Ps + PsA (OR = 1.79), HLA-DRB1(∗)01 (OR = 
2.28) and HLA-DRB1(∗)08 (OR = 3.01) with SSc, and HLA-DRB1(∗)03 with MG 
(OR = 2.98). We further observed a consistent negative association of HLA-
DRB1 (∗) 13 allele with SLE, Ps + PsA, RA, and SSc (18.3%, 19.3%, 16.3%, 
and 11.9%, resp., versus 29.8% in controls). HLA-DRB1 (∗) 13 frequency in the 
AIDs group was 20.0% (OR = 0.58). Although different alleles were associated 
with particular AIDs, the same allele, HLA-DRB1 (∗) 13, was underrepresented 
in all of the six diseases analyzed. This observation suggests that this allele 
may confer protection for AIDs, particularly for systemic and rheumatic disease.   
    The protective effect of HLA-DRB1 (∗) 13 could be explained by a 
more proficient antigen presentation of these molecules, favoring efficient clonal 
deletion during thymic selection [16]. However, an association with VDRE is yet 
to be proven. 
 
We thus postulate that vitamin D preventive role in SLE (and other 
autoimmune diseases) could be limited in time, during the development of 
the immune system. Later on, its role should be essentially a modulating 
one. 
With these ideas in mind, retrospective epigenetic susceptibility 
studies, that do not have controlled Vitamin D population levels in 
childhood, have little scientific validity. The susceptibility studies related 
with polymorphisms of vitamin D receptor are such an example, with 
different susceptibility profiles in different populations, but without 
controlled vitamin D levels in the studied population [17, 18]. 
 
 
2 - SLE and Vitamin D a paradoxical phenomenon  
 
Usually, patients with established SLE lack vitamin D. The reduced sun 
exposure, the use of sunscreens, the gut malabsorption (example: secondary to 
drugs such as corticosteroids), among others, are all significant factors for this 
steroid hormone insufficiency [19]. However, sun exposure, the most important 
factor for vitamin D precursor synthesis at the skin level, is also one of the 
strong activators of SLE flares, possibly because the ultraviolet (UV) 
wavelengths of sunlight potentiates the stimulator of interferon genes (STING)-
dependent activation of the immune signaling transcription factor interferon 
regulatory factor 3 (IRF3) in response to cytosolic DNA and cyclic dinucleotides 
in keratinocytes and other human cells [20]. 
 
This paradoxical phenomenon, being well recognized, is also 
ignored in the supplementation strategies, which are based on the general 
population guidelines. SLE patients need treatment strategies based on 
serum levels of 25-hydroxyvitamin D and not standard supplementation 
strategies, even though serum levels of 30 ng/ml are validated to 
metabolic bone disease but not for immunological effects [21]. 
 
 
3 - The emerging role of vitamin D in immunomodulation 
  
 
Vitamin D is a steroid hormone with a nuclear receptor, the Vitamin D 
receptor (VDR). This receptor is present in all immune system cells. Many key 
genes to immune regulation have VDREs [22]. So, beyond its classical function 
in calcium metabolism, it has an essential role in immune modulation. This 
Vitamin exercises its role both at the innate immunity and adaptive immunity 
levels. The hormone has a modulator role in the activation of dendritic cells and 
their ability to present antigens. Moreover, it polarizes the adaptive immune 
response to a Th2 response [4]. Finally, it is essential to the expression of the 
transcription factor forkhead box P3 (FoxP3), via VDRE present in the promoter 
region of his gene and therefore essential to the normal expression of 
regulatory T cells [21]. 
 
Taking this in consideration, it seems logical to have an 
inflammatory profile in patients with vitamin D deficiency. However, the 
benefit and efficacy of Vitamin D supplementation are very heterogeneous 
among different patients and different diseases. Many questions about 
dosage and patients’ optimization are still in debate. 
 
 
 
 
 
 
 
 
 
3.1 Vitamin D and Antigen Presenting Cells (APC) in SLE 
 
Lerman et al. studied the ability of 1,25-dihydroxyvitamin D3 to affect 
human monocyte phenotype. This phenotype was assessed by incubating cells 
with sera from 15 patients with SLE and from 5 healthy volunteers. Addition of 
1,25-dihydroxyvitamin D3 resulted in significant reductions in the expression of 
MHC Class II, CD40, and CD86 and increases in expression of CD14 in both 
types of sera. Overall, 1,25-dihydroxyvitamin D3 limited human APC activation 
via IFNα-induced and independent mechanisms. 1,25-dihydroxyvitamin D3 
inhibited APC activation by SLE sera, suggesting that it may be possible for 
1,25-dihydroxyvitamin D3 to reduce the immunostimulatory effects of the SLE 
milieu by interfering with the soluble cytokine mediators in the sera of SLE 
patients [23]. 
 
Ben-Zvi et al. studied 19 SLE patients stratified by 25-hydroxyvitamin D 
There were no differences between circulating Dendritic Cells (DC) number and 
phenotype. Monocyte-derived DCs (MDDCs) of SLE patients were normally 
responsive to the regulatory effects of vitamin D in vitro as evidenced by 
decreased activation in response to LPS stimulation in the presence of 1,25-
dihydroxyvitamin D3. Additionally, vitamin D supplementation reduced 
expression of interferon-alfa regulated genes by healthy donors and SLE 
MDDCs in response to factors in activating SLE plasma [7]. 
 
Wu HJ et al. showed that “tolerogenic” dendritic cells (DCs) are a 
potential cell-based therapy in SLE by treating monocyte-derived DCs from SLE 
patients and healthy subjects with combination of 1,25-dihydroxyvitamin D3 and 
dexamethasone followed by lipopolysaccharide-induced maturation. Lupus 
activated DCs were found to acquire semi-mature phenotype that remained 
maturation-resistant to immunostimulants and was also found to acquire 
enhancing Regulatory-T Cells phenotype [24]. 
 
Finally, Cynthia Aranow, et al. published a Randomized Controlled Trial 
(RCT) trying to prove the effect of vitamin D supplementation in interferon 
signature. The studied failed the primary outcome [25]. 
 
 
 
   We learned from Aranow’s RCT that we still do not know in vivo 
behavior of this effect on interferon signature and human studies with 
tolerogenic dendritic cells in SLE are not yet available. We also do not 
know if the effect on APC is identical in the various body compartments 
with different cytokine expression, for example in lupus nephritis, which 
can be the only manifestation of SLE. On the other hand, we do not know 
the role of MHC Class II down-regulation in APC in patients with only 
positive antinuclear antibodies, in serological active quiescent Lupus 
(SAQLs) or during severe flares. It is necessary to replicate the effect in 
vivo and to know in which stage of the disease this adjustment brings 
more benefit. Dendritic cells’ induced tolerance may be essential in the 
early stages of the disease and less important during severe flares. 
 
3.2 – Vitamin D, Regulatory T-Cells and T-Helper 17 Cells 
 
 
Terrier et al. showed the safety and efficacy of 25-hydroxyvitamin D high 
doses supplementation on restoration of regulatory and effector T cell balance 
and B cell homeostasis in 24 SLE patients [26]. However, several limitations 
were found in this study. The time established for new flares (6 months) is too 
short to evaluate this effect. On the other hand, there is no control group with 
evaluation of regulatory T cells, TH 17 cells and IL17A expression in a healthy 
population. We only know that vitamin D changes the profile of immune 
dysregulation, but its meaning is completely unknown. We also do not know if 
numerical changes correct functional changes [27]. However, one can say that 
vitamin D high doses are a safe therapy.  
 
Viviane de Souza et al. in a small open-label study from Brazil also found 
that vitamin D deficiency was more prevalent in patients with SLE and was 
associated with higher levels of interleukine-6 (IL-6) [28]. 
 
Banica LM et al. showed in vitro that rapamicin and vitamin D together 
were able to induce regulatory properties in CD4+ T-Cells. However, this 
sustained effect was observed only in rapamycin group [29]. 
 
Piantoni S et al. also showed an enhancement of T-reg cells and the 
production of Th2 cytokines after a long-term of monthly treatment with vitamin 
D in SLE patients. These numeric differences were only significant after 2 years 
of treatment [30]. 
 
Wahono CS et al. and Drozdenko et al. showed that the effect of vitamin 
D therapy was mainly on IL17-A cytokine expression and less on regulatory T-
Cells [31, 32]. 
 
In our data from Oporto, we obtained the same findings. However, 
Forkhead box P3 (FOXP3) expression can also be enhanced in patients who 
are not vitamin D deficient, in part because, may be, the reference value of 
vitamin D in autoimmune diseases, 75nmol/L (30ng/mL), is not the ideal one. 
[33]. 
 
 
In summary, we found a universal trend to vitamin D immune 
regulation based on regulatory T-Cell properties and IL17A expression. 
However, we need controlled trials with a large number of SLE patients, 
controlled methodology, especially functional studies with micro-RNA of 
inducible regulatory T-Cell genes and time dependent studies. Maja Vukić 
et al. made the first trials with this concept. They studied 71 patients from 
the VitDmet study (ClinicalTrials.gov Identifier: NCT01479933) and 10 from 
VitDbol (ClinicalTrials.gov Identifier: NCT02063334). In an interventional 
prospective study, they correlated the changes in mRNA expression with 
serum 25(OH) D3 level in primary human cells. In peripheral blood 
mononuclear cells, direct transcriptional effects were observed on 
selected VDR target genes, such as an up to 2.1-fold increase, after one 
day only of supplementation onset, showing that both long-term and 
short-term vitamin D3 supplementation studies allow monitoring of the 
vitamin D responsiveness of human individuals and represent new types 
of human in vivo vitamin D3 investigations [34]. 
 
 
 
 
 
4 - Vitamin D Inflammation and atherosclerosis 
 
Vascular protective effects of vitamin D have been postulated due to 
modulation of inflammatory cytokines. However, the effects of vitamin D 
supplementation on inflammatory cytokines in trials have been inconsistent.  
Petri et al. studied 200 patients enrolled in the Lupus Atherosclerosis 
Prevention Study and found 25-hydroxyvitamin D was not associated with any 
measure of subclinical atherosclerosis. 25-hydroxyvitamin D deficiency was 
associated with higher high sensitive C-reactive protein (hsCRP) at baseline, 
but did not predict a change in hsCRP over 2 years [35]. 
 
However, in pediatric Lupus patients enrolled in the Atherosclerosis 
Prevention in Pediatric Lupus Erythematosus (APPLE) substudy [36, 37] the 
same data were not consistent with the adult’s study. They also found that 
vitamin D deficiency is independently associated with elevated hsCRP, a 
marker of inflammation that predicts cardiovascular disease risk. Although 
association is not proof of causation and they did not study the impact of vitamin 
D supplementation in hsCRP during the follow-up of these patients. By chance, 
the same study found that Vitamin D status is a determinant of atorvastatin 
effect on carotid intima medial thickening progression rate in children with lupus 
at 3 years, and it was significant. 
 
Lertratanakul et al. reported a retrospective study from a large 
international inception cohort; they studied the risk of cardiovascular (CV) event 
incidence. Patients in the higher quartiles of 25-Hydroxivitamin D were less 
likely to have hypertension and hyperlipidemia and were more likely to have 
lower C-reactive protein levels and lower Systemic Lupus Erythematosus 
Disease Activity Index 2000 (SLEDAI 2000) scores at baseline when compared 
with the first quartile. Vitamin D levels were not independently associated with 
CV event incidence; however, hazard ratios for CVD event incidence decreased 
with successively higher quartiles [38]. 
 
 
 
 
Reynolds et al. studied 75 SLE patients in a cross-sectional retrospective 
study to correlate Vitamin D levels with disease and markers of subclinical 
vascular disease. Their results were significant and correlate Vitamin D 
deficiency with increased aortic stiffness in SLE, independent of CVD risk 
factors and insulin resistance. They concluded that increased inflammatory 
disease activity may be the mechanism by which vitamin D deficiency mediates 
vascular stiffness in this patient group [39]. Sabio et al. showed the same 
results in a RCT [40]. 
 
Reynolds et al. also made a prospective study with vitamin D deficient 
SLE patients and described the effectiveness of calcitriol to restore angiogenic 
capacity of SLE myeloid angiogenic cells and to positively modulate the 
paracrine regulation of endothelial nitric oxide synthase [41]. 
 
Abou-Raya et al have done a randomized placebo-controlled trial with 
206 patients showing that high dose cholecalciferol was effective in disease 
activity control and in the improvement of hemostatic and inflammatory markers: 
Il-1, Il-6, IL18, TNF alfa, Von Willebrand factor and fibrinogen [42].  
 
In essence, there is enough evidence to say that vitamin D 
deficiency parallels hsCRP as an inflammatory biomarker for 
atherosclerosis and this effect is independent of insulin resistance. This 
observation could be because the effect is more significant on 
endothelium dysfunction rather than an improvement of metabolic 
syndrome. SLE, like RA, is an independent risk factor for atherosclerosis 
and vitamin D deficiency may be one modifying risk factor. 
The different data between the adult and pediatric patients are 
explained by different study designs, by the lack of a follow-up on the 
hsCRP after Vitamin D supplementation and by the fact that the adult 
study screening of the carotid intima medial thickening progression rate 
was not an association study with statins. 
It would be rather important to repeat the analysis of both groups 
with the statin effect and following-up the hsCRP in pediatric patients. 
]he recognition of SLE as risk factor for cardiovascular disease is 
very important in clinical practice and, like Rheumatoid Arthritis, a 
standard practice of correcting traditional and non-traditional risk factors 
is imperative [43].  
  
 
 
5 – Vitamin D resistant state and SLE 
 
SLE could be a conceptual form of resistance to vitamin D effect. This 
resistant state has multiple steps including the epigenetic mechanisms (also 
regulation of metabolic pathways), gene regulation in different cell types and 
vitamin D receptor polymorphisms (the transcriptome). 
The following summarizes the concept of resistance: 
 
a) Epigenetic mechanisms 
 
Epigenetic mechanisms play a crucial role in regulating gene expression as we 
showed above with the VDRE elements in non-coding sequences of MHC Class 
II [13, 14]. The main mechanisms involve methylation of DNA and covalent 
modifications of histones by methylation, acetylation, phosphorylation, or 
ubiquitination. Modifications in DNA methylation are performed mainly by DNA 
methyltransferases (DNMTs) and ten-eleven translocation (TET) proteins, while 
a plethora of enzymes, such as histone acetyltransferases (HATs), histone 
deacetylases (HDACs), histone methyltransferases (HMTs), and histone 
demethylases (HDMs) regulate covalent histone modifications.  
In many diseases, such as cancer, the epigenetic regulatory system is 
often disturbed. Vitamin D interacts with the epigenome on multiple levels. 
Firstly, critical genes in the vitamin D signaling system, such as those coding for 
vitamin D receptor (VDR) and the enzymes 25-hydroxylase (CYP2R1), 1α-
hydroxylase (CYP27B1), and 24-hydroxylase (CYP24A1) have large CpG 
islands in their promoter regions and therefore can be silenced by DNA 
methylation. Secondly, VDR protein physically interacts with coactivator and 
corepressor proteins, which in turn are in contact with chromatin modifiers, such 
as HATs, HDACs, HMTs, and with chromatin remodelers. Thirdly, a number of 
genes encoding for chromatin modifiers and remodelers, such as HDMs of the 
Jumonji C (JmjC)-domain containing proteins and lysine-specific demethylase 
(LSD) families are primary targets of VDR and its ligands. Finally, there is 
evidence that certain VDR ligands 1, 25-dihydroxyvitamin D3 have DNA 
demethylating effects [44].  
 
 
This is the first resistance mechanism. SLE, like cancer, is a state of 
DNA hypermetilation. The disease itself can mute key enzymes of its 
metabolism and create a state of deficiency of 25-hydroxyvitamin D. 
Conversely, its “DNA demethylating” effect can be important to the 
maintenance of key enzymes and their target genes, maintaining immune 
system homeostasis. Once again the replacement of cholecalciferol is not 
established and is likely to need very high levels or greater affinity 
analogs to overpass this resistance. This particular field lacks evidence. 
 
 
b) VDR function in transcriptomic era  
 
Vitamin D acts via binding to an intranuclear receptor, VDR, present in target 
tissues and cells. This receptor belongs to the superfamily of transacting 
transcriptional regulatory factors. In humans, VDR gene is located on 
chromosome 12q13.1, extends over 100 kb and includes eight protein-coding 
exons, six untranslated exons, eight introns and two promoter regions [45].  
Genome-wide overview does not involve additional signal transduction steps, 
as they are known for hydrophilic signaling molecules, such as peptide 
hormones, growth factors and cytokines. VDR shares the main structural 
characteristics of nuclear receptors, which is a highly conserved DNA-binding 
domain and a structurally conserved ligand binding domain VDRs. DNA-binding 
domain specifically contacts the hexameric consensus sequence RGKTSA (R = 
A or G, K = G or T, S = C or G) within the major groove of genomic DNA. 
However, like most other transcription factors, VDR uses a partner DNA-binding 
protein, in order to bind efficiently to its target sites. More than 20 years ago, 
this heterodimeric partner turned out to be the nuclear receptor retinoid X 
receptor (RXR). Steric constraints of the dimerizing DNA-binding domains of 
VDR and RXR determine the optimal binding site of the VDR-RXR complex as 
a direct repeat of two hexameric nuclear receptor binding motifs spaced by 
three nucleotides (DR3). Within VDRs ligand-binding domain, a network of 
some 40 mostly non-polar aminoacids forms a ligand-binding pocket in which 1, 
25-dihydroxyvitamin D3 and its synthetic analogs are specifically fixed with high 
affinity. This ligand binding process induces a conformational change to the 
surface of VDRs ligand-binding domain, which results in a significant change of 
VDRs protein-protein interaction profile: it transforms from a repressor to an 
activator [46]. The genome-wide location of VDR has essential information for 
understanding the pleiotropic physiological action of 1, 25-dihydroxyvitamin D3. 
  
Probably B cells have accessible VDR binding sites. Nevertheless, it can be 
questioned whether the regulation of a few hundred primary VDR target genes 
per tissue requires a far higher number of high quality genomic VDR binding 
sites. For the total of 23,409 non-overlapping VDR binding sites, full 75% of 
them are observed only in one cell type. These unique VDR binding sites may 
be the mediators of cell-type specific actions of the receptor and its ligand. In 
fact, on the level of VDR target gene expression, as measured by microarrays, 
it is already known that in most tissues a rather different set of genes respond to 
stimulation with 1, 25-dihydroxyvitamin D3. On the other hand, VDR locations 
that overlap between two or more tissues represent independent confirmations 
of the validity of a VDR binding site. Moreover, genomic regions that are 
recognized in multiple cell types by VDR may have a more generalized, and 
therefore likely higher, impact on the physiological actions of the receptor and 
its ligand than the cell type specific sites [46,47]. 
 
 
In turn, and in light of the renewed understanding of the distribution of 
transcriptional binding patterns and the diversity of RNA species, it is also timely 
to consider how these relationships illuminate VDR function [48]. 
 
Arash et al. published a RCT showing that vitamin D supplementation 
caused at least a 1.5-fold change in the expression of 291 genes that are 
involved in apoptosis, immune function, transcriptional regulation, and 
epigenetic modification, response to stress, cell cycle activity and differentiation. 
They identified 66 genes that were most significantly affected by the subjects' 
vitamin D status, comparing those who were vitamin D deficient with 25(OH)D 
of 16.2±4.2 ng/ml to those who had a 25(OH)D of 27.5±8.4 ng/ml at baseline. 
Of these 66 genes, 17 genes whose expression significantly changed after 
vitamin D3 supplementation in both deficient and insufficient/sufficient groups 
were found to have novel VDREs [49]. 
 
 
- The VDR Transcriptome regulation 
 
With the emergence of comprehensive transcriptomic approaches 
including microarray technologies, an understanding was developed concerning 
the VDR transcriptome in different cell types and treatment conditions. In many 
ways, these studies also highlighted the heterogeneity of VDR actions. This 
heterogeneity may in part reflect experimental conditions (e.g., growth 
conditions, ligand exposures) with very different cell lines, but also genuine 
tissue-specific differences of co-factor expression that alter the amplitude and 
periodicity of VDR transcriptional actions. These transcriptomic direct actions 
can regulate cell cycle, activate key enzymes (like kinases), chromatin 
remodeling and event demethylation effects very important in cancer and 
autoimmune diseases as showed above [45]. 
 
 
- VDR Regulation of Non-Coding RNA Species 
 
Many researchers have considered roles for non-coding RNA in the 
regulation of cell function and have begun to examine the interplay between at 
least 20 different types of different non-coding RNA. Many of these RNA 
species are gene regulatory RNAs and include microRNA (miRNA) and long 
noncoding RNA (long crane), whereas others are involved in the post-
transcriptional modification of RNA, for example small nucleolar RNA (snoRNA). 
The data is still sparse, but non-coding sequences regulation is an important 
mechanism regarding vitamin D/VDR interaction and immune regulation. An 
important example is the presence of VDRE elements in non-coding sequences 
of MHC-Class II [13]. It is likely that the increased application and integration of 
microarray and next generation sequencing approaches will identify the key 
networks downstream of the VDR transcriptome, pertaining to both protein 
coding and non-coding RNA [50]. 
 
 
- The Repertoire of VDR-Protein Interactions and Genomic Binding Sites 
New microarray studies showed that VDR combines with other proteins 
in a network of interactions, quite likely in a cell type specific manner, to 
participate in diverse gene regulatory networks. It remains to be established 
how targeted this is. The variation observed in both the type and position of 
binding sites for the VDR, depending on cell phenotype and disease state, 
suggests it is directed, and at least will establish a paradigm for hypothesis 
testing concerning what directs the VDR to bind and participate in gene 
transcription. The specificity of VDR signaling may arise due to integration with 
other perhaps more dominant transcription factors. 
Again, for other nuclear receptor the concept has emerged that receptor 
binding is guided by the actions of more dominant so-called pioneer factors 
including the Forkhead (FKH) family members. However, efforts to define the 
major pioneer factors for the VDR have proven to be less consistent between 
the different VDR microarray studies and may reflect the biology of the VDR, 
given its existence in the nucleus both in the presence and absence of ligand, 
such that a single dominant pioneer factor is not so deterministic [51].  
 
 
- Genetic Variation in VDR Binding – The VDR Polymorphisms 
 
Four common single nucleotide polymorphisms (SNPs) in the VDR gene 
have been extensively investigated: FokI C>T (rs2228570), BsmI A>G 
(rs1544410), ApaI G>T (rs7975232), and TaqI C>T (rs731236). BsmI and ApaI 
SNPs are both located in intron 8, and the TaqI is a silent SNP in exon 9. 
Although these 3 polymorphisms do not produce any structural change on the 
VDR protein, they are in strong linkage disequilibrium. On the other hand, the T 
allele of the FokI SNP creates an alternative ATG initiation codon in exon 2, 
leading to a VDR protein that is three amino acids longer, suggesting a potential 
functional consequence [41]. The combination of this data allows the use of 
phenotype-driven data to identify what VDR binding sites, and interactions, are 
important.  In our own study with 170 SLE patients and 192 controls we found a 
positive association between CT genotype of FokI and TT genotype of TaqI and 
SLE accrual damage. Nevertheless, there is a lack of a clear association with 
the other analysed factors (number of affected organs, number of severe flares, 
and pharmacological therapy). This can be explained because damage in SLE 
is multifactorial and SNPs studies are more likely to give us the disease’s 
burden rather than the disease’s susceptibility [52]. 
 
There are few studies regarding transcriptomic in real life patients and all 
of them show indirect results and no microarrays essays for microRNA or 
others. 
 
Barry et al. investigated whether 41 candidate single nucleotide 
polymorphisms (SNPs) in vitamin D and calcium pathway genes (GC, DHCR7, 
CYP2R1, CY P27B1, CYP24A1, VDR, and CASR) are associated with 25-
hydroxyvitamin D or modify the increase in 25-hydroxyvitamin D from vitamin 
D3 supplementation. They studied 1878 healthy persons and showed that the 
increase in 25-hydroxyvitamin D due to vitamin D3 supplementation was 
modified by genotypes at rs10766197 near CYP2R1, rs6013897 near 
CYP24A1, and rs7968585 near VDR [53]. 
 
Monticielo et al. studied 195 SLE patients and 201 healthy controls and 
according to genotype distribution, 25-hydrovitamin D concentrations were 
significantly higher in patients carrying the FokI f/f genotype in comparison with 
patients carrying the F/F genotype (31.6 ± 14.1 ng/ml versus 23.0 ± 9.2 ng/ml, 
p = 0.004), reinforcing its role in the functional activity of VDR [54]. 
 
In summary, a number of resistance mechanisms could be 
postulated with this overview. 
 
One of the potential vitamin D resistance mechanism in SLE is the 
fact that different cells require different concentrations of active hormone, 
and we do not know the targets nor the concentrations required for each 
target at the various stages of the disease. 
 
On the other hand, there seems to be 1000–10,000 genomic VDR 
binding sites per cell type. This is far more than the number of primary 1, 
25-dihydroxyvitamin D3 target genes, which is in the order of 100-500 per 
tissue. This indicates that some genes are controlled by more than one 
VDR binding site, i.e., they may have a higher potential to be regulated by 
1,25-dihydroxyvitamin D3 rather than target genes with only one active 
VDR locus. 
This important medical problem leads to the question, whether an 
insight into the genome- and transcriptome-wide actions of VDR and 1, 
25-dihydroxyvitamin D3 help in a more accurate evaluation of the human 
individual’s responsiveness to, and needs for, vitamin D. Interestingly, 
only for a subset of individuals, significant correlations between the up-
regulation of both genes and the intervention-induced raise in serum 25-
hydroxyvitamin D concentrations were obtained. This suggests that, on a 
molecular level, not all study participants benefited from the vitamin D3 
supplementation because they had already reached their individual 
optimal vitamin D status before the start of the intervention, or they carry 
a genetic polymorphism making them less responsive to vitamin D3 or 
other undefined reasons. 
 
Finally, the VDR receptor has polymorphisms which interfere with 
their conformation, as the FokI as we showed in our data. Yet, the 
remaining key enzymes in the synthesis of 25-hydroxyvitamin D, as well 
as its carrier (the VDR binding-protein) also have polymorphisms which 
alter its enzyme activity and transport. So, the state of resistance to 
vitamin D is complex and the evaluation of the VDR polymorphisms only 
evaluates one of the key steps of the problem. 
 
 
6 – Vitamin D in SLE real practice 
 
 Many studies and revisions address Vitamin D therapy in real practice 
[55].There are some considerations that we have made which are important for 
real practice: 
 
- Can Vitamin D supplementation prevent SLE flares? 
- Can Vitamin D levels predict flares? 
- Are Vitamin D related to SLE specific clinical features? 
- What is the optimal dosage in SLE? 
- Is there a window of opportunity? 
 
 
There a large number of studies addressing this issue, however the 
evidence is sparse and some reviews have been made [56]. We present the 
two more important studies addressing this issue. 
Birmingham et al. made a study with 46 SLE patients from the specimen 
bank and database of the Ohio SLE Study. They studied the vitamin D seasonal 
variation levels and their correlation with flares. The major finding of this study 
was that in non-African-Americans SLE patients, there was a highly significant 
decrease in 25-Hydroxivitamin D serum levels at the time of flare, for those 
flares occurring during low daytime sun exposure season. This was observed in 
both nonrenal and renal flares [57]. 
Schoindre Y et al. prospectively studied the relationship between 25-
hydroxivitamin D levels and Systemic Lupus Erythematosus Disease Activity 
Index (SLEDAI) score, in 170 SLE patients and assessed the role of vitamin D 
in predicting SLE flare-ups. There was no association between baseline 25-
Hydroxivitamin D levels and relapse-free rate [58]. 
 Susmita Roy et al. published a complex paper, developing a general 
kinetic model in an attempt to capture the role of Vitamin-D in 
immunomodulatory responses. This kinetic model, developed using the ideas of 
chemical network theory, leads to a system of nine coupled equations that were 
solved both by direct and by stochastic (Gillespie) methods. They found that 
although Vitamin D plays a negligible role in the initial immune response, it 
exerts a profound influence in the long term, especially in helping the system to 
achieve a new, stable steady state. They also founded that the optimal Vitamin-
D level lies in the 50–100 moll/lit range, where both pathogen and effector T-cell 
levels remain at reasonably low risk range [59]. 
 
Finally some SLE specific clinical features and SLE associated diseases 
are being related do hypovitaminosis D, like immune cytopenias [60],neuropathy 
and Lynphoma in Sjögren’s Syndrome [61], Hashimoto’s disease [62] and others. 
 
This is a difficult to prove issue. Despite the general idea that low 
vitamin D levels are related to higher disease activity, proves are needed 
in RCT. It seems that large variations of vitamin D can be related to SLE 
flares, but Vitamin D levels themselves cannot predict flares. This 
statement thus not exclude that vitamin D basal therapy, at least in stable 
SLE patients, cannot prevent flares, and we may have a window of 
opportunity to immune modulation. Finally, in theory, immunomodulation 
can be achieved with optimal levels between 75-100 moll/l, however it is 
shown that optimal individual levels have to be tailored. 
 
 
 
 
Future directions 
 
Theoretically Vitamin D should have relevant effects on musculoskeletal 
health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, 
pregnancy, dementia and even mortality [63]. However, many of these effects 
are theoretical and it is necessary to demonstrate in vivo cellular effects, 
detected in vitro, in a large group of patients followed-up in a systematic and 
controlled manner. These studies are needed to identify the optimal dose of 
vitamin D for each patient, based on their clinical, genetic and 
physiopathological state. On a quick observation of the factors that modulate 
the response to vitamin D, it would be tempting to use very high doses, because 
they seem safe and could surpass any therapeutic resistance. However, secure 
scientific evidence only applies to calcium metabolism, being clearly unknown 
its deleterious effects on other actions of the hormone when used massively.  
As such, the big challenge is to recognize all factors involved in the 
modulation of vitamin D, such as transcriptomic and epigenetic factors, 
polymorphisms of various enzymes, key receptors of its metabolism, specific 
cellular targets and the expression of cytokines. This is the only way we can 
develop tailored therapies for each disease and each patient using an 
individualized treatment plan. 
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Evidence
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Methods of Hypothesis Testing Results
16
Vitamin D 
autoimmunity and 
SLE susceptibility
. 
Bettencou
rt A. et al.
 The Protective Role of HLA-
DRB1 (
∗
) 13 in Autoimmune 
Diseases.
2015 English
Retrospective 
cohort studie
4
1228 patients 
with AIDs 
and 281 
healthy 
controls
HLA-DRB1 genes 
assotiation with AIDs risk 
and protection.
HLA alleles 
frequency
 Stepwise logistic regression on an allelic level. 
ORs obtained in a multivariable logistic 
regression analysis are adjusted for all the other 
genes included in the model and therefore differ 
from those obtained when a given gene is 
compared with all other genes.  .
Associations of HLA-DRB1(
∗
)15 (OR = 2.17) and HLA-
DRB1(
∗
)03 (OR = 1.81) alleles with MS, HLA-DRB1(
∗
)03 
with SLE (OR = 2.49), HLA-DRB1(
∗
)01 (OR = 1.79) and HLA-
DRB1(
∗
)04 (OR = 2.81) with RA, HLA-DRB1(
∗
)07 with Ps + 
PsA (OR = 1.79), HLA-DRB1(
∗
)01 (OR = 2.28) and HLA-
DRB1(
∗
)08 (OR = 3.01) with SSc, and HLA-DRB1(
∗
)03 with 
MG (OR = 2.98). Consistent negative association of HLA-
DRB1 (
∗
) 13 allele with SLE, Ps + PsA, RA, and SSc (18.3%, 
19.3%, 16.3%, and 11.9%, resp., versus 29.8% in 
controls). HLA-DRB1 (
∗
) 13 frequency in the AIDs group 
was 20.0% (OR = 0.58). 
22
The emerging role 
of vitamin D in 
immunomodulation
Kang SW 
et al.
1,25-Dihyroxyvitamin D3 
promotes FOXP3 expression 
via binding to vitamin D 
response elements in its 
conserved noncoding 
sequence region
2012 English
Intervention in 
human cells 
stimulation in 
vitro.
4 Unknown
To prove the existence 
of a VDRE in the 
noncoding sequence 
region of FOX P3
Identification of 
putative VDREs in 
the human FOXP3 
non coding 
sequence region.
A paired t-test
 Identified three putative VDREs in the non coding 
sequence region +1714 to +2554 of the FOXP3 gene.
23
Lerman et 
al. 
1,25 dihydroxyvitamin D3 
limits monocyte maturation 
in lupus sera.
2011 English
Intervention in 
human cells 
stimulation in 
vitro.
4
5 Healthy 
donnors and 
15 Pediatric 
SLE
To examine whether 
treatment with 1,25-
dihydroxyvitaminD(3) 
affects human APC 
maturation in vitro under 
multiple cytokine 
milieus.
Monocyte 
maturation under 
vitamin D and 
different cytokines 
millieu.
Student’s t-tests . The non-parametric Spearman 
correlation coefficient.
Was demonstrated that 1,25(OH)2D3 has a broad ability 
to limit monocyte maturation, serving to limit 
maturation of cells cultured in IFNα, GM-CSF/IL-4, and 
even in a cytokine-free environment. We made the 
novel observation that 1,25(OH)2D3 retains this 
immunomodulatory capacity in the presence of SLE 
sera.
7
Ilan Ben-
Zvi
The Impact of Vitamin D on 
Dendritic Cell Function in 
Patients with Systemic Lupus 
Erythematosus
2010 English
Intervention in 
human cells 
stimulation in 
vitro.
4
198 SLE 
patients
To observe if Monocyte-
derived DCs of SLE 
patients were normally 
responsive to vitamin D 
in vitro 
Monocyte-derived 
DCs  activation 
with LPS 
stimulation under 
vitamin D presence
Pearson product moment correlation, Spearman 
rank order correlation.  Chi-square analysis-of-
contingency tables. Non-parametric Mann-
Whitney tests.
Severe 25-D deficiency presetn in a substantial 
percentage of SLE patients  and demonstrate an inverse 
correlation with disease activity. vitamin D 
supplementation will contribute to restore immune 
homeostasis in SLE patients through its inhibitory 
effects on DC maturation and activation. 
24
Vitamin D and 
Antigen Presenting 
Cells in SLE
Wu HJ.
Alternatively activated 
dendritic cells derived from 
systemic lupus 
erythematosus patients have 
tolerogenic phenotype and 
function.
2015 English
Intervention in 
human cells 
stimulation in 
vitro.
4
SLE patients 
and healthy 
controls
To generate alternatively 
activated DCs by treating 
monocyte-derived DCs 
from patients with SLE 
and healthy subjects 
with combination of 
vitD3 and 
dexamethasone 
followed by 
lipopolysaccharide-
induced maturation. 
Generation of 
alternatively 
activated DCs and 
tolerogenic effects
the non-parametric Spearman correlation 
coefficient.
 Alternative activated DCs from SLE patients with 
quiescent disease by treating peripheral monocytes in 
vitro with vitD3 and dexamethasone followed by LPS-
induced maturation have superior tolerogenic effects 
than those treated with Vitamin D alone.
25
Aranow C 
et al.
Randomized, Double-Blind, 
Placebo-Controlled Trial of 
the Effect of Vitamin D3 on 
the Interferon Signature in 
Patients With Systemic Lupus 
Erythematosus.
2015 English
Randomized, 
Double-Blind, 
Placebo-Controlled 
Trial
2
57 SLE 
patients
To investigate the 
effects of vitamin D 
supplementation on the 
IFN signature in patients 
with SLE.
3 IFN response 
genes. SLEDAI. 
Vitamin D levels.
Fisher's Exact statistics or Cochran-Mantel-
Haenzsel (CMH) statistics used to compare 
categorical outcomes among treatment groups. 
Pearson's χ2 statistics used to evaluate 
relationships between 25(OH)D repletion status 
and categorical outcomes or baseline 
characteristics. Analysis of variance (ANOVA) or 
analysis of covariance (ANCOVA) models were 
used for continuous outcomes.
Vitamin D3 supplementation up to 4,000 IU daily was 
safe and well-tolerated but failed to diminish the IFN 
signature in vitamin D-deficient SLE patients. Higher 
25(OH)D levels sustained for a longer duration may be 
required to affect immunologic outcomes.
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26
Terrier et 
al.
Restoration of regulatory and 
effector T cell balance and B 
cell homeostasis in systemic 
lupus erythematosus patients 
through vitamin D 
supplementation. 
2012 English
Prospective 
intervencional
4
20 SLE 
patients
To evaluate the safety 
and the immunological 
effects of vitamin D 
supplementation  in 20 
SLE patients with 
hypovitaminosis D
SLEDAI, Tregs, 
TH17, B-Cells
Wilcoxon signed-rank test.
Vitamin D was well tolerated and induced a 
preferential increase of naïve CD4+ T cells, an increase 
of regulatory T cells and a decrease of effector Th1 and 
Th17 cells. Vitamin D also induced a decrease of 
memory B cells and anti-DNA antibodies.
28
Viviane 
de sousa 
et al.
 Association of 
hypovitaminosis D with 
Systemic Lupus 
Erythematosus and 
inflammation. 
2014 English
Cross-sectional 
study
4
45 SLE 
patients and 
25 controls
To evaluate the 
association between 
vitamin D insufficiency 
with SLE and 
inflammatory markers.
 Vitamina D 
levels,High 
sensitivity C 
reactive protein 
interleukin-6 (IL-
6).Urinay sediment 
(AE  proteinuria 
and creatinine 
clearance in 24-
hour urine,serum 
anti-double 
stranded DNA.
The Shapiro-Wilk test,Mann-Whitney U test, chi-
square test, pearson's correlation coefficient.
The prevalence of 25(OH)D insufficiency was 55% in SLE 
patients and 8% in the controls participants (p = 0.001). 
The median of 25(OH)D was lower in patients than in 
controls. Patients with insufficient 25(OH)D had higher 
levels of IL-6 and higher prevalence of hematuria.There 
was no correlation between vitamin D and SLEDAI or 
lupus nephritis.
29
Banica LM 
et al.
Dysregulation of anergy-
related factors involved in 
regulatory T cells defects in 
Systemic Lupus 
Erythematosus patients: 
Rapamycin and Vitamin D 
efficacy in restoring 
regulatory T cells.
2014 English
Intervention in 
human cells 
stimulation in 
vitro.
4
SLE patients 
and controls
  To explore the 
expression of anergy-
related factors in CD4+ T 
cells in relation to Tregs 
frequency in SLE patients 
and to identify strategies 
to redress these defects.
Casitas B-cell 
lymphoma b  and 
'gene related to 
anergy in 
lymphocytes'  
proteins were 
analyzed in 
(PBMCs). Growth 
response factors 
(egr)2 and egr3 
messenger RNAs.  
CD4+ T cells Tregs 
caractherization 
and expansion.
Pearson product moment correlation, Spearman 
rank order correlation.  Chi-square analysis-of-
contingency tables. Non-parametric Mann-
Whitney tests.
Experimental activation of CD4+ T cells in the presence 
of IL-2 and Rapamicyn or VitD induced the expansion of 
SLE Tregs. However, on long-term, only Rapamicyn 
exposure of SLE CD4+ T cells yielded high numbers of 
Tregs with sustained suppressive activity.
30
Piantoni 
et al.
Phenotype modifications of T-
cells and their shift toward a 
Th2 response in patients with 
systemic lupus 
erythematosus 
supplemented with different 
monthly regimens of vitamin 
D.
2015 English
Prospective 
intervencional
4
34 patients 
with 
systemic 
lupus 
erythematos
us (SLE) were 
randomly 
enrolled in a 
two-year 
prospective 
study.
Effect of different 
vitaminD regimens in T-
Cell subtypes.
T-Cell subtypes by 
flow cytometry and 
vitamin D levels
Shapiro-Wilk test .  Wilcoxon signed-rank test,  
Mann-Whitney test. 
Chi-square test 
After a long-term of monthly treatment with vitamin D 
in SLE patients, an enhancement of T-reg cells and the 
production of Th2 cytokines should be expected.
Vitamin D, 
Regulatory T-Cells 
and T-Helper 17 
Cells
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31
Wahono 
et al.
.Effects of 1,25(OH)2D3 in 
immune response regulation 
of systemic lupus 
erithematosus (SLE) patient 
with hypovitamin D.
2014 English
Prospective 
intervencional
4
5 SLE patients 
and controls
 To investigate the 
effects of calcitriol  on 
dendritic cells 
maturation and Th17 and 
Treg cells activation in 
SLE patients with 
hypovitamin D.
Vitamin D levels,  
dendritic cell 
maturation (the 
percentage of 
CD40, CD86, and 
HLA-DR 
expression), 
amount of Th17 
and Treg cells;  
Cytokines 
production of IL-12, 
IL-17A, and TGF-β.
 Paired t-test.
The study concluded that 1,25(OH)2D3 inhibited 
dendritic cells maturation and Th17 cells activation in 
SLE patients. The 1,25(OH)2D3 increased Treg cells but 
not significant.
32
Drozdenk
o G. et al.
Effects of 1,25(OH)2D3 in 
immune response regulation 
of systemic lupus 
erithematosus (SLE) patient 
with hypovitamin D
2014 English
Prospective 
interventional
4
25 SLE 
patients for 
vitamin D 
supplementa
tion and 
controls 
without 
treatment
To  asses whether oral 
vitamin D  
supplementation leads 
to a systemic modulation 
of the phenotype of 
circulating lymphocyte  
and whether a defined 
serum 25-
hydroxyvitamin D 
(25(OH)D) concentration 
can be related to the 
effects on lymphocytes.
Vitamin D levels 
and circulating  B 
and T Cell 
phenotype before 
and after 
supplementation.
 Paired t-test.
Following cholecalciferol intake, the frequencies of 
circulating CD38 expressing B cells were significantly 
increased and IFN-γ+ , and/or IL-17+ CD4+ T helper cells 
were decreased. These data  indicate that increasing 
25(OH)D serum concentrations are associated with an 
increased expression of CD38 on B cells and a 
decreased T-cell-dependent proinflammatory cytokine 
production. 
33
Marinho 
A. et
Vitamin D supplementation 
effects on FoxP3 expression 
in T cells and FoxP3+/IL-17A 
ratio and clinical course in 
systemic lupus 
erythematosus patients: a 
study in a Portuguese cohort. 
2016 English
Prospective 
interventional
4
24 SLE 
patients
 The aim of this study 
was to evaluate the 
effect of vitamin D 
supplementation on 
FoxP3 expression and IL-
17A-producing T cells, 
through FoxP3+/IL-17A 
ratio
Vitamina D levels, 
FoxP3+ and Il17A 
expression after 
supplementation.
Wilcoxon signed-rank test
Serum 25(OH)D levels significantly increased under 
vitamin D supplementation (p = 0.001). The FoxP3+/IL-
17A ratio in SLE patients after 6 months of vitamin D 
supplementation was higher than that in the baseline 
(p < 0.001). The favourable effect was also observed in 
patients with baseline Vitamin D > 75 nmol/l.
34
Maja 
Vukić et 
al.
Relevance of Vitamin D 
Receptor Target Genes for 
Monitoring the Vitamin D 
Responsiveness of Primary 
Human Cells
2015 English
Prospective 
intervencional
4
71 from the 
VitDmet 
study and 10 
VitDbol 
study. 
The correlations 
between the changes in 
mRNA expression in 
relation to serum 
25(OH)D3 level in 
primary human cells
mRNA expression 
from selected VDR 
target genes.
The network analysis is based on the fit, 
measured by r2, of the changes in mRNA 
expression/clinical parameter in relation to 
25(OH)D3 serum level variations, for the 
participants not removed.
 In Peripheral blood mononuclear cells was observed 
direct transcriptional effects on the selected VDR target 
genes, such as an up to 2.1-fold increase already one 
day after supplementation onset. Both long-term and 
short-term vitamin D3 supplementation studies allow 
monitoring the vitamin D responsiveness of human 
individuals and represent new types of human in vivo 
vitamin D3 investigations.
Vitamin D, 
Regulatory T-Cells 
and T-Helper 17 
Cells
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35 Petri et al.
Vitamin D deficiency does 
not predict progression of 
coronary artery calcium, 
carotid intima media 
thickness or high-sensitivity C-
reactive protein in systemic 
lupus erythematosus. 
2013 English Prospective Cohort 2
154 SLE 
patients
To determined whether 
levels of vitamin D at 
baseline were associated 
with subclinical 
measures of 
atherosclerosis, or with 
changes in subclinical 
measures over 2 years.
Baseline and 
follow-up data 
[including coronary 
artery calcium , 
carotid intima-
media thickness 
(IMT), 25-hydroxy 
vitamin D  and high-
sensitivity CRP  
levels] were 
available for 154 
patients. 
Pearson chi-square tests and analysis of variance 
(ANOVA).
25(OH)D was not associated with any measure of 
subclinical atherosclerosis. 25(OH)D deficiency was 
associated with higher hsCRP at baseline, but did not 
predict a change in hsCRP over 2 years.
33
Angela 
Byun 
Robinson
et al.
Vitamin D status is a 
determinant of atorvastatin 
effect on carotid intima 
medial thickening 
progression rate in children 
with lupus: an 
Atherosclerosis Prevention in 
Pediatric Lupus 
Erythematosus (APPLE) 
substudy. 
2014 English
Randomized 
controle trial
2
201 SLE 
patients
 Carotid intima medial 
thickness (CIMT) 
measurements and other 
existing data from the 
Atherosclerosis 
Prevention in Pediatric 
Lupus Erythematosus 
(APPLE) trial use to 
assess interactions 
between serum 25-
hydroxyvitamin D, 
atorvastatin 
randomisation and CIMT 
progression rate.
Progression of 
CIMT wth vitamin D 
and atorvastatin 
group and placebo 
group 
The primary efficacy analysis for APPLE compared 
rates of mean-mean common CIMT progression 
between treatment groups based on a test of two-
way interaction between treatment group and 
time in a longitudinal linear mixed effects model 
under data missing at random assumptions. 
There was significant interaction between baseline 
vitamin D deficiency and atorvastatin randomisation in 
3-year progression of mean-max CIMT. In four out of six 
carotid segments, there was a greater decrease in 
mean-max CIMT progression rate in subjects who were 
treated with atorvastatin compared with placebo if 
they had baseline serum 25(OH)D levels 
≥20 ng/mL.Subjects with serum 25(OH)D ≥20 ng/mL had 
less mean-max CIMT progression following 3 years of 
atorvastatin treatment. 
36
Robinson 
AB et al.
Vitamin D deficiency is 
common and associated with 
increased C-reactive protein 
in children and young adults 
with lupus: an 
Atherosclerosis Prevention in 
Pediatric Lupus 
Erythematosus substudy.
2014 English
Randomized 
controle trial
2
201 SLE 
patients
 Assessment of 
associations between 25-
hydroxyvitamin D 
[25(OH)D] and measures 
of systemic lupus 
erythematosus (SLE) 
disease activity and 
cardiovascular risk.
 vitamin D levels 
<20, race, season, 
latitude, disease 
duration, disease 
activity, high-
sensitivity C-
reactive protein, 
proteinuria, fasting 
lipids and CIMT.
 A multivariable linear regression model was 
constructed with the outcome serum 25(OH)D 
level at baseline and the list of selected 
predictors.
In multivariable modelling, vitamin D deficiency was 
associated with age, latitude, season, minority status, 
proteinuria and hsCRP.
38
Apinya 
Lertratana
kul et al.
25-Hydroxyvitamin D and 
Cardiovascular Disease in 
Patients With Systemic Lupus 
Erythematosus: Data From a 
Large International Inception 
Cohort.
2014 English
Restrospective 
inception cohort
4
890 SLE 
patients 
to estimate the 
associations of 25(OH)D 
levels with 
Cardiovascular risk 
factors and to determine 
whether low baseline 
25(OH)D levels predict 
future Cardiovascular 
events.
 SLE activity and 
damage 
assessments, CV 
risk factors and 
events, 
medications, 
laboratory 
assessments of 
25(OH)D levels, 
and inflammatory 
markers. 
Multiple logistic and Cox regressions were used 
to estimate the associations of baseline 25(OH)D 
levels with baseline CV risk factors and CVD 
events.
Patients in the higher quartiles of 25(OH)D were less 
likely to have hypertension and hyperlipidemia and 
were more likely to have lower C-reactive protein 
levels and lower Systemic Lupus Erythematosus 
Disease Activity Index 2000 scores at baseline when 
compared with the first quartile. Vitamin D levels were 
not independently associated with CVD event 
incidence; however, hazard ratios for CVD event 
incidence decreased with successively higher quartiles.
Vitamin D 
Inflammation and 
atherosclerosis
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39
JA 
Reynolds 
et al.
25-Hydroxyvitamin D 
deficiency is associated with 
increased aortic stiffness in 
patients with systemic lupus 
erythematosus
2011 English
Retrospective 
Cross sectional
4
Women with 
SLE = 75 
 To determine the 
relationship between 
serum vitamin D and 
markers of subclinical 
cardiovascular disease in 
patients with SLE.
Vitamin D 
levels.Insulin 
resistance 
calculated using 
the homeostatic 
model assessment 
method. Vascular 
cell adhesion 
molecules (VCAM-
1, E-selectin). 
Aortic pulse wave 
velocity
Non-parametric tests (Mann–Whitney U-test). 
Linear and logistic regression models used to 
investigate linear associations between 25(OH)D 
and markers of subclinical CVD. Logistic 
regression was used to analyse binomial 
variables.
Vitamin D deficiency is associated with increased aortic 
stiffness in SLE, independent of CVD risk factors and 
insulin resistance. Increased inflammatory disease 
activity may be the mechanism by which vitamin D 
deficiency mediates vascular stiffness in this patient 
group.
40
Sabio JM 
et al.
Association between low 25-
hydroxyvitamin D, insulin 
resistance and arterial 
stiffness in nondiabetic 
women with systemic lupus 
erythematosus.
2014 English
Cohort nested 
cross-sectional 
study
4
106 SLE 
patients and 
101 match 
controls.
To examine if there is an 
association between low 
levels of 25-
hydroxyvitamin D 
(25(OH)D) and insulin 
resistance (IR) in 
nondiabetic women with 
systemic lupus 
erythematosus (SLE) and 
to evaluate its impact on 
arterial stiffness.
25(OH)D, insulin, 
insulin resistance 
measured, 
homocysteine, 
fibrinogen, 
characteristics of 
SLE, medications 
and pulse-wave 
velocity.
Data presented as interquartile range and 
percentages. Mann-Whitney’s test or Student’s 
t-test.Two-tailed Fisher’s exact test, OR, 95% 
CI. Linear regression analysis to determine 
relationship between 25(OH)D concentrations 
and PWV and other clinical and analytical 
variables. A multiple backward stepwise linear 
regression analysis to identify factors 
independently associated with PWV in women 
with SLE.
Low 25(OH)D levels were found to be associated with 
increased IR in nondiabetic women with SLE 
independently of BMI. Low 25(OH)D levels, but not IR, 
could be associated with increased arterial stiffness in 
these patients.
41
Reynalds 
JA et al.
Vitamin D improves 
endothelial dysfunction and 
restores myeloid angiogenic 
cell function via reduced 
CXCL-10 expression in 
systemic lupus 
erythematosus.
2016 English
Open-label case- 
control study
4 40
To evaluate if  CXCL-10 
(IP-10) reduced 
expression by vitamin D 
may be important, has 
anti-angiogenic 
functions in an in vitro 
Human Umbilical Vein 
Endothelial Cell (HUVEC) 
mode
 Improvement in 
endothelial 
function correlated 
with increase in 
serum 25(OH)D 
concentrations 
independently of 
disease activity
Patient-level data were compared using the 
Mann-Whitney U test (and Spearman’s 
correlation), whilst data from in vitro models 
were compared using either a two-tailed t test or 
paired t test as appropriate. 
 Effectiveness of calcitriol to restore SLE Myeloid 
angiogenic cells (MACs) phenotype, augment the 
angiogenic capacity of MACs and to positively modulate 
the paracrine regulation of endothelial nitric oxide 
synthase. 
42
Abou-
Raya A et 
al.
The effect of vitamin D 
supplementation on 
inflammatory and hemostatic 
markers and disease activity 
in patients with systemic 
lupus erythematosus: a 
randomized placebo-
controlled trial.
2013 English
 Randomized 
controlled trial
2  SLE (n = 267)
vitamin D status in 
patients with SLE and 
determined alterations 
in inflammatory and 
hemostatic markers and 
disease activity before 
and after vitamin D 
supplementation.
 Assessment of 
alterations in 
levels of 
proinflammatory 
cytokines and 
hemostatic 
markers, and 
SLEDAI after 12 
months of 
colecalciferol 
supplementation. 
Means ± SD, there were used intent-to-treat 
method, Student’s t-test, and chi-square test or 
Fisher’s exact test. Spearman’s rank correlation 
coefficient. Multivariate regression was used to 
adjust for potential codeterminants of vitamin D. 
Multivariate linear regression used when 
25(OH)D was a continuous variable and 
multivariate logistic regression used when 
25(OH)D was a categorical variable. levels, 95% 
CI;  P values.
 At 12 months of therapy, tsignificant improvement in 
levels of inflammatory and hemostatic markers as well 
as SLEDAI in the treatment group compared to the 
placebo group.
Vitamin D 
Inflammation and 
atherosclerosis
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49
Arash 
Hossein-
nezhad et. 
al.
Influence of Vitamin D Status 
and Vitamin D3 
Supplementation on Genome 
Wide Expression of White 
Blood Cells: A Randomized 
Double-Blind Clinical Trial.
2013 English
Randomized 
Clinical Trial
2
8 Healthy 
adults
To determine the effect 
of vitamin D status and 
subsequent vitamin D 
supplementation on 
broad gene expression in 
healthy adults.
Comparing gene 
expression in two 
groups (deficient 
vs. insufficient or 
sufficient) to study 
the effect of 
vitamin D status on 
broad gene 
expression. 
To identify the differentially expressed genes 
before versus after supplementation and 
between two kinds of supplementation (400 IUs 
or 2000 IUs), a 2-way ANOVA in the linear model 
was applied.
Vitamin D supplementation caused at least a 1.5 fold 
change in the expression of 291 genes that are involved 
in apoptosis, immune function, transcriptional 
regulation, epigenetic modification, response to stress, 
cell cycle activity and differentiation.  66 genes were 
identified, that were most significantly affected by the 
subjects' vitamin D status. Of these 66 genes, 17 genes 
whose expression significantly changed after vitamin 
D3 supplementation in both deficient and 
insufficient/sufficient groups were found to have novel 
VDREs.
52
Marinho 
et al.
Association between vitamin 
D receptor (VDR) gene 
polymorphisms and systemic 
lupus erythematosus in 
Portuguese patients. 
2015 English
Retrospective 
study
4
170 SLE 
patients and 
192 healthy 
patients
Correlation of VDR SNPs 
to SLE severity and 
damage.
SLEDAI, Flares, 
SLICC, VDR SNPs.
Chi-square test, Mann-Whitney test, multivariate 
analysis.
 VDR (TaqI and FokI variants) SNPs are related to a 
higher long-term cumulative damage in SLE patients, 
but not to severe flares.
53
Vitamin D resistant 
state and SLE
Barry EL
Genetic variants in CYP2R1, 
CYP24A1, and VDR modify the 
efficacy of vitamin D3 
supplementation for 
increasing serum 25-
hydroxyvitamin D levels in a 
randomized controlled trial. 
2014 English
Randomized 
controled trial
2
1787 healthy 
non-Hispanic 
white 
participants 
aged 45-75 
years.
To investigated whether 
41 candidate SNPs in 
vitamin D and calcium 
pathway genes (GC, 
DHCR7, CYP2R1, CYP27B1, 
CYP24A1, VDR, and CASR) 
are associated with 
[25(OH)D] or modify the 
increase in [25(OH)D] 
from vitamin D3 
supplementation.
Genotype main 
effects and 
interactions with 
vitamin D3 
treatment.
Multiple Linear regression
The increase in [25(OH)D] attributable to vitamin D3 
supplementation may vary according to common 
genetic differences in vitamin D 25-hydroxylase 
(CYP2R1), 24-hydroxylase (CYP24A1), and the vitamin D 
receptor (VDR) genes. These findings have implications 
for achieving optimal vitamin D status and potentially 
for vitamin D-related health outcomes.
54
Monticiel
o AO et.al.
The role of BsmI and FokI 
vitamin D receptor gene 
polymorphisms and serum 25-
hydroxyvitamin D in Brazilian 
patients with systemic lupus 
erythematosus. 
2012 English
Retrospective 
study
4
195 SLE 
patients and 
201 Healthy 
controls.
To investigate the 
influence of BsmI and 
FokI VDR SNPs on 
susceptibility to SLE. In 
addition, 25-
hydroxyvitamin D  was 
measured in SLE patients 
to evaluate  associations 
with VDR SNPs and 
clinical and laboratory 
expressions of disease. 
Vitamina D levels, 
VDR SNPs 
genotyping.
Chi-square test, Mann-Whitney test, multivariate 
analysis.
 According to genotype distribution, 25(OH)D 
concentrations were significantly higher in patients 
carrying the FokI f/f genotype compared with patients 
carrying the F/F genotype (31.6 ± 14.1 ng/ml versus 
23.0 ± 9.2 ng/ml, p = 0.004). 
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Birmingha
m DJ
Evidence that abnormally 
large seasonal declines in 
vitamin D status may trigger 
SLE flare in non-African 
Americans
2012 English
Database nested 
Case - Control
4
Specimen 
bank and 
database of 
the Ohio SLE 
Study (OSS). 
46 patients.
To inestigate the 
Influence of low daylight 
months on 25-
hydroxyvitamin D levels 
and  Flares . Influence of 
race and daylight status 
on SLE flare rates.
Vitamin D levels. 
SLE flare rates in 
white and Afro-
Americans. 
Mixed effects models 
The major finding of this study was that in non-AA SLE 
patients, there was a highly significant decrease in 
25(OH)D serum levels at the time of flare for those 
flares occurring during LDM. This was observed in both 
nonrenal and renal flares.
58
Schoindre 
Y et al.
Lower vitamin D levels are 
associated with higher 
systemic lupus 
erythematosus activity, but 
not predictive of disease 
flare-up.
2014 English Prospective Cohort 4
170 SLE 
patients
To assess the role of 
vitamin D in predicting 
SLE flare-ups.
SLEDAI and Vitamin 
D levels
Univariate analysis with a linear regression 
model for quantitative variables and with 
Mann–Whitney tests for qualitative variables. 
Variables with univariate p value <0.2 were 
included in a multivariate stepwise linear 
regression model.
There was no association between baseline 25(OH)D 
levels and relapse-free survival rate.
Vitamin D in SLE real 
practice
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Articles included in the Literature Review: trials and studies with Vitamin D intervention. SLE: Systematic Lupus Erythematosus; NCP: Non-calcified coronary plaque; RR: 
Relative Risk; OR: Odds Ratio; SD: standard deviation; CAD: coronary artery disease; 95% CI: 95% confidence interval; ESR: erythrocyte sedimentation rate; AIDs: 
Autoimmune diseases. MS: multiple sclerosis, SLE: lupus; RA: Rheumatoid arthritis; PsA: Psoriatic arthritis; Ps: psorisis; MG: Miastenia Gravis; SSc: Systemic Sclerosis; 
VDRE: Vitamin D response element. FOXP3: Forkhead box P3; APC: Antigen Presenting Cells; DCs: Dendritic Cells; LPS: Lypopolisacharide; OD: Odds Ratio; Tregs: 
regulatory T-Cells; PMBCs: peripheral blood mononuclear cells; VDR: Vitamin D receptor; SPNs: single nucleotide polymorphisms; IFN α: alpha interferon; GM-CSF: 
Granulocyte macrophage colony-stimulating factor; SLEDAI: Systemic Lupus Erythmatosus Disease Activity Index; SLICC: Systemic Lupus International Collaborating Clinics. 
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Abstract 
Vitamin D status in human populations has become a matter of great concern, in the 
wake of a multitude of published works that document widespread Vitamin D deficiency 
across Europe, even in countries with abundant sunlight. In Portugal there are no 
measures of 25-hydroxy vitamin D – 25(OH)D – levels in the general adult population. 
The purpose of this study was to measure 25(OH)D levels in a healthy population 
cohort and investigate the possible association with season and selected demographic 
and laboratory measurements. 
A cohort of 198 participants (18-67 years) living in the north of Portugal, Porto, 
conducted in July and August 2015 (summer time) and April 2016 (winter time) was 
studied to evaluate serum 25(OH)D levels. Sociodemographic characteristics (age, sex 
and body mass index) and season of the year were taken into account as possible 
25(OH)D levels codeterminants. 
In the whole group, the mean level of serum 25(OH)D was 55.4±23.4 nmol/L, with 48% 
of the population presenting levels compatible with vitamin D deficiency (below 50 
nmol/L). In the winter period, this value reaches 74%. No statistically significant 
differences were observed between genders (57.4±23.9 vs. 53.3±22.8 nmol/L, 
p=0.219) as well as no statistically significant correlation was found between age and 
25(OH)D levels (p=0.349).  As expected higher levels of 25(OH)D were observed in 
summer than in winter (68.2±21.5 vs. 42.2±16.9 nmol/L; p<0.0001). Serum 25(OH)D 
levels were significantly lower in obese compared to non-obese subjects (46.6±17.6 vs. 
57.7±24.2 nmol/L, p=0.012). 
Vitamin D deficiency is prevalent in this area, affecting almost half of the population. 
Body mass index and season are predictors for lower vitamin D levels and deficiency 
status. An effective strategy to prevent Vitamin D deficiency and insufficiency should be 
envisaged in our population. 
 
 
Key words: Portugal; 25(OH)D levels; Vitamin D deficiency; healthy adult population. 
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1. Introduction 
Vitamin D is unique among vitamins, since it works as a hormone and can be 
synthesized on the skin as a result of exposure to sunlight. It is acquired both through 
nutrition (10-20%) and by cutaneous synthesis under the action of sunlight [1]. Dietary 
sources of vitamin D include fish oils and, in some countries (USA and Northern 
Europe) fortified food products (dairy and bread products). In Portugal, vitamin 
supplements containing vitamin D exist in the market. However, the main source of 
vitamin D results from cutaneous synthesis on sun exposure and is dependent on 
various factors such as the geographical area latitude, season, time of day, the 
exposed body surface and exposure duration, use of sunscreens, skin pigmentation, 
obesity and age [2].  
Vitamin D3 or cholecalciferol, after formation in the skin, and vitamin D2 or D3, 
from dietary sources, are hydroxylated in the liver, resulting in the formation of 25-
hydroxyvitamin D [25(OH)D], the main circulating form. This form subsequently 
undergoes hydroxylation in the kidney to generate the biologically active, 
dihydroxylated form of vitamin D, calcitriol or 1,25(OH)2D, which acts through specific 
vitamin D receptors [1]. The vitamin D role on the maintenance of calcium serum 
levels, by promoting calcium and phosphorus absorption from the intestine and calcium 
bone reabsorption, is well known [3]. Recent evidences correlate insufficient vitamin D 
levels with an increased risk of developing other non-bone-related disorders: 
cardiovascular diseases, hypertension, malignant neoplasia, type I diabetes mellitus, 
multiple sclerosis, dementia, rheumatoid arthritis, and infectious disease [2-4].The 
identification of vitamin D receptors in immune system cells and the discovery that 
dendritic cells can produce the metabolically active form of vitamin D have led to the 
suggestion that vitamin D is also an immune modulator [5].  
The high prevalence of inadequate vitamin D is nowadays seen as a public 
health problem affecting several countries in Europe and the USA, particularly in those 
people at risk for osteoporosis and its consequences [2]. Vitamin D deficiency 
screening is accomplished through measurement of 25(OH)D, which is the best index 
for assessing vitamin D reserve in the body [2], due to its greater half-life comparing 
with the metabolically active form. Only at-risk populations are routinely tracked for 
Vitamin D deficiency, including the elderly, the institutionalized, pregnant women and 
post-menopausal women (increased risk of fractures) [3]. Much debate has taken place 
over the definition of vitamin D deficiency. Most agree that a 25(OH)D concentration 
<50nmol/L, or 20 ng/mL, is an indication of vitamin D deficiency, whereas a 25(OH)D 
concentration of 51–74 nmol/L, or 21–29 ng/mL, is considered to indicate insufficiency; 
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concentrations >75 nmol/L, or 30 ng/mL, are considered to be adequate [6-9]. The 
optimal serum 25(OH)D levels are those for which calcium absorption is optimized, 
parathyroid hormone (PTH) levels reduced and the greatest benefit to the bone and 
muscle function are obtained; currently levels above 75 nmol/L (30 ng/mL) are 
recommended. 
Several studies have described inadequacy of vitamin D levels all over the 
Europe, although vitamin D status within different European countries shows a high 
variation [10-12]. In Portugal, the prevalence of vitamin D deficiency is unknown 
because there are no epidemiological studies in adult healthy individuals; however, 
several studies in healthy pediatric populations and in specific hospital populations 
have been published [3, 13-22]. In 2009 a study in a healthy pediatric population from 
Porto was published. A group of 45 children (33F, 12M; 2.5-16 years) were evaluated 
in winter and spring. None of them was supplemented after the first year of life. Values 
above 100 nmol/L were considered optimal, 75-100 nmol/L sufficient, 50-74 nmol/L 
relative insufficient and <50 nmol/L deficient. A lack of vitamin D was found in 26% of 
the studied population during the months with less sunlight. According to these cut off 
values, 80% of the children did not achieve optimal levels [23]. In another pediatric 
study, 73 children (37F, 36M), aged 12 months to 17 years, from the outpatient clinic of 
Centro Hospitalar do Porto, were studied. The study occurred between March 2008 
and July 2010. The children were divided in to pre-school age (12 months to 5 years; 
23.3% (17/73)) and school age (6 to 17 years; 76.7% (56/73)). Normal 25(OH)D levels 
(>75 nmol/L) were observed in 17.8% of the children (11% with optimal values, 
>100nmol/L; and 6.8% with sufficient values, 75-100 nmol/L). On the other hand, 
82.2% had low vitamin D levels (42.5% with relative insufficiency, 50-74 nmol/L; and 
39.7% with deficiency, <50 nmol/L). Gender, residential area, BMI and season were 
not related to 25(OH)D levels. It was observed that school age children had higher 
vitamin D deficiency (p=0.013), thus establishing a relation with age [24]. Another 
cohort of 122 healthy children and adolescents (5-18 years) from Porto was studied. 
They were observed in the pediatric outpatient clinic during the winter and spring of 
2011/2012. Vitamin D status was observed to be insufficiency (≥20 and <30 ng/mL) in 
92.5% of the cases, from which 47.8% presented deficiency (≥10 and <20 ng/mL) and 
6% severe deficiency (<10 ng/mL). Only 7.5% of the sample had an adequate Vitamin 
D status (≥30 ng/mL) [25]. 
As already stated, vitamin D status is often studied in specific groups that have 
increased risk of vitamin D deficiency or osteoporosis, such as hospitalized or elderly 
people. In such groups, confounding of variables makes it difficult to translate findings 
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to the general population [26]. Thus, the aim of the current study is to evaluate Vitamin 
D status in non-supplemented healthy adults living in Porto, north of Portugal.  
 
2. Subjects and Methods 
2.1 Subjects 
The study was conducted in Porto (~41° N), in July and August 2015 (summer time) 
and April 2016 (winter time). Two hundred healthy blood donors voluntarily participated 
in this study. Two men were excluded, because they were under multivitamin 
supplementation. The average age of these individuals was 43.1±12.1 years. Subjects 
were stratified in three groups according to age [27]. 
A questionnaire about age, gender, weight, height, ethnicity, nationality, place of 
birth, occupation, sun exposure, sunscreens use, eating habits, smoking habits, 
physical activity, diagnosed pathologies, use of medicines and food supplements, was 
answered during blood donation. In order to analyze the influence of BMI on the 
25(OH)D levels, the subjects were divided into two groups based on BMI values: 
BMI<30 kg/m2 (non-obese) or BMI≥30 kg/m2 (obese). Written informed consent was 
obtained for each volunteer, and the study was approved by the Ethics Committee of 
Centro Hospitalar do Porto, according to Declaration of Helsinki. 
 
2.2 Laboratory Measurements 
Blood was collected in Vacuette® Z Serum Clot Activator tubes for the measurement of 
PTH and in Vacuette® Z Serum Separator Clot Activator tubes for the other 
measurements. Serum was obtained by centrifugation and stored in several aliquots at 
-20°C until analyzed. Serum 25(OH)D was chosen as a reliable marker of individual 
vitamin D status as it reflects vitamin D obtained from food sources and cutaneous 
synthesis, and it is not prone to diurnal variation. 
Serum 25(OH)D was measured using an electro-chemiluminescence binding 
assay (ECLIA) for the in-vitro determination of total  25-hydroxyvitamin D  (Elecsys® 
Vitamin D total, Cobas, Roche©). The reference range for 25(OH)D was >75 nmol/L 
(measurement range: 7.50-175 nmol/L). The serum PTH concentration was assessed 
using an electro-chemiluminescence assay with 15-65 pg/mL as a reference range. 
Serum total calcium, phosphate and creatinine concentrations were measured by 
routine laboratory methods in a Cobas Integra 800. 
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2.3 Statistical Analyses 
Continuous data were checked for normality using the Kolmogorov-Smirnov test and 
natural logarithm (ln) transformations were used for skewed variables previous to the 
statistical analysis. Differences between groups were tested using the Student’s t-test 
or one-way ANOVA (continuous variables) and χ2 test (dichotomous variables). 
Pearson’s or Spearman’s correlation coefficients were calculated to test relationships 
between continuous variables. 
Multiple linear regression analysis was used to consider potential determinants 
of 25(OH)D levels (dependent variable). The following independent variables: age and 
BMI (as continuous variables), season and gender (as categorical variables) were 
included in the model. 
A p-value below 0.05 was considered to be statistically significant. Statistical 
analyses were performed using Statistical Package for the Social Sciences software 
(version 23, IBM SPSS Statistics, NY, USA). 
 
3. Results 
The characteristics of the study population are shown in Table1. Approximately 48% 
were women, and the mean age (±SD) of the study population was 43.1±12.1 years. 
No statistically significant differences were observed between genders. The frequency 
of obesity was significantly higher in this population compared with the general 
Portuguese population (22.7% vs. 14.2%, p=0.001, OR=1.77, 95%CI=1.26-2.50) [28]. 
The mean serum 25(OH)D concentration was 55.4±23.4 nmol/L in all 
participants (median 50.9 nmol/L) with no significant differences between men and 
women (57.4±23.9 vs. 53.3±22.8 nmol/L; p=0.219). Fifty women (52.6%) and 45 men 
(43.7%) were deficient in 25(OH)D but the gender difference was not statistically 
significant (Table 1). 
No statistically significant correlation was found between age and 25(OH)D 
levels (p=0.349). When subjects were categorized in groups according to age (Figure 
1), no differences in 25(OH)D levels between the 3 groups (p=0.311) were found. 
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Table 1 - Characteristics of the study population. 
 
 
 
 
Figure 1 – Prevalence of 
Vitamin D deficiency and 
insuficiency by age. 
 
 
 
 
 
Characteristics 
Total 
(n=198) 
Women 
(n=95) 
Men 
(n=103) 
 
 
  
Sociodemographics   
Age, years, mean ± SD 43.1±12.1 41.9±12.5 44.2±11.7 
Season    
Summer, n (%) 101 (51.1) 44 (46.3) 57 (55.3) 
Winter, n (%) 97 (49.0) 51 (53.7) 46 (44.7) 
BMI, mean ± SD 27.0±4.3 26.9±4.4 27.2±4.2 
    
Laboratory measurements    
PTH levels (pg/mL), mean ± SD 44.9±14.7 45.6±12.6 44.3±16.5 
Creatinine levels (mg/dL), mean ± SD 0.8±0.2 0.8±0.1 0.8±0.2 
Total calcium levels (mmol/L), mean ± SD 2.4±0.1 2.4±0.1 2.4±0.1 
Phosphorus levels (mmol/L), mean ± SD 1.0±0.2 1.0±0.2 1.0±0.2 
    
25(OH)D levels (nmol/L)    
Mean ± SD 55.4±23.4 53.3±22.8 57.4±23.9 
<50 nmol/L (deficiency), n (%) 95 (48.0) 50 (52.6) 45 (43.7) 
50-75 nmol/L (insufficiency), n (%) 60 (30.3) 27 (28.4) 33 (32.0) 
>75 nmol/L (optimal), n (%) 43 (21.7) 18 (18.9) 25 (24.3) 
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Body mass index was negatively correlated with 25(OH)D levels (p=0.001, r=-
0.237) (Figure 2). In conformity, 25(OH)D levels were significantly lower in obese 
compared to non-obese subjects (46.6±17.6 vs. 57.7±24.2 nmol/L, p=0.012) (Figure 3).  
 
 
Figure 2 –Correlation between 25(OH)D and BMI. 
 
 
 
In the winter period, 74.2% of the studied population had a 25(OH)D 
concentration below 50.0 nmol/L compared with 22.8% in the summer period 
(p<0.0001). Only 5 individuals (5.2%) presented optimal levels of 25(OH)D in winter, 
and 38 (37.6%) in summer (Table 2). 
 
Table 2 – Differences in 25(OH)D concentration according to season. 
25(OH)D levels (nmol/L) Winter (n=97) Summer (n=101) p 
Mean ± SD 42.2±16.9 68.2±21.5 <0.0001 
<50 nmol/L (deficiency), n (%) 72 (74.2) 23 (22.8) 
<0.0001 50-75 nmol/L (insufficiency), n (%) 20 (20.6) 40 (39.6) 
>75 nmol/L (optimal), n (%) 5 (5.2) 38 (37.6) 
 
 
In multiple linear regression analysis, controlling for age and gender, significant 
associations between 25(OH)D levels and season and BMI were found. Winter and 
higher BMI were significantly associated with lower serum 25(OH)D levels (Table 3). 
 
Figure 3- Comparison of serum 25 (OH)D 
levels between obese (BMI≥30) and non-
obese (BMI<30) individuals. 
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Table 3 – Results of a multiple linear regression analysis on determinants of 25(OH)D levels 
Variable B SE p 
Intercept 4.224 0.189 <0.0001 
Age -0.002 0.002 0.499 
Season 0.482 0.054 <0.0001 
Gender -0.40 0.054 0.456 
Body Mass Index (kg/m2) -0.17 0.007 0.010 
Corr .r2=0.341    
 
4. Discussion 
There are many studies on vitamin D status of the general population in the USA, 
Canada, Asia Pacific, Middle East, Africa and across Europe [29], but to the best of our 
knowledge this is the first conducted in a Portuguese healthy adult population. 
Globally, vitamin D deficiency is more prevalent in winter, women, older age 
groups, individuals with darker skin, and higher latitudes [7, 30, 31]. In the present 
study, the frequency of 25(OH)D deficiency was significantly higher in winter, 
confirming the well-known seasonal fluctuation in 25(OH)D concentration. No 
association between Vitamin D levels and gender was observed in our study, although 
women presented slightly lower levels of 25(OH)D but the difference was not 
statistically significant. It has been established that the ageing skin produces less 
vitamin D [32]. However, in our study, we did not find any association between Vitamin 
D status with age. 
The negative association of vitamin D status with obesity is well documented in                                                                                                                                                                                                          
different studies [33]. This is probably due to the decreased bioavailability of vitamin D 
from cutaneous and dietary sources because of its sequestration in body fat 
compartments [34]. Our observations confirm the association of Vitamin D status with 
BMI. Furthermore, an inverse correlation between vitamin D status and BMI was found.  
There is ongoing debate related to the optimal levels of 25(OH)D. All available 
evidence suggest that children and adults should maintain a blood level of 25(OH)D 
above 50 nmol/L to prevent rickets and osteomalacia, respectively. However, to 
maximize vitamin D effect on calcium, bone, and muscle metabolism, the 25(OH)D 
blood level should be above 75 nmol/L. Numerous epidemiological studies have 
suggested that a 25(OH)D blood level above 75 nmol/L may have additional health 
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benefits in reducing the risk of common cancers, autoimmune diseases, type 2 
diabetes, cardiovascular disease, and infectious diseases [35].  
In this study we observed that almost half of the studied population presented 
serum 25(OH)D values suggestive of vitamin D deficiency, reaching 74% in winter. 
This observation is in line with a recent study that suggests that Vitamin D deficiency is 
widespread across Europe, even in countries with abundant sunlight, and at 
prevalence rates that meet the criteria of a pandemic [10]. An effective strategy to 
prevent Vitamin D deficiency and insufficiency should be envisaged. For specific high-
risk groups use of vitamin D supplements would be an effective measure. For the 
general population fortification of widely used foods could be considered, especially in 
winter. 
 
5. Conclusions 
The present study analyzed serum Vitamin D levels in healthy adults between 18-67 
years of age. BMI and season are predictors for lower vitamin D levels and deficiency 
status in this population. The strengths of this work comprise a detailed questionnaire 
documenting demographic data and blood sampling taking place through summer as 
well as wintertime. On the other hand, although the questionnaire included data about 
sun exposure, sunscreens use, eating habits, smoking habits, physical activity, 
diagnosed pathologies, and use of medicines and/or food supplements, these 
parameters were only used to exclude confounding factors that could bias our results, 
and were not used in the analysis of the results, as that was beyond the aim of the 
present study.  
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QUESTIONÁRIO – POPULAÇÃO CONTROLO NORTE 
 
IDENTIFICAÇÃO (INICIAIS):_________________________________________________________ 
SEXO:   F      M    DATA DE NASCIMENTO:  - -     
NATURALIDADE:     NACIONALIDADE:     
 
DATA DE COLHEITA:  - -      Nº REGISTO :  -         Nº PC:   
 
 
 
 
- HISTÓRIA FAMILIAR - 
 
1. NATURALIDADE DOS FAMILIARES DIRECTOS 
 
            AVÓ    AVÔ          AVÓ   AVÔ 
      PAI     MÃE        PATERNOS          MATERNOS      BISAVÓS 
TRÁS-OS MONTES                                                          
DOURO LITORAL                                                        
MINHO                                                           
BEIRA LITORAL                                                       
BEIRA-ALTA                                                        
BEIRA-BAIXA                                                        
ESTREMADURA                                                       
RIBATEJO                                                            
ALTO ALENTEJO                                                       
BAIXO ALENTEJO                                                       
ALGARVE                                                         
MADEIRA                                                        
AÇORES                                                        
OUTROS                                                        
 
COMENTÁRIOS: 
 
 
 
 
 
 
 
 
 
  
2. TIPO DE AFECÇÃO DOS FAMILIARES 
            AVÓ    AVÔ        AVÓ   AVÔ 
        PAI  MÃE         PATERNOS        MATERNOS     BISAVÓS 
AFECÇÕES OCULARES                                                           
ALTERAÇÕES DO SONO                                                  
AFECÇÕES ARTICULARES                                                     
ESPONDILOARTROPATIA                                                     
  ARTRITE REMATÓIDE                                                     
  BEHÇET                                                       
PSORÍASE                                                      
LUPUS                                                        
ESCLERODERMIA                                                      
MIASTENIA GRAVIS                                                      
EPILEPSIA                                                       
ESCLEROSE MULTIPLA                                                     
SJÖGREN                                                      
CANCRO                                                       
OUTRA                                                       
 
COMENTARIO: 
 
 
 
_______________________________________________________________________ 
 
 
 
ESTE QUESTIONÁRIO É OPCIONAL. OS CAMPOS QUE NÃO FOREM PREENCHIDOS DEVERÃO SER 
ASSINALADOS DE FORMA INEQUÍVOCA. 
TODA A INFORMAÇÃO CONSTANTE É CONFIDENCIAL E PODERÁ APENAS SER UTILIZADA PARA GESTÃO 
DAS DÁDIVAS DE SANGUE E ESTUDOS RELACCIONADOS  
TODAS AS INFORMAÇÕES SERÃO SALVAGUARDADAS DE ACORDO COM A DECLARAÇÃO DE HELSÍNQUIA 
 
 
 
Elegível? 
 
  SIM 
  NÃO 
 
 
 
 
 
IDENTIFICAÇÃO (INICIAIS):___________ 
SEXO:  F      M    DATA DE NASCIMENTO:  - -     
NATURALIDADE:     NACIONALIDADE:  
PROFISSÃO:       
LOCAL DE TRABALHO:  
Fechado, aberto, com janelas e exposição solar ou não 
 
ESCOLARIDADE (NÃO INCLUI NOVAS OPORTUNIDADES):   
 
CO-MORBILIDADES: ____________________________________________________________ 
_____________________________________________________________________________ 
 
PESO:    ALTURA:    IMC:  
Data de Resposta ao Inquérito: 
 
Exposição solar 
 O (a) Sr (a) expõe-se ao sol?  
1. Sim 
2. Não 
 
 
Se SIM, qual a frequência?  
 Verão Inverno 
1 a  2 vezes na semana 
 
  
3 a  4 vezes na semana 
 
  
5 a  6 vezes na semana 
 
  
7 vezes  na semana 
 
  
 
 
 
 
 
 
 
Qual a duração da exposição solar?  
 Verão Inverno 
Até 15 minutos  
 
  
Mais de 15 e menos de 30 
minutos  
 
  
De 30 a 60 minutos 
 
  
Mais de 60 minutos  
 
  
 
 
 Usa protetor solar? 
1. Sim 
2. Não 
 
Se SIM, qual é a frequência?  
 Verão Inverno 
1 a 2 vezes na semana 
 
  
3 a 4 vezes na semana 
 
  
5 a 6 vezes na semana 
 
  
7 vezes na semana 
 
  
 
 
 Qual o fator de proteção solar (FPS)?  
1. 15 
2. 30 
3. 50 
4. > 50 
 
 
 
 Qual o local de aplicação? 
1. Rosto 
2. Braços 
3. Rosto e braços 
 
 
 
 
 
 
 
 
Hábitos tabágicos: 
- Atuais (SIM/NÃO) ________; Se sim, indique a idade de inicio____________ 
  Quantidade dia (média) ________ 
 
- Passados (SIM/NÃO) _______; Se sim, indique a idade de inicio____________ 
  Quantidade dia (media) _________ 
  Data STOP tabaco______________ 
 
 
 
Hábitos alimentares 
 Habitualmente consome peixe? 
 1. Sim 
2. Não 
 
 
Quantidade e tipo de peixe que consome 
 Ocasionalmente 1x 
mês 
2-3x 
mês 
1-2x 
semana 
3-4x 
semana 
5-6x 
semana 
1x 
dia 
2-3x 
dia 
Solha/Bacalhau         
Salmão/Truta         
Salmão enlatado         
Cavala/carapau/chicharro         
Atum enlatado água/óleo         
Sardinhas em 
óleo/tomate 
        
Outro _________ 
Ex: enguias 
        
 
 
 
 
 
 Come carne regularmente? 
1. Sim 
2. Não 
 
 
 
 
 
 
Qantidade e tipo de carne que consome 
 Ocasionalmente 1x 
mês 
2-3x 
mês 
1-2x 
semana 
3-4x 
semana 
5-6x 
semana 
1x 
dia 
2-3x 
dia 
Salsicha/porco         
Porco         
Cordeiro         
Fígado         
Vaca         
Frango         
Outro _________         
  
 
 Habitualmente consome ovos (estrelados/cozidos/omoletes)? 
1. Sim 
2. Não 
 
 Se SIM qual a frequência? 
1. 1x mês 
2. 2-3x mês  
3. 1-2x semana 
4. 3-4x semana  
5. 5-6x semana  
6. 1x dia 
7. 2-3x dia 
 
 
 Consome habitualmente sumos ou outros alimentos fortificados em Vitamina D? 
1. Sim 
2. Não 
 
Especificar (nome do produto; data de inicio dos suplementos): ____________ 
 
 
 Toma suplementos alimentares (Vitaminas, óleo de fígado de bacalhau)? 
1. Sim 
2. Não 
 
Especificar (nome do produto; data de inicio dos suplementos): ____________ 
 
 
Hábitos farmacológicos: 
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Autoimmune diseases (AIDs) are characterized by a multifactorial aetiology and a complex genetic background, with the MHC
region playing a major role. We genotyped for HLA-DRB1 locus 1228 patients with AIDs-213 with Systemic Lupus Erythematosus
(SLE), 166 with Psoriasis or Psoriatic Arthritis (Ps + PsA), 153 with Rheumatoid Arthritis (RA), 67 with Systemic Sclerosis (SSc),
536 with Multiple Sclerosis (MS), and 93 with Myasthenia Gravis (MG) and 282 unrelated controls. We confirmed previously
established associations of HLA-DRB1∗15 (OR = 2.17) and HLA-DRB1∗03 (OR = 1.81) alleles with MS, HLA-DRB1∗03 with SLE
(OR = 2.49), HLA-DRB1∗01 (OR = 1.79) and HLA-DRB1∗04 (OR = 2.81) with RA, HLA-DRB1∗07 with Ps + PsA (OR = 1.79), HLA-
DRB1∗01 (OR = 2.28) and HLA-DRB1∗08 (OR = 3.01) with SSc, and HLA-DRB1∗03 with MG (OR = 2.98). We further observed a
consistent negative association of HLA-DRB1∗13 allele with SLE, Ps + PsA, RA, and SSc (18.3%, 19.3%, 16.3%, and 11.9%, resp., versus
29.8% in controls). HLA-DRB1∗13 frequency in the AIDs group was 20.0% (OR = 0.58). Although different alleles were associated
with particular AIDs, the same allele, HLA-DRB1∗13, was underrepresented in all of the six diseases analysed. This observation
suggests that this allele may confer protection for AIDs, particularly for systemic and rheumatic disease. The protective effect of
HLA-DRB1∗13 could be explained by a more proficient antigen presentation by these molecules, favouring efficient clonal deletion
during thymic selection.
1. Introduction
Autoimmune diseases (AIDs) are chronic disorders origi-
nated by the loss of immunological tolerance to self-antigens.
This heterogeneous group of conditions present common
genetic risk factors and share several pathophysiological
mechanisms leading to overlapping clinical manifestations
targeting specific organs or multiple organ systems [1]. There
is evidence that they share similar immunogenetic mech-
anisms, even though they exhibit varying epidemiological
features and clinical manifestations [2, 3]. Underlying these
diverse clinical phenotypes is a deregulated immune system
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with an enriched ability to respond against self-tissues. The
fact that AIDs share several clinical signs and symptoms (i.e.,
subphenotypes) and also share physiopathological mecha-
nisms and genetic factors has been called autoimmune tau-
tology and indicates that theymay have a common origin [4].
The immune system is in charge of the defence against
external pathogens. For this purpose, T and B lymphocytes
are responsible for the immune response through regulated
cell-cell interactions and secretion of cytokines, chemokines,
and other inflammatory mediators. This defence against
external pathogens must occur without causing unnecessary
harm to self. To achieve this delicate balance, the majority of
self-reactiveT andB lymphocytes are destroyed in the thymus
and bone marrow through negative selection [5]. Neverthe-
less, this process is far from perfect, and self-reactive lym-
phocytes escape into the periphery. Consequently, peripheral
tolerance mechanisms are necessary to keep these self-
reactive cells in check [6]. Activated self-reactive T and B
cells promote autoimmunity when the effector and regulatory
balance of the immune response is disturbed [7].
Major histocompatibility complex (MHC) molecules are
widely distributed surface membrane glycoproteins that
present antigenic peptides to T cell receptors (TCRs). Devel-
oping thymocytes encounter a highly heterogeneous reper-
toire of self (endogenous) peptide-MHC (pMHC) complexes
on thymic epithelial cells, the main thymus antigen present-
ing cells. The affinity/avidity with which these thymocyte
TCRs bind self pMHC determines if it is destined to perish
or if it will survive [8]. In this way, a repertoire of peripheral
T cells that is essentially self-tolerant is generated [6, 9, 10].
Several hypotheses have been put forward to explain how
MHC polymorphisms influence autoimmunity risk or pro-
tection.They must do so, somehow, by shaping the central or
peripheral T cell repertoires toward autoimmune resistance
or proclivity [8]. A protective MHC profile could achieve
this by the selection of a T cell repertoire with diminished
pathogenicity [11]. On the other hand, protective MHC
molecules may keep autoimmunity in check by favouring the
negative selection of particular self-reactive T cells [12–14].
The functional basis of the association between specific
HLA alleles and development of AIDs can be classically
explained by two possible etiopathogenic models [15].
The molecular mimicry hypothesis proposes that certain
HLA alleles are more efficient in presenting pathogen epi-
topes that share structural features with self-peptides to
mature T cells. Once the response to the pathogen is initiated
the self-antigen is also recognized and disease ensues.
Central selection failure proposes that certain HLA alleles
are less efficient at presenting self-peptides to developing T
cells in the thymus, so negative selection fails.
A different hypothesis proposes that different alleles can
modulate the immunologic profile of an individual, through
antigen-independent mechanisms, resulting in either pro-
moting a higher autoimmune predisposition or, in oppo-
sition, a more efficient immune regulation. Given the
consistent association of HLA-DRB1 alleles with different
autoimmune diseases (Table 1), we explored the idea that
the same HLA-DRB1 alleles could be influencing several
different autoimmune diseases. To this end we compared the
immunogenetic profile in different AIDs.This study includes
four autoimmune systemic diseases, namely, Systemic Lupus
Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis
or Psoriatic Arthritis (Ps + PsA), and Systemic Sclerosis (SSc).
Patients with Multiple Sclerosis (MS) and Myasthenia Gravis
(MG) were also included.
2. Patients and Methods
2.1. Patients and Controls. A total of 1228 patients with AIDs,
213 patients with SLE and 153 patients with RA diagnosed
according to the American College of Rheumatology (ACR)
criteria, 166 patients with Ps + PsA, 67 with SSc, 536 with
definitive diagnosis ofMS according to the revisedMcDonald
criteria, and 93 with MG, were recruited from the Neurology
and Medicine Outpatient Clinic of Centro Hospitalar do
Porto-Hospital de Santo Anto´nio (CHP-HSA). The HLA-
DRB1 frequencies of patients were compared with the ones
of a control group consisting of 282 unrelated individuals
without disease and from the same geographic origin (north
of Portugal).
2.2. HLA-DRB1 Genotyping. Peripheral blood samples
(10mL)were collected inEDTA.GenomicDNAwas obtained
from proteinase-K–treated peripheral blood leukocytes by
using a Salting-Out procedure [27]. Low-resolution genotyp-
ing for HLA–DRB1 locus (i.e., 2-digit HLA nomenclature)
was performed using polymerase chain reaction and
sequence-specific primers (PCR-SSP), based on methods
previously described [28]. In order to produce PCR-SSP reac-
tions able to detect and discriminate each of the knownHLA-
DRB1 genes, primers were designed using sequence align-
ments comprising all HLA-DRB1 variants and were validated
by the Twelfth International Histocompatibility Workshop.
PCR products were visualized under ultraviolet light after
running in a 1.5% agarose gel containing ethidium bromide.
2.3. Statistical Analysis. To identify the HLA-DRB1 genes
contributing to the six different AIDs, we applied stepwise
logistic regression on an allelic level, using forward selection
which involves startingwith no variables in themodel, testing
the addition of each variable using a chosen model com-
parison criterion, adding the variable (if any) that improves
the model the most, and repeating this process until none
improves themodel. It should be noted that odds ratios (ORs)
obtained in a multivariable logistic regression analysis are
adjusted for all the other genes included in the model and
therefore differ from those obtained when a given gene is
compared with all other genes. The data were analysed using
IBM SPSS 20 statistical software.
3. Results
A total of 1228 cases and 282 controls were analysed and
different types of association between alleles and AIDs were
found (Table 2). These included three risk alleles for two or
more AIDs, two protective alleles for two or more AIDs, and
three risk alleles for a particular AID.
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Table 1: HLA-DRB1 alleles associated with SLE, Ps + PsA, RA, SSc, MS, and MG.
Autoimmune disease HLA-DRB1 associated allele References
Susceptibility Protection
Systemic Lupus
Erythematosus (SLE)
HLA-DRB1∗03
HLA-DRB1∗08
HLA-DRB1∗15
HLA-DRB1∗09
HLA-DRB1∗13 [16–18]
Psoriasis or Psoriatic Arthritis
(Ps + PsA) HLA-DRB1
∗07 — [19, 20]
Rheumatoid Arthritis (RA)
HLA-DRB1∗01
HLA-DRB1∗04
HLA-DRB1∗10
HLA-DRB1∗13 [21]
Systemic Sclerosis (SSc)
HLA-DRB1∗01
HLA-DRB1∗08
HLA-DRB1∗11
HLA-DRB1∗07
HLA-DRB1∗15 [22, 23]
Multiple Sclerosis (MS)
HLA-DRB1∗03
HLA-DRB1∗08
HLA-DRB1∗15
HLA-DRB1∗10
HLA-DRB1∗14 [24, 25]
Myasthenia Gravis (MG) HLA-DRB1∗03 — [26]
Table 2: Associations between HLA class II and six AIDs: SLE, Ps + PsA, RA, SSc, MS, and MG.
Controls
(𝑛 = 282)
SLE
(𝑛 = 213)
Ps + PsA
(𝑛 = 166)
RA
(𝑛 = 153)
SSc
(𝑛 = 67)
MS
(𝑛 = 536)
MG
(𝑛 = 93)
Total
(𝑛 = 1228)
HLA-DRB1∗01 66 (23.4%) 40 (18.8%) 39 (23.5%)
50 (32.7%)
OR = 1.79
p = 0.017
28 (41.8%)
OR = 2.28
p = 0.006
100 (18.7%) 23 (24.7%) 280 (22.8%)
HLA-DRB1∗03 44 (15.6%)
73 (34.3%)
OR = 2.49
p = 4.2 × 10−5
25 (15.1%) 28 (18.3%) 11 (16.4%)
123 (22.9%)
OR = 1.81
p = 0.003
33 (35.5%)
OR = 2.98
p = 6.1 × 10−5
293 (23.9%)
OR = 1.51
p = 0.022
HLA-DRB1∗04 69 (24.5%) 42 (19.7%) 46 (27.7%)
73 (47.7%)
OR = 2.81
p = 6 × 10−6
13 (19.4%) 128 (23.9%) 23 (24.7%) 325 (26.5%)
HLA-DRB1∗07 72 (25.5%) 55 (25.8%)
66 (39.8%)
OR = 1.79
p = 0.006
38 (24.8%) 14 (20.9%) 147 (27.4%) 23 (24.7%) 343 (27.9%)
HLA-DRB1∗08 24 (8.5%) 21 (10.0%) 10 (6.0%)
3 (2.0%)
OR = 0.24
p = 0.026
15 (22.4%)
OR = 3.01
p = 0.004
65 (12.1%)
OR = 1.73
p = 0.033
7 (7.5%) 121 (9.9%)
HLA-DRB1∗09 14 (5.0%)
2 (1.0%)
OR = 0.18
p = 0.027
5 (3.0%)
0 (0.0%)∗
OR = 0.95
p = 0.003
3 (4.5%)
5 (1.0%)
OR = 0.22
p = 0.004
2 (2.2%)
17 (1.4%)
OR = 0.23
p = 1 × 10−4
HLA-DRB1∗13 84 (29.8%)
39 (18.3%)
OR = 0.58
p = 0.016
32 (19.3%)
OR = 0.62
p = 0.050
25 (16.3%)
OR = 0.58
p = 0.044
8 (11.9%)
OR = 0.42
p = 0.035
124 (23.1%) 17 (18.3%)
245 (20.0%)
OR = 0.58
p = 0.004
HLA-DRB1∗15 56 (19.9%) 55 (25.8%) 22 (13.3%) 17 (11.1%) 12 (17.9%)
175 (32.7%)
OR = 2.17
p = 2 × 10−5
15 (16.1%) 296 (24.1%)
AIDs: autoimmune diseases; SLE: Systemic Lupus Erythematosus; Ps + PsA: Psoriasis or Psoriatic Arthritis; RA: Rheumatoid Arthritis; SSc: Systemic Sclerosis;
MS: Multiple Sclerosis; MG: Myasthenia Gravis. ∗Fisher’s exact test was used to calculate this value.
HLA-DRB1∗13 was a protective allele for four AIDs: SLE
(18.3% versus 29.8%, 𝑝 = 0.016, OR = 0.58, and 95% CI =
0.37–0.90), Ps + PsA (19.3% versus 29.8%, 𝑝 = 0.050, OR =
0.621, and 95% CI = 0.39–1.00), RA (16.3% versus 29.8%, 𝑝 =
0.044, OR = 0.58, and 95% CI = 0.34–0.98), and SSc (11.9%
versus 29.8%, 𝑝 = 0.035, OR = 0.42, and 95%CI = 0.19–0.94).
There was a specific risk allele associated with three AIDs.
HLA-DRB1∗03 was found to be a risk factor for SLE (34.3%
versus 15.6%, 𝑝 = 4.2 × 10−5, OR = 2.49, and 95% CI =
1.61–3.86), MS (22.9% versus 15.6%, 𝑝 = 0.003, OR = 1.81,
and 95% CI = 1.23–2.67), and MG (35.5% versus 15.6%, 𝑝 =
6.1 × 10
−5, OR = 2.98, and 95% CI = 1.75–5.07). There were
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two risk alleles associatedwith twoAIDs:HLA-DRB1∗08was
positively associated with MS (12.1% versus 8.5%, 𝑝 = 0.033,
OR = 1.73, and 95% CI = 1.05–2.87) and SSc (22.4% versus
8.5%, 𝑝 = 0.004, OR = 3.01, and 95% CI = 1.43–6.31) and
HLA-DRB1∗01 was found to be a risk factor for RA (32.7%
versus 23.4%, 𝑝 = 0.017, OR = 1.79, and 95% CI = 1.11–2.88)
and SSc (41.8% versus 23.4%, 𝑝 = 0.006, OR = 2.28, and 95%
CI = 1.27–4.09).
HLA-DRB1∗09 was negatively associated with SLE (1.0%
versus 5.0%, 𝑝 = 0.027, OR = 0.18, and 95% CI = 0.04–0.83),
MS (1.0% versus 5.0%, 𝑝 = 0.004, OR = 0.22, and 95% CI =
0.08–0.63), and RA (0.0% versus 1.0%, 𝑝 = 0.003, OR = 0.95,
and 95% CI = 0.93–0.98).
Three risk disease-specific alleles were found: HLA-
DRB1∗04 for RA (47.7% versus 24.5%,𝑝 = 6×10−6, OR= 2.81,
and 95% CI = 1.79–4.39), HLA-DRB1∗07 for Ps + PsA (39.8%
versus 25.5%, 𝑝 = 0.006, OR = 1.79, and 95% CI = 1.18–2.72),
and HLA-DRB1∗15 forMS (32.7% versus 19.9%, 𝑝 = 2×10−5,
OR = 2.17, and 95% CI = 1.53–3.10).
Considering AIDs as a group, HLA-DRB1∗03 frequency
was significantly higher (23.9% versus 15.6%, 𝑝 = 0.022,
OR = 1.51, and 95% CI = 1.0–2.15) compared with controls;
conversely HLA-DRB1∗13 (20.0% versus 29.8%, 𝑝 = 0.004,
OR = 0.58, and 95% CI = 0.43–0.79) and HLA-DRB1∗09
(1.4% versus 5.0%, 𝑝 = 1 × 10−4, OR = 0.23, and 95% CI =
0.11–0.49) frequencies were significantly lower.
4. Discussion
Through a systematic review of published works, Cruz-Tapias
and collaborators, in 2012, identified some common HLA
class II alleles that contribute to susceptibility to AIDs in
Latin Americans [3]. The present study is, to date and to
the best of our knowledge, the only one that addresses the
hypothesis that a HLA-DRB1 allele could influence different
autoimmune diseases, using a new cohort, encompassing six
different autoimmune diseases.
In this study we observed associations of different HLA-
DRB1 alleles with several AIDs. We confirmed positive and
negative associations inMS [24, 25], SLE [16–18], Ps +PsA [19,
20], RA [21], SSc [22, 23], and MG [26], previously reported
in our or other populations.
When AIDs studied were considered as a group, HLA-
DRB1∗03 allele was significantly overrepresented, as already
described [29]. It has been shown that this allele has low
affinity for CLIP (class II-associated invariant chain peptide)
and may not require HLA-DM to ensure peptide presen-
tation, preventing efficient peptide selection and allowing
the binding of low stability peptides [30]. Concerning the
observed negative association with HLA-DRB1∗09, we think
that this is likely a spurious association, as this is a rare allele
and the frequency found in controls is, for some reason,
double the one reported for the Portuguese population [31].
Our observations suggest that the presence of HLA-
DRB1∗13 allele may confer protection for AIDs. HLA-
DRB1∗13 is a high frequency allele in the general population
both in Portugal [31] andworldwide. Our results confirm that
the lower frequency of HLA-DRB1∗13 in every individual
AIDs group is not secondary to the deviations granted by
the concurrent positive associations.When the data obtained
from previous studies are taken into consideration, the HLA-
DRB1∗13 allele seems to be a universal protective allele for
RA. It was reported as protective against RA in Asian [32,
33], Turkish [34], and several European populations [35–37].
Recently this allele was also described to be protective in
SLE in the Japanese population [18] and forANCA-associated
vasculitis in the Dutch population [38].
Subtle structural differences in the HLA molecule have
functional implications at the protein level. Specific amino
acid patterns at the peptide binding cleft are involved in dis-
ease susceptibility, such as thewell-known shared epitope first
described in the RA susceptibility alleles HLA-DRB1∗01 and
HLA-DRB1∗04 [37, 39]. Similar to the shared epitope classi-
fication of susceptibility alleles, protective HLA-DRB1 alleles
have been categorized according to several models. One of
the most accepted classifications proposes that protection
against RA is conferred by the DERAA sequence at positions
70–74 of the HLA-DRB1 allele [40]. Other models suggest
that protection is conferred by an aspartic acid at position
70 (D70 allele) [41] or an isoleucine at position 67 (I67
allele) of the HLA-DRB1 molecule. Because it was unclear
which HLA-DRB1 alleles were protective a meta-analysis
was performed involving four European populations with
>2,700 patients and >3,000 control subjects. The objective
was to investigate exhaustively which HLA-DRB1 alleles were
associated with protection against RA [36]. Interestingly,
this study showed that the protective effect attributed to
DERAA and D70 was no longer present after the exclusion
of HLA-DRB1∗13. The authors concluded that this evidence
indicates that HLA-DRB1∗13 rather than DERAA, D70, or
I67 is associated with protection [36]. In a recent study
van Heemst and collaborators identify citrullinated vinculin,
present in the joints of ACPA+ RA patients, as an autoantigen
targeted by ACPA and CD4+ T cells. These T cells recognize
an epitope with the core sequence DERAA, which is also
found in many microbes and in protective HLA-DRB1∗13
molecules, presented by predisposing HLA-DQ molecules.
Intriguingly, DERAA-directed T cells were not detected in
HLA-DRB1∗13+ donors, indicating that the DERAA epitope
fromHLA-DRB1∗13 could mediate thymic tolerance in these
donors and explain the protective effects associated with
HLA-DRB1∗13. They suggest that subjects born with HLA-
DRB1∗13 will present the HLA-DRB1∗13-derived DERAA-
peptide in the thymus, leading to tolerization of the DERAA-
reactive T cell response [42]. The negative association we
describe here supports the idea that the HLA-DRB1∗13
allele, possibly by its specific structural features, may as well
confer resistance to several other AIDs. The protective effect
of HLA-DRB1∗13 could be explained by a more proficient
antigen presentation by these molecules [43, 44], favouring
an efficient thymic selection. As a result, negative selection
anddevelopment ofDR-driven autoreactive regulatoryT cells
are promoted [8].
A different model would relate HLA molecules with the
presence of specific endophenotypes indirectly associated
with autoimmunity. Other studies of our group suggest
that the HLA genotype may primarily influence the general
activation state of CD4 T cells [45]. The protective effect
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of HLA-DRB1∗13 could also be explained by this effect.
Curiously, several reports have suggested an association
of HLA-DRB1∗13 and/or HLA-DQB1∗06 with slow dis-
ease progression in human immunodeficiency virus (HIV)
infected individuals, meaning that among HIV controllers
there is an association between the presence of certain class
II HLA alleles and strong CD4 T cell responses [46, 47].
Although different alleles are associated with particular
AIDs, the same allele, HLA-DRB1∗13, was underrepresented
in all six diseases. This difference is statistically significant
for the four rheumatic diseases studied. This observation
suggests that this allele confers protection to AIDs in general
and particularly to rheumatic diseases.
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Abstract 
SLE (Systemic Lupus Erythematosus) is a chronic autoimmune disease of unknown origin, in 
which both genetic and environmental factors are involved. One of such environmental factors is 
vitamin D, a vital hormone that plays specific functions in the immune system homeostasis, acting 
through a nuclear receptor (VDR) expressed in all immune cells.  
The aim of this study was to determine the possible association between VDR gene polymorphisms 
(BsmI, ApaI, TaqI e FokI) and SLE susceptibility and severity, in a cohort of Lupus patients from 
the North of Portugal. 
One hundred and seventy patients with SLE (diagnosed according the American College of 
Rheumatology [ACR] criteria) were studied. Patients and 192 ethnicity-matched controls were 
genotyped for BsmI (rs1544410), ApaI (rs7975232), TaqI (rs731236) and FokI (rs2228570) 
polymorphisms by TaqMan allelic discrimination assay. 
SLE patients with the CT genotype of FokI polymorphism have a higher SLICC value (p=0.031). 
The same result was observed for the group of patients with the TT genotype of TaqI polymorphism 
(p=0.046). No differences were observed in VDR genotypic frequencies between patients and 
controls. We also observed that the other analysed clinical features were not influenced by VDR 
polymorphisms.  
Our study confirms a possible role of VDR gene polymorphisms in SLE. A positive association was 
found between VDR polymorphisms and SLE severity (chronic damage). The presence of CT 
genotype of FokI and TT genotype of TaqI seems to confer a worse prognosis and may constitute a 
risk factor to a higher long term cumulative damage in SLE patients. 
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Introduction 
Systemic lupus erythematosus (SLE or lupus) is a systemic autoimmune disease with multi-organ 
inflammation, linked to loss of immune tolerance to self-antigens and the production of a diversity 
of autoantibodies. It affects mainly  women of childbearing age
1
. The female to male ratio in adults 
is approximately 9:1 and the peak age of SLE diagnosis is between 15 and 44 years. Despite 
phenotypic heterogeneity, a strong genetic contribution to the development of SLE is supported by 
numerous evidences. Familial prevalence was found to be 5.6% if one first degree relative is 
affected. Disease concordance in dizygotic twins is 2–5%, and in monozygotic twins 29–57%.2 
These evidences from epidemiologic data were the trigger for the study of the genetic basis of the 
disease.  
Candidate gene case–control studies are frequently used to calculate whether a genetic marker is 
present at a higher frequency among patients with a certain disease than in ethnically-matched 
healthy control individuals. The first genetic association described for SLE based in this 
methodology was with the HLA region at chromosome 6p21.3, which encodes over 200 genes, 
many of them with known immunological role. Candidate genes are chosen on the basis of their 
functional importance to disease pathogenesis. 
Nevertheless, these evidences suggest that although genes are important, they are not the only 
explanation, and environmental factors are presumed to play an important role in disease 
development. 
The phenotype and progression of SLE have been linked with a combination of environmental, 
genetic and hormonal factors
1,3
. One such environmental factor is vitamin D, a vital hormone with 
well-established effects on mineral metabolism, skeletal health, and more recently recognized 
profound effects on cardiovascular system
4
. The major source of vitamin D is sun exposure, but it is 
also available in some foods and supplements.  
The identification of vitamin D receptors on cells of the immune system and the discovery that 
dendritic cells can produce the metabolically active form of vitamin D, 1,25-dihydroxyvitamin D3 
4 
 
(calcitriol),  have led to the suggestion that vitamin D is an immune modulator
5,6
. This can explain 
why vitamin D deficiency-related symptoms such as fatigue are frequently observed in those with 
SLE
7
. Furthermore, it is postulated that SLE patients may be at increased risk of low vitamin D 
status as a result of both photosensitivity, with consequent sun avoidance, as well as chronic use of 
medications prescribed for SLE management, which interfere with vitamin D metabolism
8,9
. In fact, 
research has not established whether low vitamin D levels are a contributing factor to the 
development of SLE or a consequence of the disease itself. If this correlation reflects a protective 
effect of vitamin D, considering the genetic susceptibility factors, the risk to develop SLE should be 
lower among individuals carrying genetic variants that predict high 25(OH)D levels and SLE 
patients with higher 25(OH)D levels should presumably have lower SLE disease activity. 
Vitamin D acts via binding to an intranuclear receptor, Vitamin D Receptor (VDR), present in 
target tissues and cells. This receptor belongs to the superfamily of transacting transcriptional 
regulatory factors 
10
. In humans, VDR gene is located on chromosome 12q13.1, extents over 100 kb 
and includes eight protein-coding exons, six untranslated exons, eight introns and two promoter 
regions
11
. Four common single nucleotide polymorphisms (SNPs) in the VDR gene have been 
extensively investigated: FokI C>T (rs2228570), BsmI A>G (rs1544410), ApaI G>T (rs7975232), 
and TaqI C>T (rs731236). BsmI and ApaI SNPs are both located in intron 8, and the TaqI is a silent 
SNP in exon 9. Although these 3 polymorphisms do not produce any structural change on the VDR 
protein, they are in strong linkage disequilibrium. On the other hand, the T allele of the FokI SNP 
creates an alternative ATG initiation codon in exon 2, leading to a VDR protein that is three amino 
acids longer, suggesting a potential functional consequence
12
. 
The purpose of this study was to evaluate the possible association between these common VDR 
gene polymorphisms and SLE susceptibility and severity in a Northern Portuguese population. 
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Material and Methods 
 
Subjects 
The study population consisted of 170 (15 M and 155 F) sequential unrelated SLE patients and 192 
(79 M and 105 F) healthy individuals recruited from the same region of Portugal, representing the 
general population in this area. These subjects without known autoimmune disease have an average 
age of 47 ± 12.8 years.  
SLE patients (diagnosed according to the 1997 and 2012 revised ACR criteria for SLE)
13
 were 
recruited from the outpatient clinic database of the Clinical Immunology Unit from Centro 
Hospitalar do Porto (Portugal). The average age of the SLE patients was 45 ± 13.4 years and the 
mean disease duration was 14.5 ± 6.5 (7 – 43) years.  Patients with less than 5 years of disease 
where not considered. 
Disease severity was assessed using number of affected organs, number of severe flares (defined by 
the SELENA-SLEDAI flare composite)
14,15
 and the need of steroids or immunosuppressive therapy 
during disease duration (assumed as those who still have these therapeutics at the time of data 
collection). Cumulative damage was evaluated with the Systemic Lupus International Collaborative 
Clinics/American College of Rheumatology (SLICC/ACR) Damage Index 
16
.  
Clinical manifestations (kidney involvement, Central Nervous System (CNS) involvement, 
Peripheral Nervous System involvement (PNS), articular, serositis, haematological and skin 
involvement) were established using a standard protocol accordingly to ACR glossaries for SLE 
classification criteria and EULAR recommendations for neuropsiquiatric, nephritis and SLE 
management.
17-19
 
Ethical approval was obtained from the research ethics committee of Centro Hospitalar do Porto 
and written informed consent for DNA analysis was obtained from all subjects. 
 
6 
 
 
DNA Samples and Genotyping  
Genomic DNA was extracted from peripheral white blood cells following standard procedures. The 
single nucleotide polymorphisms were genotyped using pre-designed TaqMan® allelic 
discrimination assays from Applied Biosystems (Foster City, CA, USA) in a Rotor Gene 6000 
Real-Time PCR machine (Corbett Life Science). 
Genotyping of the BsmI (rs1544410), ApaI (rs7975232), TaqI (rs731236) and FokI (rs2228570) 
genetic variants, located within the 12q12-14 (VDR gene) region, was carried out. 
 
 
Statistical analysis 
Allele and genotype frequencies were obtained by direct counting. Chi-square test was used to 
determine the differences of genotypic and allelic frequencies between patients and control groups. 
The same test was also conducted for the study of the association of the different genotypes or 
alleles with SLE clinical symptoms. A p-value <0.05 was considered to be statistically significant. 
Clinical and laboratory features associated with SLE were analysed both by uni and then 
multivariate analysis (logistic regression with the significant variables in univariate analysis). 
Mann-Whitney test was used to compare SLICC distributions and Odds Ratio was calculated with a 
binary logistic regression. The prevalence of genotypes in healthy controls was examined for 
deviation from Hardy–Weinberg equilibrium by using exact Chi-square test. IBM SPSS Statistics 
v.20 software was used for analyses. 
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Results 
The demographic and clinical features of the 170 patients with SLE are presented in Table 1. 
 
 
Table 1: Demographic, clinical/laboratory features of SLE patients 
Patients Features     
        n / n total (%) 
Male 
 
15/ 170 (9) 
Female 
 
155 / 170 (91) 
Age (years) 
 
45 (±13.4) 
 > 10 years of disease 
 
118 / 170 (69) 
    ANA+ 
 
170 / 170 (100) 
ANTI ds-DNA 
 
90 / 170 (56) 
Hematological abnormalities 101 / 170 (59) 
Arthritis 
 
120 / 170 (71) 
Skin involvement 
 
140 / 170 (82) 
Nephritis 
 
47 / 170 (28) 
NS involvement 
 
13 / 170 (8) 
    Immunosuppressors/steroids * 161 / 170 (95) 
Severe Flares 
 
147 / 170 (86) 
>3 affected organs or systems 42 / 170 (25) 
        
* Patients with immunosuppressors or steroids at the time of clinical evaluation. 
 
 
 
 
Phenotypic and genotypic frequencies for VDR SNPs were in Hardy-Weinberg equilibrium.  
No statistically significant differences were observed between frequencies of the VDR 
polymorphisms in the patients group when compared with controls as shown in Table 2. 
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Table 2: Genotype and phenotype frequencies of VDR polymorphisms in SLE patients and Control 
Population. 
            
Polymorphism 
 
SLE patients n (%) 
 
Control Population n (%) 
 
Odds Ratio (95% CI) 
 
p-value 
rs1544410 (BsmI) 
 
161 
  
186 
      
Allele 
           
A 
 
105 (65.2%) 
 
131 (70.4%) 
 
0.89 (0.65-1.22) 
 
0.47 
G 
 
133 (82.6%) 
 
148 (79.6%) 
 
1.06 (0.79-1.44) 
 
0.68 
Genotype 
           
AA 
 
28 (17.4%) 
 
38 (20.4%) 
 
0.11 (0.10-1.36) 
 
0.09 
AG 
 
77 (47.8%) 
 
93 (50.0%) 
 
0.59 (0.18-1.88) 
 
0.37 
GG 
 
56 (34.8%) 
 
55 (29.6%) 
 
1 
   
            
rs7975232 (ApaI) 
 
167 
  
187 
      
Allele 
           
T 
 
132 (79.0%) 
 
159 (85.0%) 
 
0.88 (0.65-1.19) 
 
0.42 
G 
 
117 (70.1%) 
 
129 (68.9%) 
 
1.02 (0.75-1.40) 
 
0.88 
Genotype 
           
TT 
 
50 (29.9%) 
 
58 (31.0%) 
 
0.97 (0.36-2.57) 
 
0.95 
TG 
 
82 (49.1%) 
 
101 (54.0%) 
 
0.78 (0.37-1.63) 
 
0.5 
GG 
 
35 (21.0%) 
 
28 (15.0%) 
 
1 
   
            
rs731236 (TaqI) 
 
169 
  
179 
      
Allele 
           
C 
 
107 (63.3%) 
 
127 (70.9%) 
 
0.84 (0.61-1.15) 
 
0.29 
T 
 
142 (84.0%) 
 
145 (81.0%) 
 
1.06 (0.79-1.44) 
 
0.69 
Genotype 
           
CC 
 
27 (16.0%) 
 
34 (19.0%) 
 
5.6 (0.46-67.9) 
 
0.17 
CT 
 
80 (47.3%) 
 
93 (52.0%) 
 
1.39 (0.43-4.51) 
 
0.58 
TT 
 
62 (36.7%) 
 
52 (29.1%) 
 
1 
   
            
rs2228570 (FokI) 
 
164 
  
192 
      
Allele 
           
T 
 
85 (51.8%) 
 
102 (53.1%) 
 
0.97 (0.69-1.35) 
 
0.84 
C 
 
147 (88.0%) 
 
174 (90.6%) 
 
0.98 (0.73-1.32) 
 
0.89 
Genotype 
           
TT 
 
17 (10.4%) 
 
18 (9.4%) 
 
1.08 (0.50-2.31) 
 
0.85 
CT 
 
68 (41.5%) 
 
84 (43.8%) 
 
0.86 (0.54-1.37) 
 
0.53 
CC 
 
79 (48.2%) 
 
90 (46.9) 
 
1 
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The relationship between VDR polymorphisms and disease expression was analysed in patients, 
with complete clinical data compiled, according to the clinical manifestations listed in table 1, as 
well as SLICC scores, number of affected organs, number of severe FLARES and the need of 
steroids or immunosuppressive therapy during disease duration. Association of different 
polymorphisms with accrual damage was noted, namely, the frequencies of VDR genotypes TaqI 
TT and Fok I CT were significantly higher in patients with SLICC>0. 
 
Table 3: Genotype and phenotype frequencies of VDR polymorphisms TaqI and FokI in SLE patients with 
SLICC=0 and SLICC>0.  
 
                                     SLE Patients 
Polymorphism 
 
SLICC=0 n (%) 
 
SLICC>0 n (%) 
rs731236 (TaqI) 
 
98 
  
63 
 Allele 
      C 
 
68 (69.4%) 
 
34 (54.0%) 
T 
 
81 (82.7%) 
 
55 (87.3%) 
Genotype 
      CC 
 
17 (17.3%) 
 
8 (12.7%) 
CT 
 
51 (52.0%) 
 
26 (41.3%) 
TT 
 
30 (30.6%) 
 
29 (46.0%) 
              
rs2228570 (FokI) 
 
93 
  
63 
 Allele 
      T 
 
44 (47.3%) 
 
39 (61.9%) 
C 
 
81 (87.1%) 
 
58 (92.1%) 
Genotype 
      TT 
 
12 (13.3%) 
 
5 (7.9%) 
CT 
 
32 (35.6%) 
 
34 (54.0%) 
CC 
 
40 (51.1%) 
 
24 (38.1%) 
 
 
SLICC values were higher in SLE patients with FokI CT and TaqI TT genotypes (p=0.031 and 
p=0.046 respectively, Figure 1). 
10 
 
p=0.046 p=0.031 
No significant differences were observed in number of affected organs, number of severe flares and 
the probability of long term need of steroids or immunosuppressive therapy during disease duration. 
 
    Figure 1: Box-whisker plots of SLICC distribution according to FokI and TaqI genotype, in SLE patients.  
 
 
Discussion 
To the best of our knowledge, this is the first study to establish an association between VDR (TaqI 
and FokI variants) SNPs and a higher long-term cumulative damage in SLE patients. 
The concept that Vitamin D exerts immunomodulatory effects and therefore could play a role in the 
course of autoimmune diseases came from the last decade, when the perspective on how vitamin D 
influences human health was significantly altered
20
. Several epidemiological studies have shown 
that vitamin D deficiency could contribute to the risk of autoimmune diseases like systemic lupus 
erythematosus
4,21,22
.  
The main metabolic effect of 1,25(OH)2D3, which is mediated through its interaction with vitamin 
D receptors, is promoting the intestinal absorption and renal resorption of calcium in order to 
increase its circulating levels. However, the discovery that vitamin D receptor is expressed in 
multiple immune cell types, such as monocytes, dendritic cells, and activated T cells, widens 
11 
 
vitamin D role, to modulating immunological functions, of potential relevance in the susceptibility 
and development of autoimmune diseases, such as multiple sclerosis
23
, rheumatoid arthritis 
24,25
 and 
type 1 diabetes mellitus
26
.  
The Vitamin D receptor is a pleiotropic gene associated with multiple autoimmune diseases. ApaI, 
BsmI and TaqI polymorphisms do not affect directly VDR protein structure, but differences in 
stability and/or translation efficiency of the RNA have been reported. The FokI polymorphism 
seems to have consequences for both VDR protein structure and transcriptional activity
27
. Thus, 
VDR gene polymorphisms can modify the immunomodulatory action of vitamin D and may have 
an effect on the clinical manifestations of SLE, namely autoantibody production
28
.  
Four previous studies in Asian populations reported a positive association between BsmI and FokI 
VDR polymorphisms and susceptibility to SLE
29-32
. It has also been observed that VDR SNPs may 
influence clinical manifestations. Concerning nephropathy, an association with the bb genotype of 
BsmI was described in a Japanese cohort by Ozaki et al.. On a Han Chinese population, Luo et al. 
associated this nephropathy with the B allele of the same polymorphism
33
.  Emerah et al. replicated 
this result  in an Egyptian female population, observing that AA (ApaI)  and FF (FokI) genotypes 
were also risk factors for the development of nephropathy in SLE patients
34
. In a study of Polish 
females, Mostowska et al. compared patients with and without renal symptoms and observed that 
the FF and Ff genotypes of FokI had higher frequencies in patients with clinical manifestations
35
. 
Additional research associated VDR SNPs with other SLE features such as serositis, ANA, anti-
dsDNA, anti-Sm and anti-histone antibodies
31,32
. In contrast, in other studies, no association 
between VDR polymorphisms and SLE was reported
30,32,36-39
.  
In summary, the association between Vitamin D Receptor polymorphisms and SLE has been 
extensively studied, but the results described so far are widely dissonant. The comparison of data 
present in the literature is mostly difficult due to study design and ethnic differences in the several 
studies. Up to date, the role of VDR polymorphisms in this disease remains uncertain.  
12 
 
The present study is the first to suggest a role for VDR gene polymorphisms in SLE long term 
outcome. A positive association was found between VDR polymorphisms and SLE accrual damage. 
The presence of CT genotype of FokI and TT genotype of TaqI seems to confer a risk to a worse 
prognosis being a risk factor for a higher long-term cumulative damage. Several hypotheses may 
explain these results. 
It is known that VDR polymorphisms may alter VDR expression (FokI), transcription (BsmI) and 
function. These modifications may interfere with vitamin D activity. In fact, vitamin D has an 
important role in the control of inflammatory responses with  a switch from Th1 to Th2 cytokine 
profile, enhancing Th17 pathway via transcriptional modulation of interleukin-17A, as well as 
induction of regulatory T cells
40,41
. 
Additionally, VDR polymorphisms may also be in linkage disequilibrium with HLA-DRB1 alleles 
that are central players in several autoimmune diseases
42
. 
Furthermore, VDR signalling may influence the transcriptional activity of genes involved in the 
pathophysiological mechanisms of autoimmune diseases. The promoter region of HLA-DRB1 locus 
has a vitamin D responsive element (VDRE) that controls/regulates HLA-DRB1 expression
42,43
. 
Binding of 1,25(OH)2D3 originates conformational changes in VDR which promote its hetero-
dimerization with Retinoid X Receptor (RXR) and translocation of this complex into the nucleus. 
The RXR-VDR heterodimer binds to the vitamin D3 responsive elements in promoter regions of 
1,25(OH)2D3 responsive genes, such as HLA-DRB1 gene. It has been described that vitamin D 
deficiency in early childhood may lead to lower HLA-DRB1 expression, impairing thymic selection 
and promoting autoimmune disease development
42
. 
In our study, although the positive association found between CT genotype of FokI and TT 
genotype of TaqI and SLE accrual damage, there is a lack of clear association with the other 
analysed factors (number of affected organs, number of severe FLARES, and pharmacological 
therapy). This can be explained by the small number of individuals in each subgroup, nevertheless 
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the main explanation is that damage in SLE is multifactorial and not only related to disease activity 
itself 
44
.  
For example, a more inflammatory profile could be found in Lupus patients, which could explain a 
worse long term prognosis, not necessarily related to disease activity but also associated with other 
factors like cardiovascular disease, as has been already described in larger cohorts
45
. 
The results of this study provide a support to the hypothesis that vitamin D polymorphisms are 
associated with SLE disease activity, although the number of subjects studied was relatively small. 
Therefore, this finding requires independently replication in larger cohorts. 
In conclusion, in Lupus patients with the risk VDR genotypes, vitamin D supplementation could be 
a useful strategy for prevention of long term cumulative damage, compensating for a deficiency in 
VDR. Vitamin D daily dose should be adapted to the concept of “Vitamin D Resistant State” 46and 
the optimal dose should be tailored for each patient.   
Individual genotype cannot be changed however vitamin D deficiency can be searched and 
addressed. 
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Abstract 
Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with 
multi-organ inflammation, linked to loss of immune tolerance to self-antigens and the production of 
a diversity of autoantibodies, with a negative impact on the patients’ quality of life. 
Regulatory T cells have been reported as deficient in number and function in SLE patients. 
However, some authors also described an enrichment of this cell type. The hypothesis that certain 
forms of autoimmunity may result from a conversion of Treg cells into a Th17 cell phenotype, has 
been suggested by some studies. In fact, in SLE patients’ sera, the IL-17 levels were observed as 
abnormally high when compared with healthy individuals. 
Environmental factors, such as vitamin D, that is considered a potential anti-inflammatory 
agent, combined with genetic and hormonal characteristics have been associated with SLE 
phenotype and with disease progression. 
Objectives: The aim of this study was to evaluate the effect of vitamin D supplementation 
on FoxP3 expression and IL-17A producing T cells, through FoxP3
+
/IL-17A ratio. Additionally, 
disease evolution, serum vitamin D levels, serum autoantibodies levels and calcium metabolism (to 
assure safety) were also studied.  
Methods: We assessed 24 phenotypically well characterized SLE patients. All patients were 
screened before vitamin D supplementation and 3 and 6 months after the beginning of this 
treatment. Peripheral blood lymphocyte’s subsets were analysed by flow cytometry. 
Results: Serum 25(OH)D levels significantly increased under vitamin D supplementation 
(p=0.001). The FoxP3
+
/IL-17A ratio in SLE patients after 6 months of vitamin D supplementation 
was higher than that in the baseline (p<0.001). 
Conclusions: In conclusion, this study demonstrated that vitamin D supplementation 
provided favourable immunological and clinical impact in SLE. 
 
Keywords: SLE, Vitamin D, FoxP3 T cells, IL-17A T cells 
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Introduction 
Systemic lupus erythematosus (SLE or lupus) is a systemic autoimmune disease with multi-
organ inflammation [1, 2], linked to loss of immune tolerance to self-antigens and the production of 
a diversity of autoantibodies. It mainly affects women of childbearing age. This disease has a 
female to male ratio in adults of approximately 9:1, a peak age of diagnosis between 15 and 44 
years, and a known negative impact on the quality of life, including reduced levels of employment 
and income. Despite phenotypic heterogeneity and an unpredictable disease evolution, a strong 
genetic and environmental contribution to the development of SLE is supported by broad evidence. 
The autoantibodies are primarily directed against chromatin and ribonuclear particle constituents 
(nucleosomes, single- and double-stranded DNA (dsDNA), RNPs) [2-5], and play a pathogenic role 
[3]. The hyperreactivity to these self-antigens leads to the formation of immune complexes that 
cause local inflammation and tissue damage [6]. 
With the production of autoantibodies and prolonged cell life, B cell regulation is important 
in the maintenance of immune balance. B cells from patients with SLE have been shown to present 
autoantigens, induce CD4
+
 T helper cells (Th1/Th2), inhibit regulatory T cells (Tregs), and secrete 
pro-inflammatory cytokines [7]. 
Regulatory T cells are specialized suppressor cells [5, 8], with the phenotype 
CD4
+
FOXP3
+
CD25
high
CD127
low
 [9], that have the capacity to regulate the intensity and quality of 
the immune response [10]. They actively suppress effector cells, including those associated with 
autoimmune diseases [4], thereby establishing and maintaining immunological self-tolerance [11]. 
Some studies suggest that regulatory T cells are deficient in number and function in several 
autoimmune diseases including SLE [12]. However, an enrichment of this cell type has also been 
reported [13, 14]. These contradictory observations may be either due to the lack of a well-defined 
specific Treg marker in humans or to the heterogeneity of SLE phenotypes [12]. Concerning Tregs 
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markers, this population was initially characterized by CD25 alone, which could explain the 
reported contradictory results. Dysfunction of these cells could also be explained by the fact that 
FOXP3-expressing cells lose CD25 expression and consequently their suppressive functionality 
[15, 16]. 
Besides Th1 and Th2, a third subset of CD4
+
 effector Th cells was identified, named Th17 
because of its unique ability to produce IL-17 (IL-17A and IL-17F). These cells play a critical role 
in the recruitment, activation and migration of neutrophils [4]. Beyond their protective role in the 
clearance of extracellular pathogens, a major role of Th17 lymphocytes seems to be their 
involvement in the induction and maintenance of chronic inflammatory processes [4, 17]. 
 The hypothesis that certain forms of autoimmunity may result from a conversion of Treg 
cells into a Th17 cell phenotype, has been suggested by some studies [18].  
 In SLE patients’ sera, the IL-17 levels are abnormally high when compared with healthy 
individuals. IL-17 is also produced by neutrophils, Innate Lymphoid Cells (ILC), and other T cell 
types including CD4
+
, CD8
+
, double negative (CD4
-
CD8
-
) and TCR-γδ [4]. This phenomenon could 
promote the autoimmune process by increasing the activation of immune cells itself. Release of IL-
17 by infiltrating T cells in specific organs may also contribute to local tissue injury by instigating 
the inflammatory response [4].  
Environmental factors combined with genetic and hormonal characteristics have been 
associated with SLE phenotype and with disease progression [19, 20]. 
Vitamin D is one of the environmental factors likely related to SLE pathogenesis and its 
deficiency appears to be associated with immunomodulatory abnormalities in this disease [21]. 
The identification of vitamin D receptors in immune system cells and the discovery that 
dendritic cells can produce the metabolically active form of vitamin D, 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3; calcitriol),  have led to the suggestion that vitamin D is an immune modulator [1]. 
The importance of vitamin D in several autoimmune disorders has been reported and vitamin D 
deficiency has been associated with the pathogenesis and severity of multiple sclerosis (MS), 
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rheumatoid arthritis (RA), systemic sclerosis (SSc) and SLE, among others [22]. In SLE patients, 
serum vitamin D3 levels seem to correlate inversely with SLEDAI scores [6]. 
It has been found that one of the consequences of 1,25(OH)2D3 on the immune response is 
the stimulation of innate immunity and suppression of adaptive immunity [23]. Studies on the 
immunomodulatory properties of 1,25(OH)2D3 confirmed the inhibition of Th1 cell development 
via an inhibition of IL-12 production by antigen-presenting cells. Further work documented its 
ability to drive CD4 T lymphocytes to a Th2 phenotype with a reduction in Th1 type activity [17], 
by  increasing the production of  IL-5 and IL-10.Vitamin D indirectly,  reduces the production of 
IFNγ [24]. It also affects B cells causing induction of B cell apoptosis, inhibition of B cell 
proliferation, and generation of memory B cells, plasma cell differentiation and immunoglobulin 
production/secretion [24-27]. In human epidermal and dermal cells, it was demonstrated that 
1,25(OH)2D3 modulates regulatory T cell numbers and their suppressive abilities through dendritic 
cells [23]. The effect of vitamin D on dendritic cells include the differentiation of monocytes into 
immature dendritic cells, the maturation of dendritic cells and dendritic cell survival [26].  
Local vitamin D metabolism allows immune cells to modulate immune responses in an 
independent way when regulation is required, but the optimization of this autocrine and/or paracrine 
circuit is strictly dependent of the circulating 25(OH)D (the calcitriol precursor) availability. The 
levels of circulating 25(OH)D needed to meet the requirements of vitamin D sufficiency are still a 
matter of debate, especially in light of the non-classical effects of vitamin D [27]. These evidences 
justify the motivation to consider vitamin D supplementation as an immunomodulatory intervention 
in SLE.  
The FOXP3 gene has a vitamin D receptor element (VDRE) in its promoter region, being 
important for its cellular expression [28]. The immunomodulatory effect assessed by the imbalance 
of FoxP3
+
/IL-17A CD4
+
 T lymphocytes is widely recognized [29]. However, it is not known if this 
immune imbalance can be represented by a ratio between these two cell populations. This ratio can 
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be calculated by dividing the percentage of total lymphocytes that are CD4
+
 and express FoxP3 by 
the percentage of total lymphocytes that are CD4
+
 and synthesize IL-17A. 
In this study, using a well phenotypically characterized patients’ cohort and a well-defined 
therapeutic intervention, the authors investigate if the FoxP3
+
/IL-17A ratio and disease activity is 
modified after vitamin D supplementation (cholecalciferol). For this purpose, we evaluated the 
effect of vitamin D supplementation on CD4
+ 
FoxP3 expression and CD4
+ 
IL-17A producing T 
cells. Additionally, disease evolution, serum vitamin D levels, serum autoantibodies levels and 
calcium metabolism (to assure safety) were studied.  
Therefore, whether the FoxP3
+
/IL-17A ratio has a positive effect on SLE disease activity is 
the question addressed in this study.  
 
Material and Methods 
Subjects 
The study population consisted of SLE patients recruited between 1 November 2012 and 31 
January 2013. SLE patients (diagnosed according to the 1997 [30] and 2012 [31] revised ACR 
criteria for SLE) were selected from the outpatient clinic database of the Clinical Immunology Unit 
from Centro Hospitalar do Porto (North of Portugal). By protocol all these patients should have 
more than 5 years of disease, and should be in a stable phase of disease and without major flares for 
at least 1 year. Stability was defined as no new major organ involvement in the last year 
independently of the SLEDAI-2K score and no changes in steroid dose or immunosuppressive 
therapy in the last 12 months.  Baseline 25(OH)D serum level was measured. Hypovitaminosis D 
was defined as serum 25(OH)D < 75 nmol/L and patients were selected irrespectively of their 
baseline 25(OH)D levels.  
Ethical approval was obtained from the research ethics committee of Centro Hospitalar do 
Porto and written informed consent for all analysis was obtained from all subjects. 
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Study Design 
A prospective cross-sectional study with 6 months follow-up evaluations of patients with a 
dose escalating protocol of vitamin D supplementation was done. Safety of high dose vitamin D 
supplementation was also monitored (increase of serum phosphorus or calcium). 
We assessed 24 SLE patients for eligibility (1 man and 23 women). The clinical 
characterization of SLE patients comprised: 1) Evaluation of the Systemic Lupus Erythematosus 
Disease Activity Index 2000 (SLEDAI-2K) [32]; 2) Evaluation of the Systemic Lupus International 
Collaborating Clinics/American College Rheumatology (ACR) Damage Index (SLICC-SDI) [33]; 
3) Flare evaluation according to modified SLE Flare Index (SFI) [34-36]; 4) Cumulative organ 
involvement (specific data and treatment); 5) Previous and present immunosuppressive therapy and 
hydroxicloroquine. 
All patients were screened before vitamin D supplementation (Day 0 or D0), and 3 and 6 
months (M3 and M6) after the beginning of this treatment. 
At D0, before vitamin D supplementation, relevant data were compiled, namely: baseline 
SLEDAI-2K, baseline SLICC-SDI,  disease duration, concomitant therapy (including steroid 
doses), previous SLE manifestations (including cumulative organ involvement and number of 
disease flares), baseline 25(OH)D serum levels, baseline %TCD4
+
FoxP3
+
/%TCD4
+
IL-17A
+
 ratio 
(FoxP3
+
/IL-17A ratio), baseline autoantibodies levels, complement (C3 and C4) as required for 
SLEDAI-2K, serum calcium, serum phosphorus and serum PTH (parathyroid hormone) levels. 
At M3: SLEDAI-2K, concomitant therapy (including variations on steroid doses) , flare 
evaluation, 25(OH)D serum levels, autoantibodies levels and complement levels (C3 and C4) as 
required for SLEDAI-2K, serum calcium, serum phosphorus and serum PTH levels. 
At M6: SLEDAI-2K, SLICC, concomitant therapy (including variations on steroid doses), 
flare evaluation, 25(OH)D serum levels and %TCD4
+
FoxP3
+
/%TCD4
+
IL-17A
+
 ratio (FoxP3
+
/IL-
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17A ratio). Serum autoantibodies levels, complement (C3 and C4) as required for SLEDAI-2K, 
serum calcium, serum phosphorus and serum PTH levels. 
Supplementation protocol 
Baseline (Day 0) 
Vitamin D <50 nmol/l – 50,000 UI cholecalciferol/ week /8 weeks. Then 2,000U/day. 
Vitamin D >75 nmol/L – 2,000 UI/day. 
Vitamin D >50 nmol/L and <75 nmol/L – 4,000 UI/day/8 weeks, then 2,000 UI/day. 
3 months Follow-up (M3) 
<50 nmol/L – as the baseline. 
>50 nmol/L and <75 nmol/L – duplicates the baseline dose per 8 Weeks, then 4,000/day. 
>75 nmol/L and <125 nmol/L – same dose. 
>125 nmol/L – 50% reduction. 
 
Vitamin D assessment 
25(OH)D protocol: vitamin D total assay for the Elecsys analysers and Cobas modular platforms - 
Roche®. 
 
Flow Cytometry  
Peripheral blood lymphocyte’s subsets, including T, B, NK, TCD4+FoxP3+, TCD4+IL-17A+ 
were analysed by flow cytometry, in a Coulter Epics XL-MCL® cytometer. Cells counts (cells/μL) 
and proportions (%) were established from fresh blood samples using different protocols and 
monoclonal antibodies (mAbs), conjugated to fluorescein (FITC), phycoerythrin (PE), 
Phycoerythrin-Texas Red (ECD) and Phycoerythrin Cyanin 5.1 (PC5).  
T (CD3
+
/CD4
+
 and CD3
+
/CD8
+
), B (CD19
+
) and NK (CD56
+
) lymphocytes were analysed 
using a Beckman Coulter standard protocol with the following mAbs: anti-CD45 FITC (clone 
B3821F4A), anti-CD3 PC5 (clone UCHT1), anti-CD4 RD1 (clone SFCI12T4D11), anti-CD8 ECD 
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(clone SFCI21Thy2D3), anti-CD19 ECD (clone J4.119) and anti-CD56 FITC (clone N901/NKH-
1); all from Beckman Coulter, Fullerton, California, USA).  
Effector CD4
+
 T cells producing IL-17 were quantified after for 4 hour stimulation with 
phorbol 12-myristate 13-acetate (PMA) and ionomicin in the presence of brefeldin A. Cells were 
fixed and permeabilized using the IntraPrep Permeabilization Reagent (Beckman Coulter) buffer 
system and stained with anti-CD4 PC5 (clone 13B8.2; Immunotech, Marseille, France) and anti-IL-
17 PE (clone eBio64DEC17; eBioscience Inc, San Diego, CA).  
CD4
+
FoxP3
+
 T cells were quantified after cell fixation and permeabilization using the mAbs 
anti-CD4 PC5 (clone 13B8.2; Beckman Coulter - IOTest; Marseille, France), and anti-FoxP3 PE 
(clone PCH10; eBioscience Inc, San Diego, CA), according to the manufacturer's staining protocol. 
 
Statistical analysis 
We compared measures taken at baseline (before vitamin D supplementation, D0) with those 
taken at M6, using the non-parametric paired Wilcoxon Signed Ranked Test, because the data did 
not follow a Gaussian distribution. Significance level was set at α=0.05. Statistical analysis was 
performed using the SPSS v.22.  
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Results 
Demographic, clinical and laboratorial features of SLE patients at baseline are described in  
Serum 25(OH)D levels significantly increased under vitamin D supplementation from 59.32 
± 29.59 nmol/L at Day 0 to 80.39 ± 24.57 nmol/L at Month 3 (p=0.030) and to 85.25 ± 30.92 
nmol/L at Month 6 (p=0.001) (Figure 1). 
 
Treatment was safe, with no significant increase of serum phosphorus or calcium. Serum 
calcium significantly decreased from 2.34 ± 0.10 mmol/L at Day 0 to 2.27 ± 0.10 mmol/L at Month 
6 (p=0.026) but all in the normal range (Figure 2). 
 
Disease activity, assessed by SLEDAI-2K, significantly decreased from 2.75 ± 4.76 at Day 0 to 
1.67 ± 2.79 at Month 6 (p=0.026) (Figure 3). 
 
Serum anti-dsDNA levels (evaluated by immunofluorescence) remained stable during 
follow-up, while C3 complement fraction significantly decreased from 101.5 ± 23.57 mg/dL at Day 
0 to 95.46 ± 21.71 mg/dL at Month 6 (p=0.013) (Figure 4), but no new hypocomplementemia 
occurred (reference values: 88-201 mg/dL). 
None of the patients required modification of the prednisone and immunosuppressive dosage 
or initiation of new immunosuppressive agents. We did not observe SLE flares during the 6 months 
follow-up period. 
The impact of vitamin D supplementation on the proportions of CD3
+
 T cells, CD4
+
 and 
CD8
+
 T cells is shown in Figure 5.  
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The mean proportions at baseline were 80.05 ± 5.64% for CD3
+
 T cells (Figure 5A), 47.8 ± 
7.58% for CD4
+
 T cells (Figure 5B), and 30.56 ± 7.73% for CD8
+
 T cells (Figure 5C). At Month 6, 
the proportion of CD3
+
 T cells, CD4
+
 and CD8
+
 T cells remained stable.  
The impact of vitamin D supplementation on CD3
+
CD4
+
FoxP3
+
 T cells was evaluated. The 
percentage of CD4
+
FoxP3
+
 cells at baseline was 7.27 ± 5.92%. The percentage of CD4
+
FoxP3
+
 
cells was increased at 11.42 ± 6.54% at Month 6 (p<0.001) (Figure 6A). A decrease was observed 
in CD4
+
IL-17A from 3.89 ± 1.76% at Day 0 to 2.82 ± 1.03% at Month 6 (p=0.001) after vitamin D 
supplementation (Figure 6B). 
 
 
Accordingly, the FoxP3
+
/IL-17A ratio in patients with SLE after 6 months of vitamin D 
supplementation was higher than that in the baseline (p<0.001) (Figure 7).  
 
Considering patients with 25(OH)D levels at baseline ≥75 nmol/L, the increase of 
FoxP3
+
/IL-17A ratio observed for the entire group after 6 months of vitamin D supplementation 
was also valid (p=0.043) (Figure 8).  
 
The relationship between CD4
+
FoxP3
+
 and CD4
+
IL-17A cells and 25(OH)D levels, serum 
calcium, serum phosphorus and serum PTH levels was also analysed. No associations were found 
between these features and CD4
+
FoxP3
+
 and CD4
+
IL-17A proportions. 
No significant differences were observed for the other laboratory and clinical parameters, 
such as SLICC score. 
 
Discussion  
In this study, we assessed for the first time the safety, the clinical and immunological effects 
of vitamin D supplementation in patients with SLE in a Portuguese population.  
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Vitamin D deficiency is now recognized as a pandemic [37] and strong evidence exist that 
vitamin D deficiency can contribute to a raised risk for autoimmune diseases [38-41]. The definition 
of vitamin D insufficiency (25-50 nmol/L) and deficiency (<25 nmol/L) varies between studies and 
the degree of hypovitaminosis D varies from region to region. While 25(OH)D levels below 75 
nmol/L are common worldwide, levels below 25 nmol/L that constitute frank vitamin D deficiency 
are most commonly seen in groups at risk, in particular, with autoimmune diseases [42], such as MS 
[43], RA, type 1 diabetes mellitus and SLE [6, 44].  
In SLE, some studies have demonstrated an association between higher disease activity and 
low serum levels of vitamin D, but the results are controversial. Nevertheless, vitamin D 
supplementation is currently recommended as a treatment for some of these patients.  However, 
data about the effects of its administration in immune regulation in SLE is still missing [45]. 
To date, only one study has assessed the in vivo benefit of vitamin D supplementation in 
SLE, but only in vitamin D deficient patients [46]. In our study we included patients with 25(OH) 
vitamin D > 75 nmol/L.  
We confirmed the high frequency of hypovitaminosis D in SLE patients (70.8%) described 
in some studies, and we also demonstrated that vitamin D supplementation significantly increase 
serum 25(OH)D levels, at 3 and 6 months after the beginning of the study. Furthermore, we could 
show that this therapy was safe, since no alterations on phosphorus or calcium levels and no side 
effects were reported. 
It is well known that T cells initiate and sustain the secretion of antibodies by B cells. The 
high degree of hyper mutation in SLE-associated autoantibodies demonstrates the T cell 
dependency of autoantibodies development in these patients. SLE is also associated with 
pathologically altered immune responses, with hyperactive B cells playing an important role in its 
pathogenesis.  In this context, SLE  is a T and B cell-dependent disease,  associated with rather 
functional deficiency of regulatory T cells [47], an increase in T helper lymphocytes producing IL-
17 (Th17 cells) [48, 49] and an increased expression of IFN-inducible genes [50]. The 
13 
 
immunomodulatory properties of vitamin D have been under increased scrutiny in the last years. 
1,25(OH)2D3 was shown to inhibit Th17 responses, probably owing to its capacity to inhibit IL-23 
production [46], and to induce the differentiation and/or expansion of FoxP3
+
 Tregs and an 
increased expression of CTLA-4 [46]. 
In our study, after 6 months of vitamin D supplementation, we observed an increase of 
FoxP3 expression in CD4
+
 T cells and a decrease in CD4
+
IL-17A. The FoxP3
+
/IL-17A ratio was 
found to be significantly higher at the end of the treatment when compared with D0. This effect was 
also observed in patients with elevated vitamin D levels at baseline, showing that immunological 
effects were unrelated to the standard cut-off used for metabolic bone disease. It is well known that 
the imbalance between Th17 and Treg cells results in inflammation and/or autoimmunity. The 
shared requirement of cytokines in iTreg and Th17 cell differentiation naturally leads to the 
hypothesis that an imbalance between these two cell types may lead to tissue inflammation. While 
Th17 cells promote inflammation and autoimmunity, Treg cells modulate the function of effector T 
cells, preventing this phenomenon. A reestablishment of this balance may be achieved by 
decreasing Th17 function and differentiation, and by the increase of Treg cells number and 
function. This hypothesis offers numerous potential pharmacologic targets for immunomodulation. 
The inflammatory imbalance might be modified to restore immune homeostasis, resulting in 
therapeutic benefit. An intriguing alternative approach involves pharmacologically altering iTreg 
and Th17 cell differentiation or expansion, using cytokines, cytokine inhibitors, and small molecule 
inhibitors of key signalling pathways [18]. 
Our results suggested that vitamin D supplementation improves the Treg/Th17 ratio, an 
effect described for the first time in SLE patients, of real benefit, as shown by the effective decrease 
of the SLEDAI scores. Vitamin D supplementation was shown to be a safe and an efficient 
treatment for improving stable SLE patients’ condition and flare prevention. Since none of the 
patients exhibit complications resulting from vitamin D supplementation, perhaps the administered 
doses could be increased, maintaining the safety and leading to even better results. 
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In spite of displaying optimal circulating vitamin D levels, the ability to metabolize vitamin 
D may vary between individuals’ genetics and may therefore contribute to the risk of developing 
immune abnormalities. These situations are illustrated by the presence of certain gene 
polymorphisms in the vitamin D metabolizing enzymes [27], such as CYP2R1 (hydroxylates 
vitamin D3 to 25(OH)D in the liver) or CYP27B1(activated by PTH and hydroxylates 25(OH)D to 
1,25(OH)2D3 in the kidney) [51]. Even if all these steps are properly functioning, the vitamin D 
active metabolite (1,25(OH)2D3) must be recognized, bound and activated by its receptor (VDR). 
Polymorphisms in the VDR gene may also play a role in this mechanism [1].  
The main limitation of this study is the lack of an adequate Portuguese control population 
with known vitamin D levels.  
In conclusion, this study demonstrated that vitamin D supplementation seems to provide 
favourable immunological effects in patients with SLE, independently of the 25(OH)D patients 
status. We observed a decrease of IL-17A producing T cells and an increase in FoxP3 expression, 
confirming the relationship between vitamin D status and immunological balance. Nevertheless, 
these results should be interpreted with caution since previous studies evaluating the 
supplementation of 25(OH)D in SLE disease have had inconsistent results.  
It is important to consider all the existing variables and their specific outcomes in each 
patient. Therapy should be individualized, to take into account all the existing factors and 
differences between patients. Using the FoxP3
+
/IL-17A ratio it may be possible to tailor vitamin D 
therapy for each patient. An individualized therapy should be undertaken since some patients will 
need very high doses of supplementation whereas others will need only modest doses to achieve the 
same outcome. 
Finally, concerning vitamin D therapy safety, screening to monitor PTH levels will be only 
required if hypocalcaemia occurs. 
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Table 1. All patients completed the 6 months follow-up period. 
Table 1 – Demographic, clinical and laboratorial features of SLE patients at baseline 
Characteristics N=24 
Epidemiology  
Age, years, mean ± SD 47 ± 11 
Female gender, n (%) 23 (95.83%) 
Previous SLE manifestations  
Skin, n (%) 19 (79,2%) 
Joints, n (%) 18 (75%) 
Serositis, n (%) 4 (16.7%) 
Kidney, n (%) 7 (29.2%) 
Nervous system, n (%) 3 (12.5%) 
Flares, n (%) 10 (41.7%) 
Flares, mean (range) 0.66 (0-3) 
  
SLEDAI/SLICC and analytical studies  
SLEDAI at Day 0, mean (range) 2.71 (0-21) 
SLICC at Day 0, mean (range) 1.04 (0-5) 
Calcium levels, mean (range), mmol/L 2.34 (2.12-2.52) 
Phosphorus levels, mean (range), mmol/L 1.02 (0.65-1.4) 
C3 levels at Day 0, mean (range), mg/dL 101.5 (51-147) 
C4 levels at Day 0, mean (range), mg/dL 16.5 (6-35) 
Anti-dsDNA levels at Day 0, mean (range), IU/mL 34.15 (0.2-302) 
% CD3+ levels at Day 0, mean (range) 80.05 (69.1-90.5) 
% CD3+CD4+ levels at Day 0, mean (range) 47.8 (39-62.5) 
% CD3+CD8+ levels at Day 0, mean (range) 30.55 (18.2-44.9) 
%T CD4+ FoxP3+ at Day 0, mean (range) 7.27 (0.48-15.57) 
%T CD4+IL17+ at Day 0, mean (range) 3.89 (1.19-8.58) 
%T CD4+ FoxP3+/%T CD4+ IL17+ ratio at Day 0, mean (range) 2.23 (0.16-8.9) 
25-hydroxyvitamin D levels  
Mean ± SD, nmol/L 59.3 ± 29.6 
25(OH)D ≤ 25 nmol/L, n (%) 2 (8.3%) 
25 < 25(OH)D ≤ 50 nmol/L, n (%) 8 (33.3%) 
50 < 25(OH)D ≤ 75 nmol/L, n (%) 7 (29.2%) 
25(OH)D > 75 nmol/L, n (%) 7 (29.2%) 
Associated treatments*  
Prednisone, n (%) 15 (62.5%) 
Prednisone <10 mg 11 
Prednisone 10-20 mg 3 
Prednisone >20 mg 1 
Hydroxychloroquine, n (%) 17 (70.8%) 
Azathioprine, n (%) 2 (8.3%) 
Mycophenolate mofetil, n (%) 3 (12.5%) 
        *At the time of the study. 
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Figure 1 –Time evolution of serum 25(OH)D levels (M3 – month 3; M6 – month 6); *p<0.05, **p<0.01. 
 
 
Figure 2 – Time evolution of phosphorus (p=ns) and calcium levels. 
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Figure 3 – Disease activity assessed by SLEDAI-2K scores. 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Time evolution of anti-dsDNA (p=ns) and C3 complement fraction levels. 
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Figure 5 – Evolution of peripheral blood lymphocytes proportions with vitamin D supplementation. CD3
+
 (A), 
CD3
+
CD4
+
 (B) and CD3
+
CD8
+
 (C) proportions at Day 0 and M6. 
 
 
Figure 6 – Variation of the proportions of CD4
+
FoxP3
+ 
T cells (A) and CD4
+
IL-17A T cells (B) after vitamin D 
supplementation. 
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Figure 7 – Variation of FoxP3
+
/IL-17A ratio after vitamin D supplementation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Variation of FoxP3
+
/IL-17A ratio in patients group with ≥75 nmol/L 25(OH)D levels (at baseline) after 
vitamin D supplementation. 
 
 
  
 
